https://www.spreaker.com/podcast/healthcare-mysteries-uncovered--7197477
Join us as we explore the captivating and often unsettling evolution of medical science. From ancient remedies and medieval plagues to groundbreaking surgical feats and ethical dilemmas, we dissect the fascinating intersection of human ingenuity, suffering, and discovery. Each episode brings to life historical medical cases, scientific breakthroughs, and the enduring human quest to understand and conquer disease.

New episodes arrive daily, Monday through Sunday, at 7:00 PM EST, offering a fresh dose of historical intrigue and medical insights. We delve deep into specific events, figures, and concepts, ensuring a thorough and engaging exploration of each topic. Expect well-researched narratives that are both informative and thought-provoking.

This podcast is for anyone fascinated by the history of medicine, the human body, and the incredible journey of scientific progress. If you love historical podcasts and uncovering the truth behind medical myths, you’ve found your next obsession.

Subscribe now to unravel the past with Medical History Mysteries.]]>enTrue Crime© 2026 OBOMEDIA Creatorshttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/119a3ec328b20eec4bed3580cdba24bc.jpghttps://www.spreaker.com/podcast/healthcare-mysteries-uncovered--7197477Mon, 21 Sep 2026 23:00:11 +0000Creator at ObomediaCreator at Obomediacreators@obomedia.comEver wondered about the strange cures, bizarre medical practices, and forgotten pioneers that shaped modern healthcare? Medical History Mysteries unearths the most compelling stories from the annals of medicine. Join us as we explore the captivating...
Join us as we explore the captivating and often unsettling evolution of medical science. From ancient remedies and medieval plagues to groundbreaking surgical feats and ethical dilemmas, we dissect the fascinating intersection of human ingenuity, suffering, and discovery. Each episode brings to life historical medical cases, scientific breakthroughs, and the enduring human quest to understand and conquer disease.

New episodes arrive daily, Monday through Sunday, at 7:00 PM EST, offering a fresh dose of historical intrigue and medical insights. We delve deep into specific events, figures, and concepts, ensuring a thorough and engaging exploration of each topic. Expect well-researched narratives that are both informative and thought-provoking.

This podcast is for anyone fascinated by the history of medicine, the human body, and the incredible journey of scientific progress. If you love historical podcasts and uncovering the truth behind medical myths, you’ve found your next obsession.

Subscribe now to unravel the past with Medical History Mysteries.]]>falsef7aeb092-f66e-53da-9049-48baedeb8153episodichttps://www.spreaker.com/episode/when-milk-became-poison-china-s-silent-melamine-cover-up-revealed--73138509
A town of 25 reported attacks, a folded white cloth tested “clean,” and no one ever charged-yet residents experienced sudden paralysis, burning throats, and a sweet odor. How did Mattoon, Illinois, in September 1944 become convinced a gasser prowled its streets, and why do the forensic, eyewitness, and official accounts still contradict each other?

In this episode, we tell the story of the Mattoon incidents of 1944, presenting the sequence of reported symptoms, the newspaper headlines that shaped public belief, and the conflicting findings from investigators and officials-asking which pieces of the case can be trusted.

Person: Aline Kearney
Person: Beulah Cordes
Event: Series of reported gasser attacks
Date: September 1-roughly two weeks later, 1944
Location: Mattoon, Coles County, Illinois

- 25 incidents reported in Mattoon over roughly two weeks.
- White cloth found on Beulah Cordes’s porch on the night of September 5, 1944, tested clean with no chemicals detected.
- Aline Kearney became partially paralyzed around 11:00 PM on September 1 after smelling a “sweet, almost floral” odor.
- Bert Kearney reported seeing a tall, thin man in dark clothing around 12:30 AM after police had already checked the scene.
- No deaths, no arrests, and the FBI opened a file but the attacks stopped as suddenly as they began.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138509Tue, 22 Sep 2026 23:00:02 +0000Creator at ObomediaWhen Milk Became Poison: China's Silent Melamine Cover-Up Revealed A town of 25 reported attacks, a folded white cloth tested “clean,” and no one ever charged-yet residents experienced sudden paralysis, burning throats, and a sweet odor. How did...
A town of 25 reported attacks, a folded white cloth tested “clean,” and no one ever charged-yet residents experienced sudden paralysis, burning throats, and a sweet odor. How did Mattoon, Illinois, in September 1944 become convinced a gasser prowled its streets, and why do the forensic, eyewitness, and official accounts still contradict each other?

In this episode, we tell the story of the Mattoon incidents of 1944, presenting the sequence of reported symptoms, the newspaper headlines that shaped public belief, and the conflicting findings from investigators and officials-asking which pieces of the case can be trusted.

Person: Aline Kearney
Person: Beulah Cordes
Event: Series of reported gasser attacks
Date: September 1-roughly two weeks later, 1944
Location: Mattoon, Coles County, Illinois

- 25 incidents reported in Mattoon over roughly two weeks.
- White cloth found on Beulah Cordes’s porch on the night of September 5, 1944, tested clean with no chemicals detected.
- Aline Kearney became partially paralyzed around 11:00 PM on September 1 after smelling a “sweet, almost floral” odor.
- Bert Kearney reported seeing a tall, thin man in dark clothing around 12:30 AM after police had already checked the scene.
- No deaths, no arrests, and the FBI opened a file but the attacks stopped as suddenly as they began.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1408falsefullhttps://www.spreaker.com/episode/the-night-needles-appeared-how-strawberries-shattered-trust-in-2018--73138508
A single sewing needle hidden inside a perfect strawberry sparked a national panic in 2018, shutting down farms, costing hundreds of jobs and burning half a million plants - yet no criminal answer ever emerged. Who pushed the first needle in, and why did it take three days for any official warning to reach the public?

In this episode, we trace how a punnet bought at a Woolworths in Strathpine Centre ended up on a Moreton Bay emergency-room tray and then on Facebook, how retailers and regulators responded, and how that response left consumers exposed - could a social-media post become the most effective public-health alert in the country?

Person: My Ut Trinh
Date: 9 September 2018
Location: Strathpine Centre, Queensland
Brand: Berry Obsession
Event: Needle contamination incident

- A man swallowed part of a sewing needle from strawberries on the evening of 9 September 2018.
- The punnet was purchased at a Woolworths supermarket in Strathpine Centre on a Sunday.
- No public warning was issued for three days after the first hospital photograph was posted on Facebook.
- On 17 September 2018, authorities issued a trade recall rather than a consumer-level product recall.
- One Queensland farm burned 500,000 strawberry plants after the contamination crisis.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138508Mon, 21 Sep 2026 23:00:02 +0000Creator at ObomediaThe Night Needles Appeared: How Strawberries Shattered Trust in 2018 A single sewing needle hidden inside a perfect strawberry sparked a national panic in 2018, shutting down farms, costing hundreds of jobs and burning half a million plants - yet...
A single sewing needle hidden inside a perfect strawberry sparked a national panic in 2018, shutting down farms, costing hundreds of jobs and burning half a million plants - yet no criminal answer ever emerged. Who pushed the first needle in, and why did it take three days for any official warning to reach the public?

In this episode, we trace how a punnet bought at a Woolworths in Strathpine Centre ended up on a Moreton Bay emergency-room tray and then on Facebook, how retailers and regulators responded, and how that response left consumers exposed - could a social-media post become the most effective public-health alert in the country?

Person: My Ut Trinh
Date: 9 September 2018
Location: Strathpine Centre, Queensland
Brand: Berry Obsession
Event: Needle contamination incident

- A man swallowed part of a sewing needle from strawberries on the evening of 9 September 2018.
- The punnet was purchased at a Woolworths supermarket in Strathpine Centre on a Sunday.
- No public warning was issued for three days after the first hospital photograph was posted on Facebook.
- On 17 September 2018, authorities issued a trade recall rather than a consumer-level product recall.
- One Queensland farm burned 500,000 strawberry plants after the contamination crisis.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1271falsefullhttps://www.spreaker.com/episode/the-hidden-cloud-how-ground-zero-s-air-became-a-silent-execution--73138507
Breath that killed: more than five thousand deaths and 48,579 cancer diagnoses have been confirmed by the World Trade Center Health Program from illnesses tied to the dust and smoke after September 11, 2001 - but officials told the public the air was safe only six days after the towers fell. Who knew the true hazards in the cloud and why was a written warning buried while people kept working?

In this episode, we tell the story of the toxic cloud over Lower Manhattan, the conflicting official statements, and the men and women who inhaled what they were told was safe; what did written warnings say, and how did public reassurances change the fate of responders and volunteers?

Person: Frank Macri
Date: September 11, 2001
Location: Lower Manhattan
Event: South Tower collapse and resulting toxic cloud
Status: More than 5,000 deaths confirmed by the World Trade Center Health Program

- 6 days between a CDC memo advising against rapid return (September 12, 2001) and the EPA statement saying the air was safe
- 5,000+ deaths confirmed from illnesses directly linked to Ground Zero as recorded by the World Trade Center Health Program
- 48,579 cancer diagnoses recorded under the World Trade Center Health Program as of September 2025
- Frank Macri was 35 on September 11, 2001, diagnosed with stage four cancer one year later, and died at age 41 on September 3, 2007
- Thomas Cahill described sampled dust as "wildly toxic" and Dr. Michael Crane called it a "witch's brew"

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138507Sun, 20 Sep 2026 23:00:02 +0000Creator at ObomediaThe Hidden Cloud: How Ground Zero's Air Became a Silent Execution Breath that killed: more than five thousand deaths and 48,579 cancer diagnoses have been confirmed by the World Trade Center Health Program from illnesses tied to the dust and smoke...
Breath that killed: more than five thousand deaths and 48,579 cancer diagnoses have been confirmed by the World Trade Center Health Program from illnesses tied to the dust and smoke after September 11, 2001 - but officials told the public the air was safe only six days after the towers fell. Who knew the true hazards in the cloud and why was a written warning buried while people kept working?

In this episode, we tell the story of the toxic cloud over Lower Manhattan, the conflicting official statements, and the men and women who inhaled what they were told was safe; what did written warnings say, and how did public reassurances change the fate of responders and volunteers?

Person: Frank Macri
Date: September 11, 2001
Location: Lower Manhattan
Event: South Tower collapse and resulting toxic cloud
Status: More than 5,000 deaths confirmed by the World Trade Center Health Program

- 6 days between a CDC memo advising against rapid return (September 12, 2001) and the EPA statement saying the air was safe
- 5,000+ deaths confirmed from illnesses directly linked to Ground Zero as recorded by the World Trade Center Health Program
- 48,579 cancer diagnoses recorded under the World Trade Center Health Program as of September 2025
- Frank Macri was 35 on September 11, 2001, diagnosed with stage four cancer one year later, and died at age 41 on September 3, 2007
- Thomas Cahill described sampled dust as "wildly toxic" and Dr. Michael Crane called it a "witch's brew"

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1299falsefullhttps://www.spreaker.com/episode/the-doctor-who-challenged-death-jack-kevorkian-s-fatal-choice--73138506
Fear and moral outrage: between 1946 and 1948 more than 1,300 Guatemalans-many psychiatric patients, prisoners, soldiers, sex workers, orphans and leprosy patients-were deliberately infected with syphilis by U.S.-funded researchers who never obtained informed consent; how did a $1,500 payment and routine paperwork open the doors to experiments even as Nuremberg trials condemned similar abuses?

In this episode, we lay out the facts as recorded in the recovered files: who ran the programs, how subjects were selected, the role of U.S. institutions, and the medical methods used-asking how such a program could proceed under the auspices of public health and what that reveals about consent, power, and accountability.

Person: John Charles Charles
Person: John F. Mahoney
Location: Asilo de Alienados, Guatemala City
Date: 1946-1948
Funding: National Institutes of Health and United States Public Health Service

- 1,308 people were affected by the Guatemala syphilis program between 1946 and 1948.
- $1,500 was redirected to secure access to the psychiatric hospital for the experiments.
- Subjects’ ages ranged from 10 to 72 years old.
- John F. Mahoney received the Lasker Award in 1946 for his work on penicillin and syphilis treatment.
- Consent for soldiers was documented as given by officers or physicians; psychiatric patients had no consent process.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138506Sat, 19 Sep 2026 23:00:02 +0000Creator at ObomediaThe Doctor Who Challenged Death: Jack Kevorkian's Fatal Choice Fear and moral outrage: between 1946 and 1948 more than 1,300 Guatemalans-many psychiatric patients, prisoners, soldiers, sex workers, orphans and leprosy patients-were deliberately...
Fear and moral outrage: between 1946 and 1948 more than 1,300 Guatemalans-many psychiatric patients, prisoners, soldiers, sex workers, orphans and leprosy patients-were deliberately infected with syphilis by U.S.-funded researchers who never obtained informed consent; how did a $1,500 payment and routine paperwork open the doors to experiments even as Nuremberg trials condemned similar abuses?

In this episode, we lay out the facts as recorded in the recovered files: who ran the programs, how subjects were selected, the role of U.S. institutions, and the medical methods used-asking how such a program could proceed under the auspices of public health and what that reveals about consent, power, and accountability.

Person: John Charles Charles
Person: John F. Mahoney
Location: Asilo de Alienados, Guatemala City
Date: 1946-1948
Funding: National Institutes of Health and United States Public Health Service

- 1,308 people were affected by the Guatemala syphilis program between 1946 and 1948.
- $1,500 was redirected to secure access to the psychiatric hospital for the experiments.
- Subjects’ ages ranged from 10 to 72 years old.
- John F. Mahoney received the Lasker Award in 1946 for his work on penicillin and syphilis treatment.
- Consent for soldiers was documented as given by officers or physicians; psychiatric patients had no consent process.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1377falsefullhttps://www.spreaker.com/episode/the-man-who-sold-italy-its-medicines-inside-poggiolini-s-hidden-fortune--73138505
Corruption hid in plain sight: a man who decided which drugs Italy would buy amassed at least 15 billion lire in a Swiss account and enough gold, jewels and rare coins to fill an apartment - all discovered in a 12‑hour search. How did a physician‑bureaucrat turn pharmaceutical approvals into a hidden personal fortune, and who paid the unseen price?

In this episode, we tell the chronology of Duilio Poggiolini’s rise from a medical graduate in 1954 to the heart of Italy’s drug approval system, the mechanisms of his influence, and the collapse of his scheme after his arrest in Lausanne; what follows asks how institutional trust was converted into private wealth.

Person: Duilio Poggiolini
Date: 20 September 1993 (arrest in Lausanne)
Location: Naples apartment and Swiss bank account in Lausanne
Status: Arrested and returned to Italy; imprisoned at Poggioreale for seven months
Amount seized: More than 15 billion lire in a Swiss account registered to his wife

- Investigators spent 12 hours cataloguing the contents of Poggiolini’s Naples apartment.
- More than 15 billion lire were seized from a Swiss bank account registered to his wife.
- Gold ingots were hidden inside sofa cushions in his home.
- Coins bearing the face of Tsar Nicholas II were pressed into mattress linings.
- Poggiolini held roles including Inspector General at the Ministry of Health (by 1972), represented Italy at WHO in 1981, and presided over the EEC pharmaceuticals harmonization commission by 1991.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138505Fri, 18 Sep 2026 23:00:02 +0000Creator at ObomediaThe Man Who Sold Italy Its Medicines: Inside Poggiolini's Hidden Fortune Corruption hid in plain sight: a man who decided which drugs Italy would buy amassed at least 15 billion lire in a Swiss account and enough gold, jewels and rare coins to fill...
Corruption hid in plain sight: a man who decided which drugs Italy would buy amassed at least 15 billion lire in a Swiss account and enough gold, jewels and rare coins to fill an apartment - all discovered in a 12‑hour search. How did a physician‑bureaucrat turn pharmaceutical approvals into a hidden personal fortune, and who paid the unseen price?

In this episode, we tell the chronology of Duilio Poggiolini’s rise from a medical graduate in 1954 to the heart of Italy’s drug approval system, the mechanisms of his influence, and the collapse of his scheme after his arrest in Lausanne; what follows asks how institutional trust was converted into private wealth.

Person: Duilio Poggiolini
Date: 20 September 1993 (arrest in Lausanne)
Location: Naples apartment and Swiss bank account in Lausanne
Status: Arrested and returned to Italy; imprisoned at Poggioreale for seven months
Amount seized: More than 15 billion lire in a Swiss account registered to his wife

- Investigators spent 12 hours cataloguing the contents of Poggiolini’s Naples apartment.
- More than 15 billion lire were seized from a Swiss bank account registered to his wife.
- Gold ingots were hidden inside sofa cushions in his home.
- Coins bearing the face of Tsar Nicholas II were pressed into mattress linings.
- Poggiolini held roles including Inspector General at the Ministry of Health (by 1972), represented Italy at WHO in 1981, and presided over the EEC pharmaceuticals harmonization commission by 1991.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1345falsefullhttps://www.spreaker.com/episode/body-bags-on-the-gate-argentina-s-70-hidden-vaccine-privileges--73138504
Power felt like a vaccine in February 2021: Argentina had early Sputnik V doses while hospitals ran out, and someone tied real-name body bags to the Casa Rosada gate to force a confession. How did phone calls and old friendships allegedly move at least 70 people ahead of frontline workers and the elderly?

In this episode, we tell the sequence of events that began with a radio admission and grew into federal complaints, resignations, and a public outcry, asking who was protected by the system and who was left waiting.

Person: Ginés González García
Person: Horacio Verbitsky
Date: February 19, 2021
Event: Resignation accepted on February 20, 2021
Case: At least 70 people vaccinated outside priority order

- On February 27, 2021, body bags labeled with real names were tied to the Casa Rosada gate as a protest.
- Horacio Verbitsky publicly said he called Ginés González García and a vaccine team was sent to vaccinate him despite not being on any priority list.
- Federal prosecutors received 15 separate legal filings within days after Verbitsky's admission.
- Reporting by La Nación circulated that González García had reportedly reserved as many as 3,000 doses for a network of political figures, allies, and personal connections.
- President Alberto Fernández accepted Ginés González García’s resignation on February 20, 2021.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138504Thu, 17 Sep 2026 23:00:02 +0000Creator at ObomediaBody Bags on the Gate: Argentina's 70 Hidden Vaccine Privileges Power felt like a vaccine in February 2021: Argentina had early Sputnik V doses while hospitals ran out, and someone tied real-name body bags to the Casa Rosada gate to force a...
Power felt like a vaccine in February 2021: Argentina had early Sputnik V doses while hospitals ran out, and someone tied real-name body bags to the Casa Rosada gate to force a confession. How did phone calls and old friendships allegedly move at least 70 people ahead of frontline workers and the elderly?

In this episode, we tell the sequence of events that began with a radio admission and grew into federal complaints, resignations, and a public outcry, asking who was protected by the system and who was left waiting.

Person: Ginés González García
Person: Horacio Verbitsky
Date: February 19, 2021
Event: Resignation accepted on February 20, 2021
Case: At least 70 people vaccinated outside priority order

- On February 27, 2021, body bags labeled with real names were tied to the Casa Rosada gate as a protest.
- Horacio Verbitsky publicly said he called Ginés González García and a vaccine team was sent to vaccinate him despite not being on any priority list.
- Federal prosecutors received 15 separate legal filings within days after Verbitsky's admission.
- Reporting by La Nación circulated that González García had reportedly reserved as many as 3,000 doses for a network of political figures, allies, and personal connections.
- President Alberto Fernández accepted Ginés González García’s resignation on February 20, 2021.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1312falsefullhttps://www.spreaker.com/episode/when-medicine-branded-freedom-a-disease-the-drapetomania-case--73138503
Freedom was labeled a mental disorder in 1851: a respected Southern physician named a condition drapetomania and prescribed whipping as prevention - and his paper was printed for planters as well as doctors. How did clinical language, scripture, and commerce combine to turn escape into pathology?

In this episode, we present the publication history, content, and implications of Samuel A. Cartwright’s May 1851 paper, showing how it moved from a medical journal to a widely read commercial review and asking what it means that institutions gave such arguments authority.

Person: Samuel A. Cartwright
Date: May 1851
Location: Presented to the Medical Association of Louisiana; published in New Orleans Medical and Surgical Journal
Event: Reprint in De Bow's Review
Topic: Drapetomania and dysaesthesia aethiopica

- Cartwright presented "Report on the Diseases and Physical Peculiarities of the Negro Race" in May 1851 to the Medical Association of Louisiana.
- The paper was published the same month in the New Orleans Medical and Surgical Journal.
- Within weeks it was reprinted in De Bow's Review, an agricultural and commercial journal with wide Southern circulation.
- Cartwright coined drapetomania from Greek roots meaning "fugitive" and "madness" and defined the symptom as an enslaved person attempting to flee.
- He recommended whipping as preventive treatment and cited both clinical notes and the Bible in the same passages.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138503Wed, 16 Sep 2026 23:00:02 +0000Creator at ObomediaWhen Medicine Branded Freedom a Disease: The Drapetomania Case Freedom was labeled a mental disorder in 1851: a respected Southern physician named a condition drapetomania and prescribed whipping as prevention - and his paper was printed for...
Freedom was labeled a mental disorder in 1851: a respected Southern physician named a condition drapetomania and prescribed whipping as prevention - and his paper was printed for planters as well as doctors. How did clinical language, scripture, and commerce combine to turn escape into pathology?

In this episode, we present the publication history, content, and implications of Samuel A. Cartwright’s May 1851 paper, showing how it moved from a medical journal to a widely read commercial review and asking what it means that institutions gave such arguments authority.

Person: Samuel A. Cartwright
Date: May 1851
Location: Presented to the Medical Association of Louisiana; published in New Orleans Medical and Surgical Journal
Event: Reprint in De Bow's Review
Topic: Drapetomania and dysaesthesia aethiopica

- Cartwright presented "Report on the Diseases and Physical Peculiarities of the Negro Race" in May 1851 to the Medical Association of Louisiana.
- The paper was published the same month in the New Orleans Medical and Surgical Journal.
- Within weeks it was reprinted in De Bow's Review, an agricultural and commercial journal with wide Southern circulation.
- Cartwright coined drapetomania from Greek roots meaning "fugitive" and "madness" and defined the symptom as an enslaved person attempting to flee.
- He recommended whipping as preventive treatment and cited both clinical notes and the Bible in the same passages.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1382falsefullhttps://www.spreaker.com/episode/the-cotton-candy-skull-how-horror-borrowed-real-medical-atrocities--73138502
Sweetness was literally packed inside a hollow skull on the set of the 1999 House on Haunted Hill - spun sugar designed to dissolve under acetone - juxtaposing confectionery fragility with a film built around documented institutional violence. Why would a remake that borrows real cases of psychiatric experimentation and designs its hospital on Albert Speer’s monolithic architecture choose a prop that vanishes like a lie?

In this episode, we trace the chain from the 1958 original to the 1999 remake, following rights sold to fund a college education, production design choices that modeled a hospital on totalitarian architecture, and the reuse of an eighteen-year-old creature by legendary makeup artist Dick Smith - all to ask what the film was trying to make visible about real medical atrocities.

Person: Terry Castle
Date: 1958
Date: 1999
Location: Ennis House (inspiration) / Vanacutt Institute (fictional)
Author: Dick Smith (early screenplay draft)

- A prop skull was packed with spun sugar and engineered to dissolve when doused with acetone.
- Terry Castle bought the rights to House on Haunted Hill and sold them to pay for her college tuition.
- The 1999 remake’s hospital set was deliberately designed to evoke Albert Speer’s architecture with wide corridors and oppressive ceilings.
- The Vanacutt Institute backstory included documented-based psychiatric experiments and institutional violence against patients.
- A creature built by Dick Smith in 1981 for Ghost Story was stored for 18 years and later repurposed in the 1999 production.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138502Tue, 15 Sep 2026 23:00:02 +0000Creator at ObomediaThe Cotton-Candy Skull: How Horror Borrowed Real Medical Atrocities Sweetness was literally packed inside a hollow skull on the set of the 1999 House on Haunted Hill - spun sugar designed to dissolve under acetone - juxtaposing confectionery...
Sweetness was literally packed inside a hollow skull on the set of the 1999 House on Haunted Hill - spun sugar designed to dissolve under acetone - juxtaposing confectionery fragility with a film built around documented institutional violence. Why would a remake that borrows real cases of psychiatric experimentation and designs its hospital on Albert Speer’s monolithic architecture choose a prop that vanishes like a lie?

In this episode, we trace the chain from the 1958 original to the 1999 remake, following rights sold to fund a college education, production design choices that modeled a hospital on totalitarian architecture, and the reuse of an eighteen-year-old creature by legendary makeup artist Dick Smith - all to ask what the film was trying to make visible about real medical atrocities.

Person: Terry Castle
Date: 1958
Date: 1999
Location: Ennis House (inspiration) / Vanacutt Institute (fictional)
Author: Dick Smith (early screenplay draft)

- A prop skull was packed with spun sugar and engineered to dissolve when doused with acetone.
- Terry Castle bought the rights to House on Haunted Hill and sold them to pay for her college tuition.
- The 1999 remake’s hospital set was deliberately designed to evoke Albert Speer’s architecture with wide corridors and oppressive ceilings.
- The Vanacutt Institute backstory included documented-based psychiatric experiments and institutional violence against patients.
- A creature built by Dick Smith in 1981 for Ghost Story was stored for 18 years and later repurposed in the 1999 production.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1179falsefullhttps://www.spreaker.com/episode/the-doctor-the-bottles-and-the-night-michael-jackson-never-woke--73138501
When the nightstand in Michael Jackson’s Holmby Hills bedroom held industrial quantities of propofol-some bottles unlabeled, others bearing fraudulent names-the fragile life of a fifty-year-old icon ended in a way the world could not comprehend. How did a surgical anesthetic, months before a fifty-concert comeback, become the final sleep that Jackson never woke from?

In this episode, we present the facts recorded in the investigation and trial that followed, laying out the timeline, the drugs found, and the people in the house that night to ask the central question: how did a celebrity with a doctor and a team still die alone in that bed?

Date: June 25, 2009
Person: Michael Jackson
Location: Holmby Hills
Cause: Acute propofol intoxication compounded by lorazepam, midazolam, diazepam, lidocaine, and ephedrine
Ruling: Homicide by the Los Angeles County Coroner on August 28, 2009

- Propofol was present in industrial quantities on the nightstand in Jackson’s bedroom.
- The coroner’s report listed a cocktail of six drugs contributing to death.
- Nearly ninety minutes elapsed between the administration and the 9-1-1 call.
- Conrad Murray, a cardiologist, had been contracted to be Jackson’s personal physician for $150,000 per month.
- Paris Jackson, age 11, spoke at her father’s memorial on July 7, 2009, before 17,500 people and a worldwide audience.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138501Mon, 14 Sep 2026 23:00:03 +0000Creator at ObomediaThe Doctor, the Bottles, and the Night Michael Jackson Never Woke When the nightstand in Michael Jackson’s Holmby Hills bedroom held industrial quantities of propofol-some bottles unlabeled, others bearing fraudulent names-the fragile life of a...
When the nightstand in Michael Jackson’s Holmby Hills bedroom held industrial quantities of propofol-some bottles unlabeled, others bearing fraudulent names-the fragile life of a fifty-year-old icon ended in a way the world could not comprehend. How did a surgical anesthetic, months before a fifty-concert comeback, become the final sleep that Jackson never woke from?

In this episode, we present the facts recorded in the investigation and trial that followed, laying out the timeline, the drugs found, and the people in the house that night to ask the central question: how did a celebrity with a doctor and a team still die alone in that bed?

Date: June 25, 2009
Person: Michael Jackson
Location: Holmby Hills
Cause: Acute propofol intoxication compounded by lorazepam, midazolam, diazepam, lidocaine, and ephedrine
Ruling: Homicide by the Los Angeles County Coroner on August 28, 2009

- Propofol was present in industrial quantities on the nightstand in Jackson’s bedroom.
- The coroner’s report listed a cocktail of six drugs contributing to death.
- Nearly ninety minutes elapsed between the administration and the 9-1-1 call.
- Conrad Murray, a cardiologist, had been contracted to be Jackson’s personal physician for $150,000 per month.
- Paris Jackson, age 11, spoke at her father’s memorial on July 7, 2009, before 17,500 people and a worldwide audience.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1410falsefullhttps://www.spreaker.com/episode/how-a-trusted-team-doctor-hid-decades-of-abuse-behind-credentials--73138500
The horror of institutional betrayal: a trusted team physician used his credentials and access to abuse at least 265 young athletes across three decades while institutions looked away - how did framed degrees hide this system for so long? What finally broke the silence, and why did it take until 2018 for so many voices to be heard?

In this episode, we tell the story of Lawrence Gerard Nassar’s rise from a high school student trainer to a national team doctor and Michigan State University physician, and we trace the specific moments and decisions that allowed abuse to continue. We follow the victims, the institutions, and the single reports that began to dismantle the cover-up: what changed between the first complaint in 1997 and the public reckoning in 2018?

Person: Lawrence Gerard Nassar
Date: July 18, 2018
Location: Los Angeles
Period: 1978-2018
Case: Abuse of at least 265 athletes

- Nassar began as a student athletic trainer in 1978 at age 15 in Farmington Hills, Michigan.
- He completed a Bachelor of Science in kinesiology in 1985 and became USA Gymnastics athletic trainer in 1986 at age 22.
- First complaints reached Michigan State University employees in 1997, the same year he became an assistant professor earning approximately $100,000 per year.
- From 2001 onward he visited the Karolyi Ranch in Texas for 15 years without a Texas medical license, which under Texas law was a third-degree felony.
- On June 17, 2015, Maggie Nichols formally reported abuse to USA Gymnastics; the organization did not call police or suspend Nassar.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138500Sun, 13 Sep 2026 23:00:02 +0000Creator at ObomediaHow a Trusted Team Doctor Hid Decades of Abuse Behind Credentials The horror of institutional betrayal: a trusted team physician used his credentials and access to abuse at least 265 young athletes across three decades while institutions looked...
The horror of institutional betrayal: a trusted team physician used his credentials and access to abuse at least 265 young athletes across three decades while institutions looked away - how did framed degrees hide this system for so long? What finally broke the silence, and why did it take until 2018 for so many voices to be heard?

In this episode, we tell the story of Lawrence Gerard Nassar’s rise from a high school student trainer to a national team doctor and Michigan State University physician, and we trace the specific moments and decisions that allowed abuse to continue. We follow the victims, the institutions, and the single reports that began to dismantle the cover-up: what changed between the first complaint in 1997 and the public reckoning in 2018?

Person: Lawrence Gerard Nassar
Date: July 18, 2018
Location: Los Angeles
Period: 1978-2018
Case: Abuse of at least 265 athletes

- Nassar began as a student athletic trainer in 1978 at age 15 in Farmington Hills, Michigan.
- He completed a Bachelor of Science in kinesiology in 1985 and became USA Gymnastics athletic trainer in 1986 at age 22.
- First complaints reached Michigan State University employees in 1997, the same year he became an assistant professor earning approximately $100,000 per year.
- From 2001 onward he visited the Karolyi Ranch in Texas for 15 years without a Texas medical license, which under Texas law was a third-degree felony.
- On June 17, 2015, Maggie Nichols formally reported abuse to USA Gymnastics; the organization did not call police or suspend Nassar.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1347falsefullhttps://www.spreaker.com/episode/patient-one-how-an-mdma-trial-broke-a-champion-and-a-field--73138499
Fear and trust were chemically altered in a clinical setting where rules failed: the lead therapist had no active license, his wife surrendered hers, and Patient One’s testimony was read by proxy at the FDA hearing that denied approval in August 2024. How did a phase two MDMA-assisted psychotherapy trial intended to treat treatment-resistant PTSD become the case that changed an entire field?

In this episode, we present the timeline and key facts of the MAPS MDMA trial involving Meaghan Buisson, showing who was involved, what happened during and after the protocol, and why regulators and clinicians are still debating whether the protections in place were ever adequate. Was the system designed to protect participants like Buisson, or did structural gaps make harm possible?

Person: Meaghan Buisson
Event: FDA advisory committee denial in August 2024
Location: United States (FDA hearing)
Period: Enrollment December 2014 - final dosing October 2015, follow-up scheduled August 2016
Therapists: Richard Yensen (lapsed license), Donna Dryer (licensed psychiatrist)

- Buisson enrolled as Patient One in December 2014 in a MAPS phase two MDMA-assisted psychotherapy cohort initially planned for 12 people, which later shrank to 6.
- Richard Yensen’s psychologist license had lapsed in 2009 and he had no active license when Buisson was enrolled.
- The final MDMA dosing session for Buisson occurred in October 2015; her final follow-up appointment was scheduled for August 2016.
- MAPS reviewed the case and characterized Yensen’s admitted sexual relationship with Buisson as sexual abuse and serious ethical misconduct.
- At the FDA hearing in August 2024, Buisson’s testimony was not delivered in person; her words were read aloud by someone else because she was completing a graduate degree across the country.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138499Sat, 12 Sep 2026 23:00:02 +0000Creator at ObomediaPatient One: How an MDMA Trial Broke a Champion and a Field Fear and trust were chemically altered in a clinical setting where rules failed: the lead therapist had no active license, his wife surrendered hers, and Patient One’s testimony was read...
Fear and trust were chemically altered in a clinical setting where rules failed: the lead therapist had no active license, his wife surrendered hers, and Patient One’s testimony was read by proxy at the FDA hearing that denied approval in August 2024. How did a phase two MDMA-assisted psychotherapy trial intended to treat treatment-resistant PTSD become the case that changed an entire field?

In this episode, we present the timeline and key facts of the MAPS MDMA trial involving Meaghan Buisson, showing who was involved, what happened during and after the protocol, and why regulators and clinicians are still debating whether the protections in place were ever adequate. Was the system designed to protect participants like Buisson, or did structural gaps make harm possible?

Person: Meaghan Buisson
Event: FDA advisory committee denial in August 2024
Location: United States (FDA hearing)
Period: Enrollment December 2014 - final dosing October 2015, follow-up scheduled August 2016
Therapists: Richard Yensen (lapsed license), Donna Dryer (licensed psychiatrist)

- Buisson enrolled as Patient One in December 2014 in a MAPS phase two MDMA-assisted psychotherapy cohort initially planned for 12 people, which later shrank to 6.
- Richard Yensen’s psychologist license had lapsed in 2009 and he had no active license when Buisson was enrolled.
- The final MDMA dosing session for Buisson occurred in October 2015; her final follow-up appointment was scheduled for August 2016.
- MAPS reviewed the case and characterized Yensen’s admitted sexual relationship with Buisson as sexual abuse and serious ethical misconduct.
- At the FDA hearing in August 2024, Buisson’s testimony was not delivered in person; her words were read aloud by someone else because she was completing a graduate degree across the country.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1250falsefullhttps://www.spreaker.com/episode/the-trial-tape-how-mdma-therapy-unraveled-on-a-remote-island--73138498
Fear and awe collide as a clinical camera quietly recorded the therapy that would topple a landmark MDMA trial: the footage contradicted the trial architects and helped prompt the FDA's rejection in August 2024. How did a remote island study, a taped final dosing session, and a therapist with a lapsed license become the hinge for a major regulatory decision?

In this episode, we tell the story of Meaghan Buisson and the Cortes Island phase two MDMA-assisted psychotherapy study, laying out the sequence of events, key people, and the evidence the tape revealed that raised questions about safety and protocol. What exactly did the recordings show, and how did that footage change the fate of a high-profile psychedelic therapy?

Person: Meaghan Buisson
Date: December 2014 (enrollment); October 2015 (final MDMA dosing session); August 2024 (FDA decision)
Location: Cortes Island, British Columbia
Organization: MAPS and Lykos Therapeutics

- Buisson was the first patient enrolled in the Cortes Island MDMA trial in December 2014.
- The Cortes site was planned for 12 participants but ultimately treated 6.
- Meaghan Buisson was born in 1989 and had 47 Canadian national championships in inline speed skating.
- Richard Yensen’s psychologist license had lapsed in 2009; he was unlicensed during the trial.
- Cameras recorded every MDMA session at the Cortes Island site, including Buisson’s final dosing session in October 2015.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138498Fri, 11 Sep 2026 23:00:02 +0000Creator at ObomediaThe Trial Tape: How MDMA Therapy Unraveled on a Remote Island Fear and awe collide as a clinical camera quietly recorded the therapy that would topple a landmark MDMA trial: the footage contradicted the trial architects and helped prompt the FDA's...
Fear and awe collide as a clinical camera quietly recorded the therapy that would topple a landmark MDMA trial: the footage contradicted the trial architects and helped prompt the FDA's rejection in August 2024. How did a remote island study, a taped final dosing session, and a therapist with a lapsed license become the hinge for a major regulatory decision?

In this episode, we tell the story of Meaghan Buisson and the Cortes Island phase two MDMA-assisted psychotherapy study, laying out the sequence of events, key people, and the evidence the tape revealed that raised questions about safety and protocol. What exactly did the recordings show, and how did that footage change the fate of a high-profile psychedelic therapy?

Person: Meaghan Buisson
Date: December 2014 (enrollment); October 2015 (final MDMA dosing session); August 2024 (FDA decision)
Location: Cortes Island, British Columbia
Organization: MAPS and Lykos Therapeutics

- Buisson was the first patient enrolled in the Cortes Island MDMA trial in December 2014.
- The Cortes site was planned for 12 participants but ultimately treated 6.
- Meaghan Buisson was born in 1989 and had 47 Canadian national championships in inline speed skating.
- Richard Yensen’s psychologist license had lapsed in 2009; he was unlicensed during the trial.
- Cameras recorded every MDMA session at the Cortes Island site, including Buisson’s final dosing session in October 2015.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1192falsefullhttps://www.spreaker.com/episode/patient-one-mdma-a-recorded-abuse-that-toppled-a-trial--73138497
The camera in a therapy room kept recording as Meaghan Buisson lay under the influence of MDMA in October 2015 - footage that later showed her therapist making repeated physical contact with a patient who could not meaningfully consent. How did a preserved recording of abuse inside a federally sanctioned trial fail to stop the study immediately, and what did it reveal about structural loopholes in psychedelic research?

In this episode, we tell what happened to Patient One One in a Phase Two MDMA-assisted psychotherapy trial, how institutional rules allowed a therapist with a lapsed license to work alongside a licensed colleague, and why a decade-old recording eventually reached regulators and influenced a federal advisory vote. What does Meaghan Buisson’s experience reveal about safety, consent, and oversight in clinical trials?

Person: Meaghan Buisson
Event: October 2015 therapy session recording
Organization: MAPS (Multidisciplinary Association for Psychedelic Studies)
Therapists: Richard Yensen and Donna Dryer
Trial Phase: Phase Two for treatment-resistant PTSD

- Buisson enrolled as Patient One One in December 2014.
- The planned cohort size was twelve patients; the trial ultimately treated six.
- Richard Yensen’s psychologist license had lapsed in 2009, five years before Buisson’s enrollment.
- The dosing phase ran until October 2015 with follow-up continuing through June 2016.
- The institution settled with Buisson for fifteen thousand Canadian dollars and a signed waiver.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138497Thu, 10 Sep 2026 23:00:02 +0000Creator at ObomediaPatient One: MDMA, A Recorded Abuse That Toppled a Trial The camera in a therapy room kept recording as Meaghan Buisson lay under the influence of MDMA in October 2015 - footage that later showed her therapist making repeated physical contact with...
The camera in a therapy room kept recording as Meaghan Buisson lay under the influence of MDMA in October 2015 - footage that later showed her therapist making repeated physical contact with a patient who could not meaningfully consent. How did a preserved recording of abuse inside a federally sanctioned trial fail to stop the study immediately, and what did it reveal about structural loopholes in psychedelic research?

In this episode, we tell what happened to Patient One One in a Phase Two MDMA-assisted psychotherapy trial, how institutional rules allowed a therapist with a lapsed license to work alongside a licensed colleague, and why a decade-old recording eventually reached regulators and influenced a federal advisory vote. What does Meaghan Buisson’s experience reveal about safety, consent, and oversight in clinical trials?

Person: Meaghan Buisson
Event: October 2015 therapy session recording
Organization: MAPS (Multidisciplinary Association for Psychedelic Studies)
Therapists: Richard Yensen and Donna Dryer
Trial Phase: Phase Two for treatment-resistant PTSD

- Buisson enrolled as Patient One One in December 2014.
- The planned cohort size was twelve patients; the trial ultimately treated six.
- Richard Yensen’s psychologist license had lapsed in 2009, five years before Buisson’s enrollment.
- The dosing phase ran until October 2015 with follow-up continuing through June 2016.
- The institution settled with Buisson for fifteen thousand Canadian dollars and a signed waiver.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1245falsefullhttps://www.spreaker.com/episode/the-first-patient-how-a-clinical-trial-became-a-crime-scene--73138496
A licensed psychiatrist surrendered her medical license and police recommended criminal charges after video from a clinical trial showed what prosecutors later called inappropriate physical contact during MDMA-assisted therapy. How did a trial run by a major nonprofit, with cameras rolling and a therapist whose license had lapsed, become the setting for allegations that would take nearly a decade to surface?

In this episode, we chronicle the sequence of events from enrollment through the final dosing session and the regulatory fallout, laying out who was involved, what the recorded sessions showed, and the structural rule that allowed an unlicensed therapist to participate. How did the trial’s own policies contribute to what happened to the first patient?

Person: Meaghan Buisson
Event: MDMA-assisted psychotherapy trial dosing sessions
Organization: MAPS (Multidisciplinary Association for Psychedelic Studies)
Therapists: Richard Yensen and Donna Dryer
Date enrolled: December 2014

- Meaghan Buisson was the first patient enrolled in the cohort in December 2014.
- Buisson completed her final formal trial procedures in June 2016, with the final dosing session in October 2015.
- Richard Yensen’s psychologist license had lapsed in 2009, but MAPS policy required only one current medical license per session.
- Video recordings of dosing sessions existed and later matched Buisson’s allegations of physical contact such as cuddling and spoons.
- The case led to a licensed psychiatrist surrendering her medical license and police recommending criminal charges, though no convictions were recorded.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138496Wed, 09 Sep 2026 23:00:02 +0000Creator at ObomediaThe First Patient: How a Clinical Trial Became a Crime Scene A licensed psychiatrist surrendered her medical license and police recommended criminal charges after video from a clinical trial showed what prosecutors later called inappropriate...
A licensed psychiatrist surrendered her medical license and police recommended criminal charges after video from a clinical trial showed what prosecutors later called inappropriate physical contact during MDMA-assisted therapy. How did a trial run by a major nonprofit, with cameras rolling and a therapist whose license had lapsed, become the setting for allegations that would take nearly a decade to surface?

In this episode, we chronicle the sequence of events from enrollment through the final dosing session and the regulatory fallout, laying out who was involved, what the recorded sessions showed, and the structural rule that allowed an unlicensed therapist to participate. How did the trial’s own policies contribute to what happened to the first patient?

Person: Meaghan Buisson
Event: MDMA-assisted psychotherapy trial dosing sessions
Organization: MAPS (Multidisciplinary Association for Psychedelic Studies)
Therapists: Richard Yensen and Donna Dryer
Date enrolled: December 2014

- Meaghan Buisson was the first patient enrolled in the cohort in December 2014.
- Buisson completed her final formal trial procedures in June 2016, with the final dosing session in October 2015.
- Richard Yensen’s psychologist license had lapsed in 2009, but MAPS policy required only one current medical license per session.
- Video recordings of dosing sessions existed and later matched Buisson’s allegations of physical contact such as cuddling and spoons.
- The case led to a licensed psychiatrist surrendering her medical license and police recommending criminal charges, though no convictions were recorded.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1317falsefullhttps://www.spreaker.com/episode/the-surgeon-without-a-license-who-amputated-a-man-s-life--73138494
A man whose medical license had been revoked 21 years earlier performed an amputation that left a 79-year-old dead - and it began with a desire no U.S. surgeon would legally honor. What drove Philip Bondy to seek removal of a healthy limb, and why did John Ronald Brown continue operating despite revocation, criminal arrest, and at least one earlier patient death?

In this episode, we tell the events leading up to the May 10, 1998 discovery of Philip Bondy’s body and the context around the decades-long practice of John Ronald Brown, showing how gaps in mainstream medicine shaped the choices patients made. What does Bondy’s case reveal about a condition barely recognized in 1998 and the practitioners who filled that void?

Person: Philip Bondy
Date: May 10, 1998
Location: National City, California
Person: John Ronald Brown
Event: California Medical Board revocation in 1977

- Philip Bondy was seventy-nine years old when Gregg Furth found him dead on May 10, 1998.
- Bondy’s left leg had been amputated the day before in Tijuana by John Ronald Brown.
- Brown’s medical license was revoked by the California Medical Board in 1977 for gross negligence, incompetence, and moral turpitude.
- Brown failed the American Board of Plastic Surgery oral examination and never held U.S. board certification in that specialty.
- Brown was arrested in 1990 after operating without a license on a thirty-year-old transgender woman and served nineteen months.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138494Tue, 08 Sep 2026 23:00:02 +0000Creator at ObomediaThe Surgeon Without a License Who Amputated a Man's Life A man whose medical license had been revoked 21 years earlier performed an amputation that left a 79-year-old dead - and it began with a desire no U.S. surgeon would legally honor. What drove...
A man whose medical license had been revoked 21 years earlier performed an amputation that left a 79-year-old dead - and it began with a desire no U.S. surgeon would legally honor. What drove Philip Bondy to seek removal of a healthy limb, and why did John Ronald Brown continue operating despite revocation, criminal arrest, and at least one earlier patient death?

In this episode, we tell the events leading up to the May 10, 1998 discovery of Philip Bondy’s body and the context around the decades-long practice of John Ronald Brown, showing how gaps in mainstream medicine shaped the choices patients made. What does Bondy’s case reveal about a condition barely recognized in 1998 and the practitioners who filled that void?

Person: Philip Bondy
Date: May 10, 1998
Location: National City, California
Person: John Ronald Brown
Event: California Medical Board revocation in 1977

- Philip Bondy was seventy-nine years old when Gregg Furth found him dead on May 10, 1998.
- Bondy’s left leg had been amputated the day before in Tijuana by John Ronald Brown.
- Brown’s medical license was revoked by the California Medical Board in 1977 for gross negligence, incompetence, and moral turpitude.
- Brown failed the American Board of Plastic Surgery oral examination and never held U.S. board certification in that specialty.
- Brown was arrested in 1990 after operating without a license on a thirty-year-old transgender woman and served nineteen months.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1359falsefullhttps://www.spreaker.com/episode/when-medicine-says-no-the-tijuana-amputations-that-killed-a-man--73138493
A retired satellite engineer flew to Tijuana because medicine refused to remove a healthy limb; he returned dead from gas gangrene after an unlicensed surgeon used a large knife, not a scalpel. What happens when the medical system says no to a condition it barely recognizes, and someone finds a different yes across the border?

In this episode, we tell the story of two men with body integrity identity disorder who sought elective amputations, the surgeon who agreed to operate despite revoked licenses, and the aftermath that produced a death and a criminal conviction. How did a history of denied care, clandestine surgery, and a simple choice of instrument lead to fatal infection?

Person: Philip Bondy
Person: Gregg Furth
Person: John Ronald Brown
Date: May 10, 1998
Cause: Gas gangrene from Clostridium perfringens

- Philip Bondy was 79 years old when he died.
- Both Bondy and Furth traveled to Tijuana on May 9, 1998 for elective amputations.
- John Ronald Brown was 75 years old in May 1998 and had his California medical license revoked in 1977.
- Brown had claimed to have performed roughly 600 gender-affirming surgeries and failed the oral plastic surgery board exam.
- The fatal infection was identified as Clostridium perfringens causing gas gangrene.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138493Mon, 07 Sep 2026 23:00:02 +0000Creator at ObomediaWhen Medicine Says No: The Tijuana Amputations That Killed a Man A retired satellite engineer flew to Tijuana because medicine refused to remove a healthy limb; he returned dead from gas gangrene after an unlicensed surgeon used a large knife, not...
A retired satellite engineer flew to Tijuana because medicine refused to remove a healthy limb; he returned dead from gas gangrene after an unlicensed surgeon used a large knife, not a scalpel. What happens when the medical system says no to a condition it barely recognizes, and someone finds a different yes across the border?

In this episode, we tell the story of two men with body integrity identity disorder who sought elective amputations, the surgeon who agreed to operate despite revoked licenses, and the aftermath that produced a death and a criminal conviction. How did a history of denied care, clandestine surgery, and a simple choice of instrument lead to fatal infection?

Person: Philip Bondy
Person: Gregg Furth
Person: John Ronald Brown
Date: May 10, 1998
Cause: Gas gangrene from Clostridium perfringens

- Philip Bondy was 79 years old when he died.
- Both Bondy and Furth traveled to Tijuana on May 9, 1998 for elective amputations.
- John Ronald Brown was 75 years old in May 1998 and had his California medical license revoked in 1977.
- Brown had claimed to have performed roughly 600 gender-affirming surgeries and failed the oral plastic surgery board exam.
- The fatal infection was identified as Clostridium perfringens causing gas gangrene.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1322falsefullhttps://www.spreaker.com/episode/the-surgeon-with-no-license-who-cut-off-a-stranger-s-leg--73138491
Curiosity about dangerous certainties drives this episode: a revoked physician with hundreds of super glue tubes, blood-soaked mattresses, and videotapes of amateur operations, and a 79-year-old engineer who paid to have his left leg removed-then bled to death in a hotel room. How did someone with a revoked license and prior arrests end up amputating a healthy limb in Tijuana and walking away?

In this episode, we lay out the facts of the case and the sequence of events that led to the fatal amputation, following the apartment evidence, autopsy findings, and witness testimony to ask the central question: what happened between two certainties-that Philip Bondy knew what he was paying for, and that John Ronald Brown knew exactly what he was doing?

Person: John Ronald Brown
Person: Philip Bondy
Date: May 9, 1998
Location: Tijuana / National City
Status: License revoked in 1977

- The search warrant found hundreds of tubes of super glue, blood-soaked mattresses, surgical instruments, and videotapes in Brown's San Ysidro apartment.
- Philip Bondy, age 79, died in a National City hotel room after his left leg had been surgically removed.
- John Ronald Brown graduated from the University of Utah School of Medicine in 1947 and failed the oral board for the American Board of Plastic Surgery.
- Brown's California medical license was revoked in 1977 for gross negligence, incompetence, moral turpitude, and related charges.
- Gregg Furth, also seeking amputation, traveled from New York with Bondy and withdrew when an assistant produced a large knife rather than surgical instruments.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138491Sun, 06 Sep 2026 23:00:02 +0000Creator at ObomediaThe Surgeon With No License Who Cut Off a Stranger's Leg Curiosity about dangerous certainties drives this episode: a revoked physician with hundreds of super glue tubes, blood-soaked mattresses, and videotapes of amateur operations, and a...
Curiosity about dangerous certainties drives this episode: a revoked physician with hundreds of super glue tubes, blood-soaked mattresses, and videotapes of amateur operations, and a 79-year-old engineer who paid to have his left leg removed-then bled to death in a hotel room. How did someone with a revoked license and prior arrests end up amputating a healthy limb in Tijuana and walking away?

In this episode, we lay out the facts of the case and the sequence of events that led to the fatal amputation, following the apartment evidence, autopsy findings, and witness testimony to ask the central question: what happened between two certainties-that Philip Bondy knew what he was paying for, and that John Ronald Brown knew exactly what he was doing?

Person: John Ronald Brown
Person: Philip Bondy
Date: May 9, 1998
Location: Tijuana / National City
Status: License revoked in 1977

- The search warrant found hundreds of tubes of super glue, blood-soaked mattresses, surgical instruments, and videotapes in Brown's San Ysidro apartment.
- Philip Bondy, age 79, died in a National City hotel room after his left leg had been surgically removed.
- John Ronald Brown graduated from the University of Utah School of Medicine in 1947 and failed the oral board for the American Board of Plastic Surgery.
- Brown's California medical license was revoked in 1977 for gross negligence, incompetence, moral turpitude, and related charges.
- Gregg Furth, also seeking amputation, traveled from New York with Bondy and withdrew when an assistant produced a large knife rather than surgical instruments.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1346falsefullhttps://www.spreaker.com/episode/the-surgeon-who-amputated-a-stranger-s-life-john-r-brown--73138490
A seventy-nine-year-old man had his perfectly functional left leg removed in Tijuana twelve hours before he was found dead in a motel room-by a surgeon who had been operating without a valid license for decades. What drives someone with Body Integrity Identity Disorder to seek an illegal amputation, and how did John Ronald Brown keep practicing despite revocations, arrests and warnings?

In this episode, we tell the story of Philip Bondy, Gregg Furth, and John Ronald Brown, covering Bondy’s decades-long struggle with Body Integrity Identity Disorder, the journey to a clinic across the border, and Brown’s history of revoked licenses, prison time, and unlicensed surgeries. How did a once-credentialed doctor end up operating in motel rooms, garages and Tijuana clinics, and what led to Bondy’s death?

Person: Philip Bondy
Person: Gregg Furth
Person: John Ronald Brown
Date: May 10, 1998
Event: Amputation in Tijuana followed by death twelve hours later

- Philip Bondy was found dead at age 79 in a motel room in National City, California.
- The left leg amputated by Brown was described as perfectly functional before surgery.
- John Ronald Brown graduated from University of Utah School of Medicine in 1947 and later failed the oral board for plastic surgery.
- Brown’s California medical license was revoked in 1977 for gross negligence, incompetence, moral turpitude and other violations.
- In 1990 Brown was arrested for operating without a license and served 19 months in prison.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138490Sat, 05 Sep 2026 23:00:02 +0000Creator at ObomediaThe Surgeon Who Amputated a Stranger's Life: John R. Brown A seventy-nine-year-old man had his perfectly functional left leg removed in Tijuana twelve hours before he was found dead in a motel room-by a surgeon who had been operating without a...
A seventy-nine-year-old man had his perfectly functional left leg removed in Tijuana twelve hours before he was found dead in a motel room-by a surgeon who had been operating without a valid license for decades. What drives someone with Body Integrity Identity Disorder to seek an illegal amputation, and how did John Ronald Brown keep practicing despite revocations, arrests and warnings?

In this episode, we tell the story of Philip Bondy, Gregg Furth, and John Ronald Brown, covering Bondy’s decades-long struggle with Body Integrity Identity Disorder, the journey to a clinic across the border, and Brown’s history of revoked licenses, prison time, and unlicensed surgeries. How did a once-credentialed doctor end up operating in motel rooms, garages and Tijuana clinics, and what led to Bondy’s death?

Person: Philip Bondy
Person: Gregg Furth
Person: John Ronald Brown
Date: May 10, 1998
Event: Amputation in Tijuana followed by death twelve hours later

- Philip Bondy was found dead at age 79 in a motel room in National City, California.
- The left leg amputated by Brown was described as perfectly functional before surgery.
- John Ronald Brown graduated from University of Utah School of Medicine in 1947 and later failed the oral board for plastic surgery.
- Brown’s California medical license was revoked in 1977 for gross negligence, incompetence, moral turpitude and other violations.
- In 1990 Brown was arrested for operating without a license and served 19 months in prison.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1247falsefullhttps://www.spreaker.com/episode/the-surgeon-without-a-license-who-amputated-a-stranger-s-life--73138489
Desperation pushed a 79-year-old retired engineer across an international border to a man whose medical license had been revoked for gross negligence and moral turpitude-yet this unlicensed surgeon claimed to have performed roughly 600 gender-affirming operations and kept cutting anyway. How did a physician stripped of his license, convicted of practicing without one, come to amputate a stranger’s leg and leave him dead less than 24 hours later?

In this episode, we trace the events that led a man with body integrity identity disorder to seek an illegal amputation in Tijuana, the history of John Ronald Brown’s revoked career, and the single operation that ended in a death and a criminal prosecution. What failed in the hours after the surgery, and how did Brown continue operating despite multiple bans?

Person: John Ronald Brown
Person: Philip Bondy
Date: May 9-10, 1998
Location: Tijuana, Mexico; National City hotel room, California
Status: Death and subsequent murder prosecution

- Brown was born July 4, 1922, and earned his medical degree in 1947 from the University of Utah School of Medicine.
- The California Medical Board revoked Brown’s license in 1977 for charges including gross negligence, incompetence, and submitting false insurance claims.
- Brown claimed to have completed roughly 600 gender-affirming surgeries while mainstream programs approved far fewer applicants (Johns Hopkins approved 24 out of 2,000 applicants).
- In 1990 Brown was arrested for performing surgery without a license and served 19 months in jail before briefly working as a taxi driver and returning to surgery.
- Philip Bondy, age 79, had body integrity identity disorder and underwent leg amputation by Brown on May 9, 1998; he was found dead in a hotel room less than 24 hours later.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138489Fri, 04 Sep 2026 23:00:02 +0000Creator at ObomediaThe Surgeon Without a License Who Amputated a Stranger's Life Desperation pushed a 79-year-old retired engineer across an international border to a man whose medical license had been revoked for gross negligence and moral turpitude-yet this...
Desperation pushed a 79-year-old retired engineer across an international border to a man whose medical license had been revoked for gross negligence and moral turpitude-yet this unlicensed surgeon claimed to have performed roughly 600 gender-affirming operations and kept cutting anyway. How did a physician stripped of his license, convicted of practicing without one, come to amputate a stranger’s leg and leave him dead less than 24 hours later?

In this episode, we trace the events that led a man with body integrity identity disorder to seek an illegal amputation in Tijuana, the history of John Ronald Brown’s revoked career, and the single operation that ended in a death and a criminal prosecution. What failed in the hours after the surgery, and how did Brown continue operating despite multiple bans?

Person: John Ronald Brown
Person: Philip Bondy
Date: May 9-10, 1998
Location: Tijuana, Mexico; National City hotel room, California
Status: Death and subsequent murder prosecution

- Brown was born July 4, 1922, and earned his medical degree in 1947 from the University of Utah School of Medicine.
- The California Medical Board revoked Brown’s license in 1977 for charges including gross negligence, incompetence, and submitting false insurance claims.
- Brown claimed to have completed roughly 600 gender-affirming surgeries while mainstream programs approved far fewer applicants (Johns Hopkins approved 24 out of 2,000 applicants).
- In 1990 Brown was arrested for performing surgery without a license and served 19 months in jail before briefly working as a taxi driver and returning to surgery.
- Philip Bondy, age 79, had body integrity identity disorder and underwent leg amputation by Brown on May 9, 1998; he was found dead in a hotel room less than 24 hours later.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1305falsefullhttps://www.spreaker.com/episode/the-surgeon-who-cut-a-healthy-leg-off-a-deadly-compulsion--73138487
A retired engineer paid to have his anatomically normal left leg removed and died after a surgeon with a 1947 medical degree but no valid U.S. license operated in a Tijuana clinic; how did a procedure that a pathologist later called entirely preventable end in death? What responsibility did the surgeon owe to a patient who asked for amputation decades before medicine had a name for the condition?

In this episode, we tell the documented record of Philip Bondy’s trip to Tijuana, the life and practice of John Ronald Brown, and the legal and ethical aftermath that followed Bondy’s death - could access, desperation, and a surgeon’s history explain how this could happen?

Person: Philip Bondy
Date: May 10, 1998
Person: John Ronald Brown
Degree: Doctor of Medicine, University of Utah School of Medicine, 1947
Event: Amputation in Tijuana resulting in patient death

- Bondy was 79 years old when he crossed into Tijuana to have his left leg amputated.
- The left leg was anatomically normal and caused Bondy no physical pain the day before surgery.
- Brown was 75 years old in spring 1998 and earned his MD in 1947.
- Brown’s California medical license was revoked in 1977 for gross negligence, demonstrated incompetence, moral turpitude, involvement in a patient's death, and related charges.
- Johns Hopkins Gender Identity Clinic approved 24 patients out of the first 2,000 applicants during the same period.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138487Thu, 03 Sep 2026 23:00:02 +0000Creator at ObomediaThe Surgeon Who Cut a Healthy Leg Off - A Deadly Compulsion A retired engineer paid to have his anatomically normal left leg removed and died after a surgeon with a 1947 medical degree but no valid U.S. license operated in a Tijuana clinic; how did...
A retired engineer paid to have his anatomically normal left leg removed and died after a surgeon with a 1947 medical degree but no valid U.S. license operated in a Tijuana clinic; how did a procedure that a pathologist later called entirely preventable end in death? What responsibility did the surgeon owe to a patient who asked for amputation decades before medicine had a name for the condition?

In this episode, we tell the documented record of Philip Bondy’s trip to Tijuana, the life and practice of John Ronald Brown, and the legal and ethical aftermath that followed Bondy’s death - could access, desperation, and a surgeon’s history explain how this could happen?

Person: Philip Bondy
Date: May 10, 1998
Person: John Ronald Brown
Degree: Doctor of Medicine, University of Utah School of Medicine, 1947
Event: Amputation in Tijuana resulting in patient death

- Bondy was 79 years old when he crossed into Tijuana to have his left leg amputated.
- The left leg was anatomically normal and caused Bondy no physical pain the day before surgery.
- Brown was 75 years old in spring 1998 and earned his MD in 1947.
- Brown’s California medical license was revoked in 1977 for gross negligence, demonstrated incompetence, moral turpitude, involvement in a patient's death, and related charges.
- Johns Hopkins Gender Identity Clinic approved 24 patients out of the first 2,000 applicants during the same period.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1375falsefullhttps://www.spreaker.com/episode/the-doctor-with-bumblebees-how-a-community-missed-the-warning-signs--73138485
A children's pediatric office with carnival rides, Buzz Lightyear and bumblebee-painted Beetles hid thirteen hours of recorded evidence and a paper trail of ignored reports for fifteen years - so how did seven thousand families and multiple institutions fail to stop him? What exactly was recorded, and why were repeated warnings absorbed rather than acted on?

In this episode, we lay out the timeline and records surrounding Dr. Earl Brian Brian’s practice, the sealed complaints, the internal reports, and the December 2009 arrest that finally forced the hidden evidence into view. What does the case reveal about the gaps between complaint and consequence?

Person: Earl Brian Brian
Date: Arrest December 16, 2009
Location: Lewes, Delaware
Period: 1994-2009
Case: Approximately seven thousand pediatric patients

- Brian was born May 10, 1953, in Philadelphia, Pennsylvania.
- He earned his medical degree from Temple University School of Medicine in 1983 and completed pediatric residency in 1986.
- In 1994 and 1995 Thomas Jefferson University Hospital had sealed sexual misconduct complaints against Brian.
- By 2009 Brian had treated roughly seven thousand pediatric patients at BayBees Pediatrics with bumblebee-painted Volkswagen Beetles and a full-size Buzz Lightyear in the office.
- On December 16, 2009, Brian was arrested on nine counts including felony fourth-degree rape with bail set at $2.9 million cash.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138485Wed, 02 Sep 2026 23:00:02 +0000Creator at ObomediaThe Doctor with Bumblebees: How a Community Missed the Warning Signs A children's pediatric office with carnival rides, Buzz Lightyear and bumblebee-painted Beetles hid thirteen hours of recorded evidence and a paper trail of ignored reports for...
A children's pediatric office with carnival rides, Buzz Lightyear and bumblebee-painted Beetles hid thirteen hours of recorded evidence and a paper trail of ignored reports for fifteen years - so how did seven thousand families and multiple institutions fail to stop him? What exactly was recorded, and why were repeated warnings absorbed rather than acted on?

In this episode, we lay out the timeline and records surrounding Dr. Earl Brian Brian’s practice, the sealed complaints, the internal reports, and the December 2009 arrest that finally forced the hidden evidence into view. What does the case reveal about the gaps between complaint and consequence?

Person: Earl Brian Brian
Date: Arrest December 16, 2009
Location: Lewes, Delaware
Period: 1994-2009
Case: Approximately seven thousand pediatric patients

- Brian was born May 10, 1953, in Philadelphia, Pennsylvania.
- He earned his medical degree from Temple University School of Medicine in 1983 and completed pediatric residency in 1986.
- In 1994 and 1995 Thomas Jefferson University Hospital had sealed sexual misconduct complaints against Brian.
- By 2009 Brian had treated roughly seven thousand pediatric patients at BayBees Pediatrics with bumblebee-painted Volkswagen Beetles and a full-size Buzz Lightyear in the office.
- On December 16, 2009, Brian was arrested on nine counts including felony fourth-degree rape with bail set at $2.9 million cash.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1298falsefullhttps://www.spreaker.com/episode/the-doctor-who-built-a-playground-to-hide-a-monster--73138484
Children trusted a waiting room with a Buzz Lightyear statue, Volkswagen Beetles painted like bumblebees, and a tiny movie theater-yet that same space concealed years of warnings ignored by institutions. How did a pediatrician who treated an estimated seven thousand children keep practicing for fifteen years after repeated complaints?

In this episode, we tell the story of Earl Brian Brian and the sequence of reports, sealed investigations, and unacted-upon warnings that allowed him to continue seeing patients; what happened between the first report and the arrest, and why the system failed to stop him?

Person: Earl Brian Brian
Date: October 10, 2011
Location: Lewes, Delaware
Period: 1995-2011
Case: Pediatric abuse allegations

- Brian was sentenced to fourteen consecutive life terms plus 165 additional years.
- He treated an estimated 7,000 pediatric patients over his career.
- BayBees Pediatrics featured two Volkswagen Beetles painted like bumblebees and a Buzz Lightyear statue in the waiting room.
- Complaints were raised in 1994 and 1995 at Thomas Jefferson University Hospital; records from those investigations were sealed.
- In 2005, Milford police sought an arrest warrant but the Delaware Attorney General's office found the evidence insufficient for prosecution.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138484Tue, 01 Sep 2026 23:00:02 +0000Creator at ObomediaThe Doctor Who Built a Playground to Hide a Monster Children trusted a waiting room with a Buzz Lightyear statue, Volkswagen Beetles painted like bumblebees, and a tiny movie theater-yet that same space concealed years of warnings ignored by...
Children trusted a waiting room with a Buzz Lightyear statue, Volkswagen Beetles painted like bumblebees, and a tiny movie theater-yet that same space concealed years of warnings ignored by institutions. How did a pediatrician who treated an estimated seven thousand children keep practicing for fifteen years after repeated complaints?

In this episode, we tell the story of Earl Brian Brian and the sequence of reports, sealed investigations, and unacted-upon warnings that allowed him to continue seeing patients; what happened between the first report and the arrest, and why the system failed to stop him?

Person: Earl Brian Brian
Date: October 10, 2011
Location: Lewes, Delaware
Period: 1995-2011
Case: Pediatric abuse allegations

- Brian was sentenced to fourteen consecutive life terms plus 165 additional years.
- He treated an estimated 7,000 pediatric patients over his career.
- BayBees Pediatrics featured two Volkswagen Beetles painted like bumblebees and a Buzz Lightyear statue in the waiting room.
- Complaints were raised in 1994 and 1995 at Thomas Jefferson University Hospital; records from those investigations were sealed.
- In 2005, Milford police sought an arrest warrant but the Delaware Attorney General's office found the evidence insufficient for prosecution.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1270falsefullhttps://www.spreaker.com/episode/the-pediatrician-next-door-how-7-000-children-trusted-a-monster--73138483
Trust can be built with rides, movies, and a friendly statue - and it can hide horror. A pediatrician who drove bumblebee cars and staffed a waiting room with carnival rides is estimated to have seen about 7,000 children over two decades; what investigators found were more than thirteen hours of recordings showing infants and toddlers in distress. How could so many warnings be ignored and such a practice continue for so long?

In this episode, we tell the story of Earl Bradley and the sequence of events, complaints, and institutional responses that let him remain in practice until his arrest. We trace his career from medical school to the cheerful BayBees Pediatrics waiting room and ask how documented complaints and investigations failed to stop him.

Person: Earl Bradley
Event: Arrest on December 16, 2009
Location: Lewes, Delaware
Period: Career spanning roughly two decades
Evidence: More than thirteen hours of recorded footage

- Bradley was born on May 10, 1953, and earned his medical degree from Temple University School of Medicine in 1983.
- Investigators estimated Bradley saw approximately 7,000 pediatric patients over his career.
- Complaints were filed in 1994 and 1995 in Philadelphia, including a 1994 investigation by Thomas Jefferson Hospital.
- In 2004, Bradley’s sister Lynda Barnes, his office manager, reported parental complaints and other concerns to the state medical society.
- Upon arrest investigators seized organized recordings totaling over thirteen hours showing children in diapers, children screaming, and children appearing to lose consciousness.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138483Mon, 31 Aug 2026 23:00:02 +0000Creator at ObomediaThe Pediatrician Next Door: How 7,000 Children Trusted a Monster Trust can be built with rides, movies, and a friendly statue - and it can hide horror. A pediatrician who drove bumblebee cars and staffed a waiting room with carnival rides is...
Trust can be built with rides, movies, and a friendly statue - and it can hide horror. A pediatrician who drove bumblebee cars and staffed a waiting room with carnival rides is estimated to have seen about 7,000 children over two decades; what investigators found were more than thirteen hours of recordings showing infants and toddlers in distress. How could so many warnings be ignored and such a practice continue for so long?

In this episode, we tell the story of Earl Bradley and the sequence of events, complaints, and institutional responses that let him remain in practice until his arrest. We trace his career from medical school to the cheerful BayBees Pediatrics waiting room and ask how documented complaints and investigations failed to stop him.

Person: Earl Bradley
Event: Arrest on December 16, 2009
Location: Lewes, Delaware
Period: Career spanning roughly two decades
Evidence: More than thirteen hours of recorded footage

- Bradley was born on May 10, 1953, and earned his medical degree from Temple University School of Medicine in 1983.
- Investigators estimated Bradley saw approximately 7,000 pediatric patients over his career.
- Complaints were filed in 1994 and 1995 in Philadelphia, including a 1994 investigation by Thomas Jefferson Hospital.
- In 2004, Bradley’s sister Lynda Barnes, his office manager, reported parental complaints and other concerns to the state medical society.
- Upon arrest investigators seized organized recordings totaling over thirteen hours showing children in diapers, children screaming, and children appearing to lose consciousness.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1254falsefullhttps://www.spreaker.com/episode/he-built-a-playground-for-predators-the-baybees-doctor-revealed--73138482
Trust turned to horror: a pediatric office with a Buzz Lightyear statue, a Disney theatre, carnival rides and two yellow-and-black bumblebee Volkswagens welcomed families - while investigators later found more than thirteen hours of recorded sexual assault in the home and office of a licensed pediatrician. How did warnings across fifteen years, from a sister, nurses and other physicians, fail to stop him until a two-year-old's complaint finally broke the case?

In this episode, we tell the sequence of events in straightforward terms: the career path, the early complaints, the moves between Pennsylvania and Delaware, and the December 16, 2009 search that uncovered the recordings - and we follow the question that opened the investigation: why were decades of warnings ignored until that single complaint?

Person: Earl Brian Bradley
Date: December 16, 2009
Location: Lewes, Delaware
Period: 1983-2009
Case: BayBees Pediatrics recordings

- 7,000 children passed through BayBees Pediatrics.
- 103 children have been identified as victims.
- The youngest identified victim was three months old.
- Bradley was born May 10, 1953, in Philadelphia, Pennsylvania.
- Investigators found more than thirteen hours of recorded sexual assault in his home and office.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138482Sun, 30 Aug 2026 23:00:02 +0000Creator at ObomediaHe Built a Playground for Predators: The BayBees Doctor Revealed Trust turned to horror: a pediatric office with a Buzz Lightyear statue, a Disney theatre, carnival rides and two yellow-and-black bumblebee Volkswagens welcomed families - while...
Trust turned to horror: a pediatric office with a Buzz Lightyear statue, a Disney theatre, carnival rides and two yellow-and-black bumblebee Volkswagens welcomed families - while investigators later found more than thirteen hours of recorded sexual assault in the home and office of a licensed pediatrician. How did warnings across fifteen years, from a sister, nurses and other physicians, fail to stop him until a two-year-old's complaint finally broke the case?

In this episode, we tell the sequence of events in straightforward terms: the career path, the early complaints, the moves between Pennsylvania and Delaware, and the December 16, 2009 search that uncovered the recordings - and we follow the question that opened the investigation: why were decades of warnings ignored until that single complaint?

Person: Earl Brian Bradley
Date: December 16, 2009
Location: Lewes, Delaware
Period: 1983-2009
Case: BayBees Pediatrics recordings

- 7,000 children passed through BayBees Pediatrics.
- 103 children have been identified as victims.
- The youngest identified victim was three months old.
- Bradley was born May 10, 1953, in Philadelphia, Pennsylvania.
- Investigators found more than thirteen hours of recorded sexual assault in his home and office.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1347falsefullhttps://www.spreaker.com/episode/the-pediatrician-who-stole-childhood-hidden-videos-7-000-patients--73138481
A chill of betrayal: a beloved pediatrician with carnival rides, a Buzz Lightyear at the door, and roughly 7,000 children as patients-yet complaints, sealed records, and missed chances allowed him to keep practicing for decades; what was on the thirteen-plus hours of video that finally forced Delaware to confront its failures?

In this episode, we lay out the timeline and evidence uncovered about a physician whose reputation masked repeated allegations and sealed hospital complaints, and we follow how a single family’s report in 2008 eventually led to prosecutors discovering hours of recordings-what finally changed and why earlier interventions failed?

Person: Earl Brian Bradley
Date of birth: May 10, 1953
Education: Temple University MD (1983); Pediatrics residency Thomas Jefferson University Hospital (1986)
Estimated patients: 7,000 children
Discovery: December 2009 - over 13 hours of video recordings found

- In 1994 a parent reported an incident at a Philadelphia hospital and the hospital sealed the records with no charges filed.
- Bradley closed his Philadelphia practice after a second complaint in 1995 and relocated to Lewes, Delaware, where he opened BayBees Pediatrics.
- In 2004 his sister, Lynda Barnes, reported inappropriate touching, alleged abuse of his son, and theft of antidepressants to the Delaware state medical society.
- In 2005 a nurse reported observing Bradley videotaping children and other physicians reported unnecessary vaginal examinations; Milford Police sought an arrest warrant but prosecutors found evidence insufficient.
- Investigators in December 2009 found more than 13 hours of video recordings at Bradley’s office and home, triggering the largest child abuse prosecution in Delaware history.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138481Sat, 29 Aug 2026 23:00:02 +0000Creator at ObomediaThe Pediatrician Who Stole Childhood: Hidden Videos, 7,000 Patients A chill of betrayal: a beloved pediatrician with carnival rides, a Buzz Lightyear at the door, and roughly 7,000 children as patients-yet complaints, sealed records, and missed...
A chill of betrayal: a beloved pediatrician with carnival rides, a Buzz Lightyear at the door, and roughly 7,000 children as patients-yet complaints, sealed records, and missed chances allowed him to keep practicing for decades; what was on the thirteen-plus hours of video that finally forced Delaware to confront its failures?

In this episode, we lay out the timeline and evidence uncovered about a physician whose reputation masked repeated allegations and sealed hospital complaints, and we follow how a single family’s report in 2008 eventually led to prosecutors discovering hours of recordings-what finally changed and why earlier interventions failed?

Person: Earl Brian Bradley
Date of birth: May 10, 1953
Education: Temple University MD (1983); Pediatrics residency Thomas Jefferson University Hospital (1986)
Estimated patients: 7,000 children
Discovery: December 2009 - over 13 hours of video recordings found

- In 1994 a parent reported an incident at a Philadelphia hospital and the hospital sealed the records with no charges filed.
- Bradley closed his Philadelphia practice after a second complaint in 1995 and relocated to Lewes, Delaware, where he opened BayBees Pediatrics.
- In 2004 his sister, Lynda Barnes, reported inappropriate touching, alleged abuse of his son, and theft of antidepressants to the Delaware state medical society.
- In 2005 a nurse reported observing Bradley videotaping children and other physicians reported unnecessary vaginal examinations; Milford Police sought an arrest warrant but prosecutors found evidence insufficient.
- Investigators in December 2009 found more than 13 hours of video recordings at Bradley’s office and home, triggering the largest child abuse prosecution in Delaware history.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1355falsefullhttps://www.spreaker.com/episode/the-pediatrician-with-carnival-rides-how-warnings-were-ignored--73138480
The image is almost unbearable: a pediatric office with carnival rides, a Buzz Lightyear statue, and Volkswagen Beetles painted like bumblebees-an environment designed to lower resistance while investigators later found more than thirteen hours of recordings of children as young as three months old. How did fifteen years of complaints, including reports from his sister and office staff, fail to stop him?

In this episode, we tell the sequence of events that led parents in coastal Delaware to trust Dr. Earl Brian Bradley, what professionals and institutions knew and reported over fifteen years, and how those warnings were handled before the case that finally triggered arrest-what breakdowns allowed him to keep practicing?

Person: Earl Brian Bradley
Date of birth: May 10, 1953
Location: Lewes, Delaware
Period: mid-1990s to 2009
Event: Arrest on December 16, 2009

- Bradley earned his medical degree from Temple University in 1983 and completed pediatrics residency in 1986.
- An investigation into sexual misconduct began at Thomas Jefferson University Hospital in 1994, followed by a second allegation in 1995.
- In 2004 his sister Lynda Barnes reported parents' complaints and alleged he was stealing antidepressants and abusing his son to the Delaware state medical society.
- In 2005 a nurse reported Bradley videotaping children and other physicians raised concerns about unnecessary vaginal examinations on young patients.
- Bradley was arrested on December 16, 2009 on nine counts including fourth-degree rape; bail was set at $2,900,000 cash.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138480Fri, 28 Aug 2026 23:00:02 +0000Creator at ObomediaThe Pediatrician with Carnival Rides: How Warnings Were Ignored The image is almost unbearable: a pediatric office with carnival rides, a Buzz Lightyear statue, and Volkswagen Beetles painted like bumblebees-an environment designed to lower...
The image is almost unbearable: a pediatric office with carnival rides, a Buzz Lightyear statue, and Volkswagen Beetles painted like bumblebees-an environment designed to lower resistance while investigators later found more than thirteen hours of recordings of children as young as three months old. How did fifteen years of complaints, including reports from his sister and office staff, fail to stop him?

In this episode, we tell the sequence of events that led parents in coastal Delaware to trust Dr. Earl Brian Bradley, what professionals and institutions knew and reported over fifteen years, and how those warnings were handled before the case that finally triggered arrest-what breakdowns allowed him to keep practicing?

Person: Earl Brian Bradley
Date of birth: May 10, 1953
Location: Lewes, Delaware
Period: mid-1990s to 2009
Event: Arrest on December 16, 2009

- Bradley earned his medical degree from Temple University in 1983 and completed pediatrics residency in 1986.
- An investigation into sexual misconduct began at Thomas Jefferson University Hospital in 1994, followed by a second allegation in 1995.
- In 2004 his sister Lynda Barnes reported parents' complaints and alleged he was stealing antidepressants and abusing his son to the Delaware state medical society.
- In 2005 a nurse reported Bradley videotaping children and other physicians raised concerns about unnecessary vaginal examinations on young patients.
- Bradley was arrested on December 16, 2009 on nine counts including fourth-degree rape; bail was set at $2,900,000 cash.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1166falsefullhttps://www.spreaker.com/episode/the-heart-drug-that-silenced-an-olympic-shooter-and-the-world--73138479
Fear enters quietly: a heart drug patented in 1962 and approved in 1964 went from saving lives to silencing hands, voices and medals when it crossed into the brain. Propranolol was designed to block cardiac beta receptors - but by reaching brain concentrations up to 33:1 versus blood, it muted the physical symptoms of fear; how did a drug meant for coronaries end up on an Olympic shooting range and in the spotlight?

In this episode, we tell the story of propranolol from its invention to its unintended effects beyond cardiology, outlining the science, the decades of medical use, and the moment its reach became a contested moral question: what does it mean when a cardiac drug suppresses fear itself?

Person: James W. Black
Date: 1962 (patent) and 1964 (approval)
Brand: Inderal
Mechanism: non-cardioselective competitive beta-adrenergic blocker
Brain:blood ratio: up to 33:1 for propranolol (vs ~0.2:1 for atenolol)

- Propranolol was patented in 1962 and approved for medical use in 1964 under the brand name Inderal.
- The drug is non-cardioselective, blocking both beta-1 receptors in the heart and beta-2 receptors elsewhere.
- Propranolol’s lipophilicity produced brain:blood ratios reported as high as 15:1 and sometimes 33:1.
- Atenolol, a later beta blocker, reaches the brain at a ratio of roughly 0.2:1 compared to blood levels.
- Propranolol’s central effects suppress the cascade from adenylate cyclase to cyclic AMP to protein kinase A, reducing calcium influx and dampening physical symptoms of fear.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138479Thu, 27 Aug 2026 23:00:02 +0000Creator at ObomediaThe Heart Drug That Silenced an Olympic Shooter - and the World Fear enters quietly: a heart drug patented in 1962 and approved in 1964 went from saving lives to silencing hands, voices and medals when it crossed into the brain. Propranolol was...
Fear enters quietly: a heart drug patented in 1962 and approved in 1964 went from saving lives to silencing hands, voices and medals when it crossed into the brain. Propranolol was designed to block cardiac beta receptors - but by reaching brain concentrations up to 33:1 versus blood, it muted the physical symptoms of fear; how did a drug meant for coronaries end up on an Olympic shooting range and in the spotlight?

In this episode, we tell the story of propranolol from its invention to its unintended effects beyond cardiology, outlining the science, the decades of medical use, and the moment its reach became a contested moral question: what does it mean when a cardiac drug suppresses fear itself?

Person: James W. Black
Date: 1962 (patent) and 1964 (approval)
Brand: Inderal
Mechanism: non-cardioselective competitive beta-adrenergic blocker
Brain:blood ratio: up to 33:1 for propranolol (vs ~0.2:1 for atenolol)

- Propranolol was patented in 1962 and approved for medical use in 1964 under the brand name Inderal.
- The drug is non-cardioselective, blocking both beta-1 receptors in the heart and beta-2 receptors elsewhere.
- Propranolol’s lipophilicity produced brain:blood ratios reported as high as 15:1 and sometimes 33:1.
- Atenolol, a later beta blocker, reaches the brain at a ratio of roughly 0.2:1 compared to blood levels.
- Propranolol’s central effects suppress the cascade from adenylate cyclase to cyclic AMP to protein kinase A, reducing calcium influx and dampening physical symptoms of fear.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1444falsefullhttps://www.spreaker.com/episode/the-heart-pill-that-calmed-hands-minds-and-rewrote-medicine--73138478
A drug invented to stop a racing heart quietly crossed into the mind: by 2023 propranolol was prescribed over nine million times in the U.S., and its brain concentration can be 15-to-1 or even 33-to-1 compared with blood plasma - so how did a cardiac pill end up costing an Olympic shooter his medals and changing how musicians, memory researchers, and doctors think about treatment and enhancement?

In this episode, we trace the path of propranolol from James W. Black's lab at Imperial Chemical Industries to the 2008 Beijing Olympics, and through concert halls and memory labs, asking how a non-selective beta blocker meant for the heart became a drug that alters performance, emotion, and recollection.

Person: James W. Black
Date: 1964 (medical approval), 1962 (patent filed)
Event: 2008 Beijing Olympics drug test disqualification of a North Korean pistol shooter
Topic: propranolol crossing the blood-brain barrier and its off-target effects
Statistic: 2023 U.S. prescriptions - more than 9 million

- Propranolol's patent was filed in 1962 and received medical approval in 1964.
- By 1965 propranolol was marketed under the brand name Inderal.
- Propranolol is non-selective, blocking both beta-1 and beta-2 receptors.
- Brain-to-plasma concentration ratios for propranolol range from 15:1 up to 33:1.
- A 1987 survey found 27% of surveyed professional musicians had used beta blockers before performances.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138478Wed, 26 Aug 2026 23:00:02 +0000Creator at ObomediaThe Heart Pill That Calmed Hands, Minds - And Rewrote Medicine A drug invented to stop a racing heart quietly crossed into the mind: by 2023 propranolol was prescribed over nine million times in the U.S., and its brain concentration can be 15-to-1...
A drug invented to stop a racing heart quietly crossed into the mind: by 2023 propranolol was prescribed over nine million times in the U.S., and its brain concentration can be 15-to-1 or even 33-to-1 compared with blood plasma - so how did a cardiac pill end up costing an Olympic shooter his medals and changing how musicians, memory researchers, and doctors think about treatment and enhancement?

In this episode, we trace the path of propranolol from James W. Black's lab at Imperial Chemical Industries to the 2008 Beijing Olympics, and through concert halls and memory labs, asking how a non-selective beta blocker meant for the heart became a drug that alters performance, emotion, and recollection.

Person: James W. Black
Date: 1964 (medical approval), 1962 (patent filed)
Event: 2008 Beijing Olympics drug test disqualification of a North Korean pistol shooter
Topic: propranolol crossing the blood-brain barrier and its off-target effects
Statistic: 2023 U.S. prescriptions - more than 9 million

- Propranolol's patent was filed in 1962 and received medical approval in 1964.
- By 1965 propranolol was marketed under the brand name Inderal.
- Propranolol is non-selective, blocking both beta-1 and beta-2 receptors.
- Brain-to-plasma concentration ratios for propranolol range from 15:1 up to 33:1.
- A 1987 survey found 27% of surveyed professional musicians had used beta blockers before performances.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1348falsefullhttps://www.spreaker.com/episode/the-little-white-pill-that-rewrote-memory-and-modern-medicine--73138477
Fear and fascination meet in a single molecule: a cardiac drug introduced in 1964 that reaches concentrations up to 33 times higher in the brain than in blood and was prescribed nine million times in the U.S. in 2023 - but what happens when a medicine meant for failing hearts begins to soften human memory and show up in concert halls and Olympic urine samples?

In this episode, we trace the path of propranolol from its origins in a Scottish lab and an English pharmaceutical patent to its routine use by performers and patients, and ask how a lipid‑soluble beta blocker that crosses the blood‑brain barrier changed medicine, memory, and ethics.

Person: James W. Black
Date: 1964
Location: Alderley Park, Cheshire, England
Topic: Propranolol crossing the blood‑brain barrier and its uses
Status: Nine million prescriptions in the United States in 2023

- Patent filed by ICI Pharmaceuticals in 1962 and product on market as Inderal by 1964-1965.
- Brain-to-blood concentration ratio for propranolol ranges between 15:1 and 33:1.
- Onset of action when taken orally begins within 30 minutes and peaks between 60 and 90 minutes.
- Half-life of propranolol ranges from 2.8 to 8 hours; toxicity begins at ~1 mg/L plasma concentration.
- A 1987 survey found 27% of symphony and opera musicians reported using beta blockers before performances.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138477Tue, 25 Aug 2026 23:00:02 +0000Creator at ObomediaThe Little White Pill That Rewrote Memory and Modern Medicine Fear and fascination meet in a single molecule: a cardiac drug introduced in 1964 that reaches concentrations up to 33 times higher in the brain than in blood and was prescribed nine...
Fear and fascination meet in a single molecule: a cardiac drug introduced in 1964 that reaches concentrations up to 33 times higher in the brain than in blood and was prescribed nine million times in the U.S. in 2023 - but what happens when a medicine meant for failing hearts begins to soften human memory and show up in concert halls and Olympic urine samples?

In this episode, we trace the path of propranolol from its origins in a Scottish lab and an English pharmaceutical patent to its routine use by performers and patients, and ask how a lipid‑soluble beta blocker that crosses the blood‑brain barrier changed medicine, memory, and ethics.

Person: James W. Black
Date: 1964
Location: Alderley Park, Cheshire, England
Topic: Propranolol crossing the blood‑brain barrier and its uses
Status: Nine million prescriptions in the United States in 2023

- Patent filed by ICI Pharmaceuticals in 1962 and product on market as Inderal by 1964-1965.
- Brain-to-blood concentration ratio for propranolol ranges between 15:1 and 33:1.
- Onset of action when taken orally begins within 30 minutes and peaks between 60 and 90 minutes.
- Half-life of propranolol ranges from 2.8 to 8 hours; toxicity begins at ~1 mg/L plasma concentration.
- A 1987 survey found 27% of symphony and opera musicians reported using beta blockers before performances.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1450falsefullhttps://www.spreaker.com/episode/the-heart-drug-that-secretly-floods-the-brain-and-why-it-matters--73138475
A single heart medication can reach up to 33 times higher concentration in brain tissue than in blood, while its therapeutic blood range is 0.02-0.3 mg/L and toxicity begins at 1 mg/L-so why did a drug intended for the heart become a tool for quieting fear, performance nerves, and traumatic memories? What happens when a compound meant to save lives is simultaneously concentrated in the mind?

In this episode, we tell the scientific and social journey of propranolol from its invention at Alderley Park to its widespread use beyond cardiology, and we follow the surprising consequences that arise when a heart drug accumulates in the brain-could that accumulation explain its adoption by musicians, athletes, and therapists?

Person: James W. Black
Location: Alderley Park
Date: patented 1962, approved 1964, marketed 1965
Topic: propranolol distribution between blood and brain
Event: 27% of professional orchestral musicians used beta blockers before performances

- Propranolol can concentrate in brain tissue up to 33 times the concentration found in blood.
- Therapeutic blood concentration range is 0.02-0.3 mg per liter; toxicity starts at 1 mg per liter.
- Documented coma and death have occurred at blood concentrations between 4 and 10 mg per liter.
- Individual metabolism of propranolol can vary by a factor of 20 between people taking identical doses.
- Nine million prescriptions for propranolol were filled in the United States in 2023.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138475Mon, 24 Aug 2026 23:00:02 +0000Creator at ObomediaThe Heart Drug That Secretly Floods the Brain-And Why It Matters A single heart medication can reach up to 33 times higher concentration in brain tissue than in blood, while its therapeutic blood range is 0.02-0.3 mg/L and toxicity begins at 1...
A single heart medication can reach up to 33 times higher concentration in brain tissue than in blood, while its therapeutic blood range is 0.02-0.3 mg/L and toxicity begins at 1 mg/L-so why did a drug intended for the heart become a tool for quieting fear, performance nerves, and traumatic memories? What happens when a compound meant to save lives is simultaneously concentrated in the mind?

In this episode, we tell the scientific and social journey of propranolol from its invention at Alderley Park to its widespread use beyond cardiology, and we follow the surprising consequences that arise when a heart drug accumulates in the brain-could that accumulation explain its adoption by musicians, athletes, and therapists?

Person: James W. Black
Location: Alderley Park
Date: patented 1962, approved 1964, marketed 1965
Topic: propranolol distribution between blood and brain
Event: 27% of professional orchestral musicians used beta blockers before performances

- Propranolol can concentrate in brain tissue up to 33 times the concentration found in blood.
- Therapeutic blood concentration range is 0.02-0.3 mg per liter; toxicity starts at 1 mg per liter.
- Documented coma and death have occurred at blood concentrations between 4 and 10 mg per liter.
- Individual metabolism of propranolol can vary by a factor of 20 between people taking identical doses.
- Nine million prescriptions for propranolol were filled in the United States in 2023.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1474falsefullhttps://www.spreaker.com/episode/the-heart-drug-that-steals-memories-how-propranolol-rewrote-fear--73138474
Propranolol, a heart tablet taken by silver-medalists and symphony musicians, concentrates in the brain at ratios reported between 15:1 and 33:1 - and that unexpected property may blunt the chemical stamp that makes traumatic memories persist. Could a pill originally meant to calm a failing heart actually erase the fear that defines who we are?

In this episode, we trace the story from a 1960s Scottish lab to Olympic controversy and concert halls, explaining how a drug designed by James W. Black to block adrenaline in the heart wound up altering norepinephrine signaling in the brain, and asking whether dampening that signal can change memories.

Person: James W. Black
Date: 1962 (patent filed)
Date: 1964 (medical approval)
Event: 2008 Olympic drug test positive (Kim Jong-su)
Topic: propranolol crossing blood-brain barrier

- The drug patent was filed in 1962 and received medical approval in 1964.
- Propranolol concentrates inside the brain at reported ratios of 15:1 up to 33:1 versus the bloodstream.
- A 1987 study found 27% of professional symphony and opera musicians used beta blockers before performances.
- Kim Jong-su tested positive for propranolol after the 2008 Beijing Olympics and lost two medals.
- James W. Black designed propranolol to act as a competitive antagonist at the beta-adrenergic receptor to protect failing hearts.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138474Sun, 23 Aug 2026 23:00:02 +0000Creator at ObomediaThe Heart Drug That Steals Memories: How Propranolol Rewrote Fear Propranolol, a heart tablet taken by silver-medalists and symphony musicians, concentrates in the brain at ratios reported between 15:1 and 33:1 - and that unexpected property may...
Propranolol, a heart tablet taken by silver-medalists and symphony musicians, concentrates in the brain at ratios reported between 15:1 and 33:1 - and that unexpected property may blunt the chemical stamp that makes traumatic memories persist. Could a pill originally meant to calm a failing heart actually erase the fear that defines who we are?

In this episode, we trace the story from a 1960s Scottish lab to Olympic controversy and concert halls, explaining how a drug designed by James W. Black to block adrenaline in the heart wound up altering norepinephrine signaling in the brain, and asking whether dampening that signal can change memories.

Person: James W. Black
Date: 1962 (patent filed)
Date: 1964 (medical approval)
Event: 2008 Olympic drug test positive (Kim Jong-su)
Topic: propranolol crossing blood-brain barrier

- The drug patent was filed in 1962 and received medical approval in 1964.
- Propranolol concentrates inside the brain at reported ratios of 15:1 up to 33:1 versus the bloodstream.
- A 1987 study found 27% of professional symphony and opera musicians used beta blockers before performances.
- Kim Jong-su tested positive for propranolol after the 2008 Beijing Olympics and lost two medals.
- James W. Black designed propranolol to act as a competitive antagonist at the beta-adrenergic receptor to protect failing hearts.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1186falsefullhttps://www.spreaker.com/episode/the-heart-pill-that-lived-inside-the-brain-for-decades--73138473
A single white pill, approved in 1964 to calm overworked hearts, concentrates in the brain at up to 33:1 versus the blood - a fact hidden in pharmacology data for decades. How did a heart drug come to live almost entirely in the mind, and what have clinicians and patients been unaware of all this time?

In this episode, we tell the history of propranolol from its design by James W. Black to its broad clinical use and surprising brain accumulation, asking how a molecule intended for the heart quietly became a neuroactive presence.

Person: James W. Black
Date: 1964
Brand: Inderal
Annual prescriptions (2023): more than 9,000,000
Brain-to-blood ratio: up to 33 to 1

- Patented in 1962 and approved for clinical use in 1964.
- Manufactured under the brand name Inderal and introduced in 1965.
- Oral bioavailability approximately 25% with peak plasma concentration about 2 hours after ingestion.
- Half-life ranges from 2.8 to 8 hours, extending up to 12 hours with a single high dose.
- Adverse effects reported at plasma levels ≥1 mg/L with coma and death associated with 4-10 mg/L.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138473Sat, 22 Aug 2026 23:00:02 +0000Creator at ObomediaThe Heart Pill That Lived Inside the Brain for Decades A single white pill, approved in 1964 to calm overworked hearts, concentrates in the brain at up to 33:1 versus the blood - a fact hidden in pharmacology data for decades. How did a heart drug...
A single white pill, approved in 1964 to calm overworked hearts, concentrates in the brain at up to 33:1 versus the blood - a fact hidden in pharmacology data for decades. How did a heart drug come to live almost entirely in the mind, and what have clinicians and patients been unaware of all this time?

In this episode, we tell the history of propranolol from its design by James W. Black to its broad clinical use and surprising brain accumulation, asking how a molecule intended for the heart quietly became a neuroactive presence.

Person: James W. Black
Date: 1964
Brand: Inderal
Annual prescriptions (2023): more than 9,000,000
Brain-to-blood ratio: up to 33 to 1

- Patented in 1962 and approved for clinical use in 1964.
- Manufactured under the brand name Inderal and introduced in 1965.
- Oral bioavailability approximately 25% with peak plasma concentration about 2 hours after ingestion.
- Half-life ranges from 2.8 to 8 hours, extending up to 12 hours with a single high dose.
- Adverse effects reported at plasma levels ≥1 mg/L with coma and death associated with 4-10 mg/L.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1319falsefullhttps://www.spreaker.com/episode/how-four-berlin-chemists-accidentally-invented-oral-progesterone--73138472
Danger and astonishment: a chemical miscalculation in Berlin in 1938 produced a drug swallowed by patients on six continents for more than six decades - but it was not the progesterone replacement doctors thought they had. How did a project to make oral testosterone become the world's first orally active progestogen, and what crucial limitation kept it from being the hormonal miracle it promised?

In this episode, we tell how four chemists at Schering AG synthesized ethisterone while pursuing an orally active testosterone and how that compound entered clinical use worldwide. We outline the chemistry, the initial marketing, and the pharmacological limits that defined ethisterone's role in medicine - and ask why its real effects were misunderstood for years.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Location: Berlin; Schering AG
Event: Synthesis of ethisterone (ethinyltestosterone, pregneninolone)
Product names: Proluton C (Germany, 1939); Pranone (United States, 1945)

- Ethisterone was synthesized in 1938 by four chemists at Schering AG in Berlin.
- Progesterone was first isolated in 1934 and could only be given by injection because it broke down orally.
- Ethisterone was orally active and became the first progestin introduced into clinical medicine, marketed in Germany in 1939 and the U.S. in 1945.
- The compound was sold under more than fifteen trade names and in tablets of 5, 10, and 25 mg and capsules up to 250 mg.
- To transform the endometrial lining, clinicians prescribed between 200 and 700 mg of ethisterone over 10-14 days, and common side effects included acne and hirsutism.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138472Fri, 21 Aug 2026 23:00:02 +0000Creator at ObomediaHow Four Berlin Chemists Accidentally Invented Oral Progesterone Danger and astonishment: a chemical miscalculation in Berlin in 1938 produced a drug swallowed by patients on six continents for more than six decades - but it was not the...
Danger and astonishment: a chemical miscalculation in Berlin in 1938 produced a drug swallowed by patients on six continents for more than six decades - but it was not the progesterone replacement doctors thought they had. How did a project to make oral testosterone become the world's first orally active progestogen, and what crucial limitation kept it from being the hormonal miracle it promised?

In this episode, we tell how four chemists at Schering AG synthesized ethisterone while pursuing an orally active testosterone and how that compound entered clinical use worldwide. We outline the chemistry, the initial marketing, and the pharmacological limits that defined ethisterone's role in medicine - and ask why its real effects were misunderstood for years.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Location: Berlin; Schering AG
Event: Synthesis of ethisterone (ethinyltestosterone, pregneninolone)
Product names: Proluton C (Germany, 1939); Pranone (United States, 1945)

- Ethisterone was synthesized in 1938 by four chemists at Schering AG in Berlin.
- Progesterone was first isolated in 1934 and could only be given by injection because it broke down orally.
- Ethisterone was orally active and became the first progestin introduced into clinical medicine, marketed in Germany in 1939 and the U.S. in 1945.
- The compound was sold under more than fifteen trade names and in tablets of 5, 10, and 25 mg and capsules up to 250 mg.
- To transform the endometrial lining, clinicians prescribed between 200 and 700 mg of ethisterone over 10-14 days, and common side effects included acne and hirsutism.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1202falsefullhttps://www.spreaker.com/episode/the-accidental-birth-of-oral-progestogens-how-ethisterone-changed-medicine--73138471
Oral progestogen therapy was impossible until a 1938 Berlin lab accidentally made a compound that could survive stomach acid: ethisterone - a molecule born from a failed attempt to make oral testosterone that nonetheless bound the progesterone receptor with about 44% of progesterone’s affinity. How did a tweak meant to protect a hormone from digestion create a drug that let women take progestogen at home, and what consequences did the molecule’s androgenic past carry?

In this episode, we tell the story of four chemists at Schering AG and the unexpected pathway from a synthesis aimed at testosterone to the first orally active progestogen, and we follow the drug’s journey into clinics and pharmacies - could the same modification that delivered oral therapy also embed lasting androgenic effects?

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938 (discovery); 1939 (Proluton C in Germany); 1945 (Pranone in US)
Location: Berlin, Schering AG laboratory
Topic: Synthesis of 17-alpha-ethynyltestosterone (ethisterone) and its clinical adoption
Dose: 25 mg tablet, up to four times a day; total 200-700 mg over 10-14 days for full endometrial treatment

- The chemists aimed to ethynylate testosterone at carbon 17 to survive stomach acid.
- The produced compound, 17-alpha-ethynyltestosterone (ethisterone), bound progesterone receptors with ~44% of progesterone’s affinity.
- Ethisterone reached market in Germany as Proluton C in 1939 and in the United States as Pranone in 1945.
- By later decades ethisterone appeared under at least 12 additional brand names across multiple countries.
- A typical oral regimen in 1940 used 25 mg tablets taken four times daily, totaling 200-700 mg across 10-14 days.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138471Thu, 20 Aug 2026 23:00:02 +0000Creator at ObomediaThe Accidental Birth of Oral Progestogens: How Ethisterone Changed Medicine Oral progestogen therapy was impossible until a 1938 Berlin lab accidentally made a compound that could survive stomach acid: ethisterone - a molecule born from a failed...
Oral progestogen therapy was impossible until a 1938 Berlin lab accidentally made a compound that could survive stomach acid: ethisterone - a molecule born from a failed attempt to make oral testosterone that nonetheless bound the progesterone receptor with about 44% of progesterone’s affinity. How did a tweak meant to protect a hormone from digestion create a drug that let women take progestogen at home, and what consequences did the molecule’s androgenic past carry?

In this episode, we tell the story of four chemists at Schering AG and the unexpected pathway from a synthesis aimed at testosterone to the first orally active progestogen, and we follow the drug’s journey into clinics and pharmacies - could the same modification that delivered oral therapy also embed lasting androgenic effects?

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938 (discovery); 1939 (Proluton C in Germany); 1945 (Pranone in US)
Location: Berlin, Schering AG laboratory
Topic: Synthesis of 17-alpha-ethynyltestosterone (ethisterone) and its clinical adoption
Dose: 25 mg tablet, up to four times a day; total 200-700 mg over 10-14 days for full endometrial treatment

- The chemists aimed to ethynylate testosterone at carbon 17 to survive stomach acid.
- The produced compound, 17-alpha-ethynyltestosterone (ethisterone), bound progesterone receptors with ~44% of progesterone’s affinity.
- Ethisterone reached market in Germany as Proluton C in 1939 and in the United States as Pranone in 1945.
- By later decades ethisterone appeared under at least 12 additional brand names across multiple countries.
- A typical oral regimen in 1940 used 25 mg tablets taken four times daily, totaling 200-700 mg across 10-14 days.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1407falsefullhttps://www.spreaker.com/episode/the-accidental-pill-how-a-mistake-created-oral-progestin-ethisterone--73138470
A single chemical tweak in a Berlin lab in 1938 turned a would-be oral testosterone into the first orally active progestin, a pill that let women skip injections and take progesterone-like therapy at home-so how did a modification aimed at preserving androgenicity create a new drug no one had asked for?

In this episode, we tell the story of the Schering AG team and their unexpected discovery, tracing how an ethynyl group at C17α transformed testosterone chemistry into a medically useful progestin and asking what consequences followed when a molecule born from error entered global markets.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Location: Berlin; Schering AG laboratory
Event: Synthesis of ethisterone (first orally active progestin)
Brand: Proluton C (Germany, 1939); Pranone (United States, 1945)

- The ethynyl group was added at the carbon position labeled C17α to a testosterone backbone in 1938.
- Proluton C was introduced in Germany in 1939 and reached the United States as Pranone in 1945.
- Over the following decade ethisterone was sold under more than fifteen brand names including Amenoren, Duosterone, and Ora-Lutin.
- Proluton C tablets were manufactured in dosages of 5 mg, 10 mg, and 25 mg, with capsules reaching 50 mg, 100 mg, and 250 mg.
- A typical oral regimen could be up to 100 mg daily, taken four times a day if needed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138470Wed, 19 Aug 2026 23:00:02 +0000Creator at ObomediaThe Accidental Pill: How a Mistake Created Oral Progestin Ethisterone A single chemical tweak in a Berlin lab in 1938 turned a would-be oral testosterone into the first orally active progestin, a pill that let women skip injections and take...
A single chemical tweak in a Berlin lab in 1938 turned a would-be oral testosterone into the first orally active progestin, a pill that let women skip injections and take progesterone-like therapy at home-so how did a modification aimed at preserving androgenicity create a new drug no one had asked for?

In this episode, we tell the story of the Schering AG team and their unexpected discovery, tracing how an ethynyl group at C17α transformed testosterone chemistry into a medically useful progestin and asking what consequences followed when a molecule born from error entered global markets.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Location: Berlin; Schering AG laboratory
Event: Synthesis of ethisterone (first orally active progestin)
Brand: Proluton C (Germany, 1939); Pranone (United States, 1945)

- The ethynyl group was added at the carbon position labeled C17α to a testosterone backbone in 1938.
- Proluton C was introduced in Germany in 1939 and reached the United States as Pranone in 1945.
- Over the following decade ethisterone was sold under more than fifteen brand names including Amenoren, Duosterone, and Ora-Lutin.
- Proluton C tablets were manufactured in dosages of 5 mg, 10 mg, and 25 mg, with capsules reaching 50 mg, 100 mg, and 250 mg.
- A typical oral regimen could be up to 100 mg daily, taken four times a day if needed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1430falsefullhttps://www.spreaker.com/episode/the-accidental-pill-that-rewrote-hormones-ethisterone-s-secret-legacy--73138469
A single laboratory accident in 1938 produced ethisterone, the first orally active progestin that would remain in clinical use for over six decades yet cause masculinization in some female fetuses; how did a molecule meant to act like oral testosterone become a cornerstone of hormonal medicine-and what cost did that “wrong” design impose?

In this episode, we tell how four chemists in Berlin pursued convenience and accidentally created a drug that solved the needle problem for progesterone but carried unexpected androgenic effects, raising questions about dosage, side effects, and fetal safety that followed it for decades. What unfolded from a chemical tweak to testosterone that echoed through clinical practice from 1939 to around 2000?

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938 (synthesis), 1939 (German introduction), 1945 (U.S. introduction), 1957 (later discovery)
Location: Berlin, Schering AG laboratories
Product names: Proluton C, Pranone, Amenoren, Lutocyclin, Nugestoral, Ora-Lutin
Affinity: ~44% of natural progesterone for progesterone receptor

- Ethisterone was synthesized in 1938 by four chemists at Schering AG in Berlin.
- Schering introduced ethisterone in Germany in 1939 as Proluton C and in the U.S, in 1945 as Pranone.
- The molecule’s progesterone receptor affinity was approximately 44% of natural progesterone.
- Typical therapeutic dosing ranged up to 25 mg taken four times daily, totaling roughly 200-700 mg over 10-14 days.
- Administration in pregnancy was documented to masculinize female fetuses, a significant adverse effect in its clinical record.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138469Tue, 18 Aug 2026 23:00:03 +0000Creator at ObomediaThe Accidental Pill That Rewrote Hormones: Ethisterone's Secret Legacy A single laboratory accident in 1938 produced ethisterone, the first orally active progestin that would remain in clinical use for over six decades yet cause masculinization in...
A single laboratory accident in 1938 produced ethisterone, the first orally active progestin that would remain in clinical use for over six decades yet cause masculinization in some female fetuses; how did a molecule meant to act like oral testosterone become a cornerstone of hormonal medicine-and what cost did that “wrong” design impose?

In this episode, we tell how four chemists in Berlin pursued convenience and accidentally created a drug that solved the needle problem for progesterone but carried unexpected androgenic effects, raising questions about dosage, side effects, and fetal safety that followed it for decades. What unfolded from a chemical tweak to testosterone that echoed through clinical practice from 1939 to around 2000?

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938 (synthesis), 1939 (German introduction), 1945 (U.S. introduction), 1957 (later discovery)
Location: Berlin, Schering AG laboratories
Product names: Proluton C, Pranone, Amenoren, Lutocyclin, Nugestoral, Ora-Lutin
Affinity: ~44% of natural progesterone for progesterone receptor

- Ethisterone was synthesized in 1938 by four chemists at Schering AG in Berlin.
- Schering introduced ethisterone in Germany in 1939 as Proluton C and in the U.S, in 1945 as Pranone.
- The molecule’s progesterone receptor affinity was approximately 44% of natural progesterone.
- Typical therapeutic dosing ranged up to 25 mg taken four times daily, totaling roughly 200-700 mg over 10-14 days.
- Administration in pregnancy was documented to masculinize female fetuses, a significant adverse effect in its clinical record.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1357falsefullhttps://www.spreaker.com/episode/the-accidental-pill-how-a-failed-testosterone-created-oral-progestogen--73138468
A discovery in a Berlin lab in 1938 turned a failed oral testosterone into the first oral progestogen, introducing a tablet option where previously only injections existed and creating a drug that required up to 700 mg over 10-14 days to transform the endometrium. How did a single ethynyl group produce a medicine that changed women’s treatment yet could not prevent ovulation?

In this episode, we tell how four chemists at Schering AG synthesized ethisterone, how it reached markets across countries under multiple brand names, and why its weak antigonadotropic effect prevented it from becoming the birth control breakthrough people expected.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Compound: Ethisterone
First market name: Proluton C (1939)
Relative receptor affinity: 44% of progesterone

- The molecule required between 200 and 700 mg administered over 10 to 14 days to produce endometrial transformation.
- Ethisterone’s progesterone receptor affinity was measured at 44% relative to progesterone.
- Schering marketed ethisterone in Germany in 1939 as Proluton C and in the U.S, by 1945 as Pranone.
- The drug appeared under at least nine documented brand names, including Amenoren, Luteosterone, and Ora-Lutin.
- Ethisterone retained weak androgenic activity that could cause acne, hirsutism, and risk of fetal masculinization when used in pregnancy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138468Mon, 17 Aug 2026 23:00:02 +0000Creator at ObomediaThe Accidental Pill: How a Failed Testosterone Created Oral Progestogen A discovery in a Berlin lab in 1938 turned a failed oral testosterone into the first oral progestogen, introducing a tablet option where previously only injections existed and...
A discovery in a Berlin lab in 1938 turned a failed oral testosterone into the first oral progestogen, introducing a tablet option where previously only injections existed and creating a drug that required up to 700 mg over 10-14 days to transform the endometrium. How did a single ethynyl group produce a medicine that changed women’s treatment yet could not prevent ovulation?

In this episode, we tell how four chemists at Schering AG synthesized ethisterone, how it reached markets across countries under multiple brand names, and why its weak antigonadotropic effect prevented it from becoming the birth control breakthrough people expected.

Person: Hans Herloff Inhoffen; Willy Logemann; Walter Hohlweg; Arthur Serini
Date: 1938
Compound: Ethisterone
First market name: Proluton C (1939)
Relative receptor affinity: 44% of progesterone

- The molecule required between 200 and 700 mg administered over 10 to 14 days to produce endometrial transformation.
- Ethisterone’s progesterone receptor affinity was measured at 44% relative to progesterone.
- Schering marketed ethisterone in Germany in 1939 as Proluton C and in the U.S, by 1945 as Pranone.
- The drug appeared under at least nine documented brand names, including Amenoren, Luteosterone, and Ora-Lutin.
- Ethisterone retained weak androgenic activity that could cause acne, hirsutism, and risk of fetal masculinization when used in pregnancy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1317falsefullhttps://www.spreaker.com/episode/how-a-failed-testosterone-pill-secretly-reinvented-women-s-hormones--73138467
A single laboratory mistake in 1938 turned a quest to make oral testosterone into the world's first pill that could replace a hormone once deliverable only by needle - and that pill carried an unexpected androgenic shadow. How did a modification at one carbon atom create an oral progestogen that later caused acne, hirsutism, and fetal masculinization at high doses?

In this episode, we tell the story of four chemists at Schering AG, the chemical steps they took, the markets that adopted the drug, and the clinical consequences that followed - asking how a drug born from a failed goal reshaped women's hormonal medicine.

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938
Location: Berlin
Event: Synthesis of ethisterone (first orally active progestogen)
Status: Marketed from 1939 with 15+ brand names

- The chemists added an ethynyl group at the carbon 17 alpha position to a testosterone backbone in 1938.
- Ethisterone bound to the progesterone receptor with 44% of progesterone's receptor affinity.
- Clinical endometrial transformation required 200-700 mg over a 10-14 day course.
- By 1939 the drug was sold in Germany as Proluton C and reached the US in 1945 as Pranone.
- Ethisterone appeared under more than 15 brand names across multiple countries.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138467Sun, 16 Aug 2026 23:00:02 +0000Creator at ObomediaHow a Failed Testosterone Pill Secretly Reinvented Women's Hormones A single laboratory mistake in 1938 turned a quest to make oral testosterone into the world's first pill that could replace a hormone once deliverable only by needle - and that...
A single laboratory mistake in 1938 turned a quest to make oral testosterone into the world's first pill that could replace a hormone once deliverable only by needle - and that pill carried an unexpected androgenic shadow. How did a modification at one carbon atom create an oral progestogen that later caused acne, hirsutism, and fetal masculinization at high doses?

In this episode, we tell the story of four chemists at Schering AG, the chemical steps they took, the markets that adopted the drug, and the clinical consequences that followed - asking how a drug born from a failed goal reshaped women's hormonal medicine.

Person: Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg, Arthur Serini
Date: 1938
Location: Berlin
Event: Synthesis of ethisterone (first orally active progestogen)
Status: Marketed from 1939 with 15+ brand names

- The chemists added an ethynyl group at the carbon 17 alpha position to a testosterone backbone in 1938.
- Ethisterone bound to the progesterone receptor with 44% of progesterone's receptor affinity.
- Clinical endometrial transformation required 200-700 mg over a 10-14 day course.
- By 1939 the drug was sold in Germany as Proluton C and reached the US in 1945 as Pranone.
- Ethisterone appeared under more than 15 brand names across multiple countries.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1133falsefullhttps://www.spreaker.com/episode/how-childproof-caps-ended-america-s-kitchen-killings-in-1970--73138466
Every year before 1970 roughly 500 American children under five died from common household products like aspirin, furniture polish, and drain cleaner-items stored on low shelves with ordinary screw caps. What finally stopped those kitchen killings was not a warning label but a simple mechanical barrier that toddlers could not defeat: how did design - not language - change the death count?

In this episode, we tell how postwar consumer chemistry filled homes with lethal products, how fragmented data hid a national crisis until 1957, and how two failed decades of warning labels led to a radical design solution that reduced child fatalities. How did centralizing poison data and confronting child development realities produce a cap that saved thousands?

Period: 1945-1970
Event: Establishment of the National Clearinghouse for Poison Control Centers in 1957
Person: Food and Drug Administration and American Medical Association (authors of the Hazardous Substances Labeling Act)
Topic: Accidental childhood poisonings from household products
Case: Approximately 500 deaths per year of children aged five and under before 1970

- About 500 children aged five and under died each year from accidental poisonings before 1970.
- The National Clearinghouse for Poison Control Centers centralized local data in 1957.
- The Hazardous Substances Labeling Act was passed in 1960 but did not reduce child deaths.
- The highest-risk age group was children between two and four years old.
- Aspirin, furniture polish, turpentine, and methyl alcohol were the most common household toxins.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138466Sat, 15 Aug 2026 23:00:03 +0000Creator at ObomediaHow Childproof Caps Ended America's Kitchen Killings in 1970 Every year before 1970 roughly 500 American children under five died from common household products like aspirin, furniture polish, and drain cleaner-items stored on low shelves with...
Every year before 1970 roughly 500 American children under five died from common household products like aspirin, furniture polish, and drain cleaner-items stored on low shelves with ordinary screw caps. What finally stopped those kitchen killings was not a warning label but a simple mechanical barrier that toddlers could not defeat: how did design - not language - change the death count?

In this episode, we tell how postwar consumer chemistry filled homes with lethal products, how fragmented data hid a national crisis until 1957, and how two failed decades of warning labels led to a radical design solution that reduced child fatalities. How did centralizing poison data and confronting child development realities produce a cap that saved thousands?

Period: 1945-1970
Event: Establishment of the National Clearinghouse for Poison Control Centers in 1957
Person: Food and Drug Administration and American Medical Association (authors of the Hazardous Substances Labeling Act)
Topic: Accidental childhood poisonings from household products
Case: Approximately 500 deaths per year of children aged five and under before 1970

- About 500 children aged five and under died each year from accidental poisonings before 1970.
- The National Clearinghouse for Poison Control Centers centralized local data in 1957.
- The Hazardous Substances Labeling Act was passed in 1960 but did not reduce child deaths.
- The highest-risk age group was children between two and four years old.
- Aspirin, furniture polish, turpentine, and methyl alcohol were the most common household toxins.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1258falsefullhttps://www.spreaker.com/episode/how-a-secret-standard-quietly-rewired-every-medicine-on-earth--73138465
Every pill, vaccine, and biologic therapy you encounter today routes through a single electronic dossier standard that went live across US regulators on May 5, 2017 - a quiet global change negotiated by an organization almost nobody knows. That format, the eCTD, replaced paper submissions and reshaped how drugs move from lab to pharmacy shelf; how did a technical document end up dictating the speed of access to medicine?

In this episode, we outline how the eCTD and its predecessor, the CTD, were created, who built them, and what practical consequences followed for companies and patients; why did ICH members push versions 2.0 and 3.0 through within one year, and what delayed universal adoption for years afterward?

Person: International Council for Harmonisation
Event: eCTD finalization versions 2.0 and 3.0
Date: February 12, 2002; October 8, 2002
Location: United States (deadline for paper submissions May 5, 2017)
Topic: Transition from paper dossiers to electronic Common Technical Dossier (eCTD)

- On May 5, 2017, paper submissions to the FDA were no longer accepted for new drug applications, biologics licenses, and generic drug filings.
- The eCTD version 2.0 was finalized on February 12, 2002, and version 3.0 on October 8, 2002 - both within the same calendar year.
- The CTD organized submissions into five modules, with modules two through five shared across regions for quality, nonclinical, and clinical information.
- The European Medicines Agency began accepting eCTD submissions in 2003, one year after eCTD version 3.0.
- Before harmonization, the same safety study had to be reformatted and repackaged separately for the US, Europe, and Japan, causing duplicated work and delays.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138465Fri, 14 Aug 2026 23:00:02 +0000Creator at ObomediaHow a Secret Standard Quietly Rewired Every Medicine on Earth Every pill, vaccine, and biologic therapy you encounter today routes through a single electronic dossier standard that went live across US regulators on May 5, 2017 - a quiet global...
Every pill, vaccine, and biologic therapy you encounter today routes through a single electronic dossier standard that went live across US regulators on May 5, 2017 - a quiet global change negotiated by an organization almost nobody knows. That format, the eCTD, replaced paper submissions and reshaped how drugs move from lab to pharmacy shelf; how did a technical document end up dictating the speed of access to medicine?

In this episode, we outline how the eCTD and its predecessor, the CTD, were created, who built them, and what practical consequences followed for companies and patients; why did ICH members push versions 2.0 and 3.0 through within one year, and what delayed universal adoption for years afterward?

Person: International Council for Harmonisation
Event: eCTD finalization versions 2.0 and 3.0
Date: February 12, 2002; October 8, 2002
Location: United States (deadline for paper submissions May 5, 2017)
Topic: Transition from paper dossiers to electronic Common Technical Dossier (eCTD)

- On May 5, 2017, paper submissions to the FDA were no longer accepted for new drug applications, biologics licenses, and generic drug filings.
- The eCTD version 2.0 was finalized on February 12, 2002, and version 3.0 on October 8, 2002 - both within the same calendar year.
- The CTD organized submissions into five modules, with modules two through five shared across regions for quality, nonclinical, and clinical information.
- The European Medicines Agency began accepting eCTD submissions in 2003, one year after eCTD version 3.0.
- Before harmonization, the same safety study had to be reformatted and repackaged separately for the US, Europe, and Japan, causing duplicated work and delays.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1490falsefullhttps://www.spreaker.com/episode/the-day-a-superhero-film-released-and-its-creator-died-quietly--73138464
Grief and astonishment collide: a Superman animated film hit stores on February 21, 2011, the same morning Dwayne McDuffie-who turned 49 the day before-died on a surgical table in Burbank. How did a Detroit-born writer who reshaped representation in comics leave a legacy that kept arriving even as he slipped away?

In this episode, we tell the story of Dwayne McDuffie's life and career, from Detroit childhood to Marvel editorial work to co-founding Milestone Media, and how his death coincided with the release of All-Star Superman-what does that convergence reveal about his impact?

Person: Dwayne Glenn McDuffie
Date: February 21, 2011
Event: Release of the film All-Star Superman
Location: Burbank, California
Age: 49

- Dwayne McDuffie was born on February 20, 1962, in Detroit.
- He turned 49 on February 20, 2011, and died on February 21, 2011, during surgery.
- All-Star Superman arrived in stores across America on February 21, 2011.
- McDuffie graduated from the Roeper School in 1980 and earned a BA in English in 1983 and an MA in Physics from the University of Michigan.
- He co-founded Milestone Media in the early 1990s, later described by The Plain Dealer (2000) as "the industry's most successful minority-owned-and-operated comic company."

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138464Thu, 13 Aug 2026 23:00:02 +0000Creator at ObomediaThe Day a Superhero Film Released and Its Creator Died Quietly Grief and astonishment collide: a Superman animated film hit stores on February 21, 2011, the same morning Dwayne McDuffie-who turned 49 the day before-died on a surgical table in...
Grief and astonishment collide: a Superman animated film hit stores on February 21, 2011, the same morning Dwayne McDuffie-who turned 49 the day before-died on a surgical table in Burbank. How did a Detroit-born writer who reshaped representation in comics leave a legacy that kept arriving even as he slipped away?

In this episode, we tell the story of Dwayne McDuffie's life and career, from Detroit childhood to Marvel editorial work to co-founding Milestone Media, and how his death coincided with the release of All-Star Superman-what does that convergence reveal about his impact?

Person: Dwayne Glenn McDuffie
Date: February 21, 2011
Event: Release of the film All-Star Superman
Location: Burbank, California
Age: 49

- Dwayne McDuffie was born on February 20, 1962, in Detroit.
- He turned 49 on February 20, 2011, and died on February 21, 2011, during surgery.
- All-Star Superman arrived in stores across America on February 21, 2011.
- McDuffie graduated from the Roeper School in 1980 and earned a BA in English in 1983 and an MA in Physics from the University of Michigan.
- He co-founded Milestone Media in the early 1990s, later described by The Plain Dealer (2000) as "the industry's most successful minority-owned-and-operated comic company."

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1175falsefullhttps://www.spreaker.com/episode/the-lungs-that-lasted-thirteen-years-floyd-spence-s-impossible-transplant--73138462
Fear and awe collide in this true medical milestone: a 60-year-old congressman received one of the earliest standalone double-lung transplants in 1988 and those lungs kept working for thirteen years-so what finally killed him? Could an organ outlive expectations while the rest of the body failed?

In this episode, we tell the life and medical story of Floyd Spence Spence and the 1988 double-lung transplant at the University of Mississippi Medical Center, tracing his military and political career, the pioneering surgery, and the unexpected cause of death that ended his record survival. How did a procedure with almost no prior data become a thirteen-year success story, and what did his case change for medicine?

Person: Floyd Spence Spence
Date: April 9, 1928
Event: Double-lung transplant at University of Mississippi Medical Center in 1988
Status: Died August 16, 2001; lungs still functioning at admission
Location: Jackson, Mississippi

- He was 60 years old when he received a double-lung transplant in 1988, making him the oldest patient to have received that procedure at the time.
- He survived for thirteen years after the transplant, becoming the longest-surviving standalone lung transplant patient in the United States then.
- He was admitted to St. Dominic Memorial Hospital in Jackson on August 16, 2001 for nerve pain in his face, not for lung failure.
- He married Deborah E. Williams on July 3, 1988, the same year as his transplant.
- He served fifteen consecutive terms in Congress and remained in office until his death.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138462Wed, 12 Aug 2026 23:00:02 +0000Creator at ObomediaThe Lungs That Lasted Thirteen Years: Floyd Spence's Impossible Transplant Fear and awe collide in this true medical milestone: a 60-year-old congressman received one of the earliest standalone double-lung transplants in 1988 and those lungs kept...
Fear and awe collide in this true medical milestone: a 60-year-old congressman received one of the earliest standalone double-lung transplants in 1988 and those lungs kept working for thirteen years-so what finally killed him? Could an organ outlive expectations while the rest of the body failed?

In this episode, we tell the life and medical story of Floyd Spence Spence and the 1988 double-lung transplant at the University of Mississippi Medical Center, tracing his military and political career, the pioneering surgery, and the unexpected cause of death that ended his record survival. How did a procedure with almost no prior data become a thirteen-year success story, and what did his case change for medicine?

Person: Floyd Spence Spence
Date: April 9, 1928
Event: Double-lung transplant at University of Mississippi Medical Center in 1988
Status: Died August 16, 2001; lungs still functioning at admission
Location: Jackson, Mississippi

- He was 60 years old when he received a double-lung transplant in 1988, making him the oldest patient to have received that procedure at the time.
- He survived for thirteen years after the transplant, becoming the longest-surviving standalone lung transplant patient in the United States then.
- He was admitted to St. Dominic Memorial Hospital in Jackson on August 16, 2001 for nerve pain in his face, not for lung failure.
- He married Deborah E. Williams on July 3, 1988, the same year as his transplant.
- He served fifteen consecutive terms in Congress and remained in office until his death.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1108falsefullhttps://www.spreaker.com/episode/the-ambassador-who-carried-papers-that-led-to-auschwitz--73138461
Fear and culpability: a single diplomat's routine paperwork helped set a chain of events tied to 49,000 deaths, yet he died after a simple appendix operation in Madrid - was it accident, or consequence? What exactly did the papers Hans-Adolf von Moltke carried contain, and how did diplomatic routine become a route to Auschwitz?

In this episode, we chart Hans-Adolf von Moltke's life from his birth in Oppeln to his eleven weeks as Germany's ambassador to Spain and the papers he brought with him to Madrid, asking how a cautious career diplomat produced a paper trail that reached from 1939 Warsaw to Auschwitz in 1943.

Person: Hans-Adolf von Moltke
Date of death: 22 March 1943
Location: Ruber Clinic, Madrid
Event: Appendectomy and subsequent death
Documented deaths linked: 49,000

- Born 29 November 1884 in Oppeln, Upper Silesia (later Opole, Poland).
- Joined the German Foreign Ministry (Auswärtiges Amt) in January 1913 after studying law at Heidelberg (1903-1907).
- Served as Germany's minister in Warsaw from February 1931 for eight years, through the rise of Hitler.
- Died after an appendix operation on the morning of 22 March 1943, eleven weeks into his posting in Madrid.
- His son Gebhardt had the body exhumed years later; autopsy confirmed cause of death as surgical complication, and in June 2006 Gebhardt formally denied murder.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138461Tue, 11 Aug 2026 23:00:02 +0000Creator at ObomediaThe Ambassador Who Carried Papers That Led to Auschwitz Fear and culpability: a single diplomat's routine paperwork helped set a chain of events tied to 49,000 deaths, yet he died after a simple appendix operation in Madrid - was it accident, or...
Fear and culpability: a single diplomat's routine paperwork helped set a chain of events tied to 49,000 deaths, yet he died after a simple appendix operation in Madrid - was it accident, or consequence? What exactly did the papers Hans-Adolf von Moltke carried contain, and how did diplomatic routine become a route to Auschwitz?

In this episode, we chart Hans-Adolf von Moltke's life from his birth in Oppeln to his eleven weeks as Germany's ambassador to Spain and the papers he brought with him to Madrid, asking how a cautious career diplomat produced a paper trail that reached from 1939 Warsaw to Auschwitz in 1943.

Person: Hans-Adolf von Moltke
Date of death: 22 March 1943
Location: Ruber Clinic, Madrid
Event: Appendectomy and subsequent death
Documented deaths linked: 49,000

- Born 29 November 1884 in Oppeln, Upper Silesia (later Opole, Poland).
- Joined the German Foreign Ministry (Auswärtiges Amt) in January 1913 after studying law at Heidelberg (1903-1907).
- Served as Germany's minister in Warsaw from February 1931 for eight years, through the rise of Hitler.
- Died after an appendix operation on the morning of 22 March 1943, eleven weeks into his posting in Madrid.
- His son Gebhardt had the body exhumed years later; autopsy confirmed cause of death as surgical complication, and in June 2006 Gebhardt formally denied murder.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1475falsefullhttps://www.spreaker.com/episode/how-carman-filled-texas-stadium-for-free-the-hidden-mechanism--73138459
Seventy-one thousand, one hundred and thirty-two people packed Texas Stadium on October 22, 1994 - more than the NFL seating there - and not one paid to get in. How did a born-again singer from Trenton, New Jersey, who sold over ten million records and drew tens of thousands without mainstream crossover, build that scale while remaining almost invisible to the world next door?

In this episode, we trace Carman Domenic Licciardello’s path from Atlantic City and Las Vegas casino shows to mega-church spectacle, and outline the nonprofit-funded model that made free mass events possible. What logistical and cultural mechanisms turned theatrical evangelical performance into stadium-sized attendance?

Person: Carman Domenic Licciardello
Date: October 22, 1994
Event: Texas Stadium concert with free admission
Organization: Carman Domenic (nonprofit)
Record sales: more than ten million

- Texas Stadium attendance recorded as 71,132 on October 22, 1994.
- Texas Stadium held fewer than 64,000 seats for NFL games.
- Carman sold more than 10,000,000 records and received four Grammy nominations.
- Carman signed a Priority Records deal in Tulsa, Oklahoma, in October 1981; the label folded in July 1983.
- Carman made his first record in 1980 titled God's Not Finished with Me.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138459Mon, 10 Aug 2026 23:00:03 +0000Creator at ObomediaHow Carman Filled Texas Stadium for Free - The Hidden Mechanism Seventy-one thousand, one hundred and thirty-two people packed Texas Stadium on October 22, 1994 - more than the NFL seating there - and not one paid to get in. How did a born-again...
Seventy-one thousand, one hundred and thirty-two people packed Texas Stadium on October 22, 1994 - more than the NFL seating there - and not one paid to get in. How did a born-again singer from Trenton, New Jersey, who sold over ten million records and drew tens of thousands without mainstream crossover, build that scale while remaining almost invisible to the world next door?

In this episode, we trace Carman Domenic Licciardello’s path from Atlantic City and Las Vegas casino shows to mega-church spectacle, and outline the nonprofit-funded model that made free mass events possible. What logistical and cultural mechanisms turned theatrical evangelical performance into stadium-sized attendance?

Person: Carman Domenic Licciardello
Date: October 22, 1994
Event: Texas Stadium concert with free admission
Organization: Carman Domenic (nonprofit)
Record sales: more than ten million

- Texas Stadium attendance recorded as 71,132 on October 22, 1994.
- Texas Stadium held fewer than 64,000 seats for NFL games.
- Carman sold more than 10,000,000 records and received four Grammy nominations.
- Carman signed a Priority Records deal in Tulsa, Oklahoma, in October 1981; the label folded in July 1983.
- Carman made his first record in 1980 titled God's Not Finished with Me.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1227falsefullhttps://www.spreaker.com/episode/when-engineers-knew-the-fix-gm-chose-profit-over-safety--73138457
A chill of disbelief: engineers identified a near-costless anti-roll bar that would have stabilized the Corvair, yet management rejected it despite 26,000 sales in two days and Motor Trend naming it Car of the Year - why did they choose not to fit a simple steel bar? What happened when engineering certainty met corporate calculation at seventy miles an hour?

In this episode, we tell how the Corvair was conceived, launched, and later challenged by safety concerns, following the choices made inside General Motors and the single design decision that became the axis of a national controversy: would a tiny part have changed everything?

Person: Ed Cole
Date: Production began July 1959; name registered August 6, 1959; public launch October 2, 1959
Event: Motor Trend Car of the Year 1960
Location: Willow Run plant, Michigan
Case: Corvair handling controversy over omission of a front anti-roll bar

- 26,000 Corvairs sold in the first two days of sales
- 110,000 Monza Club Coupes sold by 1961, roughly half of all Corvair sales
- One internal estimate described the cost of including the anti-roll bar as essentially nothing
- The production concept included a rear-mounted air-cooled flat-six engine and all-wheel independent suspension
- The implemented workaround required lower front tire pressure than rear to compensate for swing-axle dynamics

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138457Sun, 09 Aug 2026 23:00:02 +0000Creator at ObomediaWhen Engineers Knew the Fix - GM Chose Profit Over Safety A chill of disbelief: engineers identified a near-costless anti-roll bar that would have stabilized the Corvair, yet management rejected it despite 26,000 sales in two days and Motor Trend...
A chill of disbelief: engineers identified a near-costless anti-roll bar that would have stabilized the Corvair, yet management rejected it despite 26,000 sales in two days and Motor Trend naming it Car of the Year - why did they choose not to fit a simple steel bar? What happened when engineering certainty met corporate calculation at seventy miles an hour?

In this episode, we tell how the Corvair was conceived, launched, and later challenged by safety concerns, following the choices made inside General Motors and the single design decision that became the axis of a national controversy: would a tiny part have changed everything?

Person: Ed Cole
Date: Production began July 1959; name registered August 6, 1959; public launch October 2, 1959
Event: Motor Trend Car of the Year 1960
Location: Willow Run plant, Michigan
Case: Corvair handling controversy over omission of a front anti-roll bar

- 26,000 Corvairs sold in the first two days of sales
- 110,000 Monza Club Coupes sold by 1961, roughly half of all Corvair sales
- One internal estimate described the cost of including the anti-roll bar as essentially nothing
- The production concept included a rear-mounted air-cooled flat-six engine and all-wheel independent suspension
- The implemented workaround required lower front tire pressure than rear to compensate for swing-axle dynamics

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1347falsefullhttps://www.spreaker.com/episode/the-loaf-that-poisoned-hong-kong-arsenic-trial-and-silence--73138456
Fear of contamination and imperial scandal - nearly 300 to 500 European residents were violently poisoned after eating a single bakery's morning loaf, and the same slice sat sealed in the Chief Justice's office for almost eighty years, preserved by the arsenic it contained. Who put nearly one drachm of arsenic trioxide per pound into the dough, and why did so many survive?

In this episode, we recount the January 15, 1857 poisoning in colonial Hong Kong, the medical response, the forensic findings tying the toxin to a specific moment in the baking process, and the ensuing trial and uncertainties - can the envelopes of evidence explain motive and culpability?

Person: Cheong Ah-lum
Event: Arsenic poisoning of bread
Date: January 15, 1857
Location: Hong Kong
Survivors: Between 300 and 500 people

- A single piece of bread was kept in the Chief Justice's office for nearly eighty years.
- The contaminant was arsenic trioxide introduced after ingredients were combined, close to or during baking.
- The dose was nearly one drachm of arsenic trioxide per pound of baked bread, about sixty grains per drachm.
- Surgeon General Aurelius Harland ordered vomiting, raw eggs, and patients kept upright as emergency treatment.
- The Esing Bakery supplied bread to hotels, households, and the military and was run by Cheong Ah-lum.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138456Sat, 08 Aug 2026 23:00:04 +0000Creator at ObomediaThe Loaf That Poisoned Hong Kong: Arsenic, Trial, and Silence Fear of contamination and imperial scandal - nearly 300 to 500 European residents were violently poisoned after eating a single bakery's morning loaf, and the same slice sat sealed in...
Fear of contamination and imperial scandal - nearly 300 to 500 European residents were violently poisoned after eating a single bakery's morning loaf, and the same slice sat sealed in the Chief Justice's office for almost eighty years, preserved by the arsenic it contained. Who put nearly one drachm of arsenic trioxide per pound into the dough, and why did so many survive?

In this episode, we recount the January 15, 1857 poisoning in colonial Hong Kong, the medical response, the forensic findings tying the toxin to a specific moment in the baking process, and the ensuing trial and uncertainties - can the envelopes of evidence explain motive and culpability?

Person: Cheong Ah-lum
Event: Arsenic poisoning of bread
Date: January 15, 1857
Location: Hong Kong
Survivors: Between 300 and 500 people

- A single piece of bread was kept in the Chief Justice's office for nearly eighty years.
- The contaminant was arsenic trioxide introduced after ingredients were combined, close to or during baking.
- The dose was nearly one drachm of arsenic trioxide per pound of baked bread, about sixty grains per drachm.
- Surgeon General Aurelius Harland ordered vomiting, raw eggs, and patients kept upright as emergency treatment.
- The Esing Bakery supplied bread to hotels, households, and the military and was run by Cheong Ah-lum.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1490falsefullhttps://www.spreaker.com/episode/the-croquette-that-exposed-japan-s-9-838-ton-meat-deception--73138454
A single frozen croquette labeled "one hundred percent beef" contained pork, chicken, and unidentifiable material - and it led journalists to uncover 9,838 tons of fraudulent ground meat shipped from one plant in a year. How did expired cuts, pig intestines, and rainwater-thawed product reach school lunches, military mess halls, and family tables across 22 prefectures before anyone stopped it?

In this episode, we lay out the timeline from the Asahi Shimbun genetic tests in spring 2007 to the whistleblower's anonymous complaints and the institutional failures that followed, following the question: what happens when one person sees clearly and every system around them refuses to look?

Person: Minoru Tanaka
Person: Kiroku Akahane
Location: Tomakomai, Hokkaido
Event: Asahi Shimbun genetic tests on a frozen korokke in spring 2007
Quantity: 9,838 tons shipped in a twelve-month period

- The frozen korokke tested by Asahi Shimbun in spring 2007 was labeled "one hundred percent beef" but contained pork and chicken.
- Meat Hope Inc was founded by Minoru Tanaka in 1976 and by January 2006 employed roughly 100 people directly and supported about 500 through associated companies.
- Fraudulent ground meat from the Tomakomai plant was shipped to destinations across 22 Japanese prefectures.
- Kiroku Akahane, born in 1935, filed anonymous complaints with multiple agencies including the Tomakomai Health Center and the Ministry of Agriculture, Forestry, and Fisheries.
- Sausages that tested positive for salmonella had their laboratory data falsified before being cleared and were delivered to school lunch programs.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138454Fri, 07 Aug 2026 23:00:02 +0000Creator at ObomediaThe Croquette That Exposed Japan's 9,838-Ton Meat Deception A single frozen croquette labeled "one hundred percent beef" contained pork, chicken, and unidentifiable material - and it led journalists to uncover 9,838 tons of fraudulent ground meat...
A single frozen croquette labeled "one hundred percent beef" contained pork, chicken, and unidentifiable material - and it led journalists to uncover 9,838 tons of fraudulent ground meat shipped from one plant in a year. How did expired cuts, pig intestines, and rainwater-thawed product reach school lunches, military mess halls, and family tables across 22 prefectures before anyone stopped it?

In this episode, we lay out the timeline from the Asahi Shimbun genetic tests in spring 2007 to the whistleblower's anonymous complaints and the institutional failures that followed, following the question: what happens when one person sees clearly and every system around them refuses to look?

Person: Minoru Tanaka
Person: Kiroku Akahane
Location: Tomakomai, Hokkaido
Event: Asahi Shimbun genetic tests on a frozen korokke in spring 2007
Quantity: 9,838 tons shipped in a twelve-month period

- The frozen korokke tested by Asahi Shimbun in spring 2007 was labeled "one hundred percent beef" but contained pork and chicken.
- Meat Hope Inc was founded by Minoru Tanaka in 1976 and by January 2006 employed roughly 100 people directly and supported about 500 through associated companies.
- Fraudulent ground meat from the Tomakomai plant was shipped to destinations across 22 Japanese prefectures.
- Kiroku Akahane, born in 1935, filed anonymous complaints with multiple agencies including the Tomakomai Health Center and the Ministry of Agriculture, Forestry, and Fisheries.
- Sausages that tested positive for salmonella had their laboratory data falsified before being cleared and were delivered to school lunch programs.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1258falsefullhttps://www.spreaker.com/episode/a-government-publicly-cancelled-its-destruction-plan-while-bulldozers-were-still-demolishing-the-city--73138452
A public cancellation and continued demolition unfolded on the same morning of May 18, 2004: the government announced it was cancelling its plan to widen the buffer zone along the Gaza-Egypt border while army bulldozers in Tel al-Sultan kept moving, leaving 254 houses destroyed and nearly 4,000 people homeless. How did a declared halt coexist with continuing razing, and who records that contradiction?

In this episode, we tell what the record shows about Rafah in May 2004, tracing the timeline from prior clearances and the April demolitions through the events that accelerated after May 11, and we ask whether the stated justifications explain the documented outcomes.

Person: Israeli government, Israeli army, Israeli High Court, human rights investigators, United Nations
Date: May 2004 (key events: May 11, May 13, May 14, May 15, May 16, May 17, May 18)
Location: Rafah, Tel al-Sultan, Gaza Strip (along the Philadelphi Route)
Event: Operation Rainbow (Mivtza Keshet Be-Anan)
Status: Public cancellation announced May 18, 2004; demolitions continued

- 254 houses destroyed during the twelve-day military operation
- Nearly 4,000 people rendered homeless as a result of the operation
- 487 houses demolished in Rafah between April 2003 and April 2004 prior to Operation Rainbow
- Eleven Israeli soldiers killed on May 11, 2004, when two M113 armored personnel carriers were destroyed
- Between 100 and 120 houses demolished by the morning of May 15, 2004, after a plan approved before dawn on May 13 declared intent to destroy "dozens or perhaps hundreds" of homes

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138452Thu, 06 Aug 2026 23:00:03 +0000Creator at ObomediaA government publicly cancelled its destruction plan while bulldozers were still demolishing the city A public cancellation and continued demolition unfolded on the same morning of May 18, 2004: the government announced it was cancelling its plan...
A public cancellation and continued demolition unfolded on the same morning of May 18, 2004: the government announced it was cancelling its plan to widen the buffer zone along the Gaza-Egypt border while army bulldozers in Tel al-Sultan kept moving, leaving 254 houses destroyed and nearly 4,000 people homeless. How did a declared halt coexist with continuing razing, and who records that contradiction?

In this episode, we tell what the record shows about Rafah in May 2004, tracing the timeline from prior clearances and the April demolitions through the events that accelerated after May 11, and we ask whether the stated justifications explain the documented outcomes.

Person: Israeli government, Israeli army, Israeli High Court, human rights investigators, United Nations
Date: May 2004 (key events: May 11, May 13, May 14, May 15, May 16, May 17, May 18)
Location: Rafah, Tel al-Sultan, Gaza Strip (along the Philadelphi Route)
Event: Operation Rainbow (Mivtza Keshet Be-Anan)
Status: Public cancellation announced May 18, 2004; demolitions continued

- 254 houses destroyed during the twelve-day military operation
- Nearly 4,000 people rendered homeless as a result of the operation
- 487 houses demolished in Rafah between April 2003 and April 2004 prior to Operation Rainbow
- Eleven Israeli soldiers killed on May 11, 2004, when two M113 armored personnel carriers were destroyed
- Between 100 and 120 houses demolished by the morning of May 15, 2004, after a plan approved before dawn on May 13 declared intent to destroy "dozens or perhaps hundreds" of homes

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1318falsefullhttps://www.spreaker.com/episode/ten-million-dead-by-2050-how-antibiotics-are-losing-control--73138448
Antibiotics once turned routine infections into minor setbacks; today researchers project ten million deaths per year from drug-resistant infections by 2050. Ordinary acts-a prescription, a farmer adding powder to a trough, a patient stopping pills early-have multiplied into a global selection engine for resistant bacteria; can the erosion of modern medicine be stopped in time?

In this episode, we lay out how the discovery of penicillin in 1928 and its rapid development in the 1940s rewired medicine, why the antibiotic pipeline slowed while resistance accelerated, and where resistant organisms are already spreading through hospitals, farms, water and food-what will it take to slow or reverse that trend?

Person: Alexander Fleming
Date: 1928
Event: Discovery of Penicillium notatum antibacterial effect
Period: 1940s-1960s antibiotic expansion
Projection: Ten million annual deaths by 2050

- Fleming observed a mold killing bacteria on a petri dish in 1928.
- Penicillin was developed into a usable medicine by a team at Oxford during the Second World War.
- Life expectancy rose and surgeries became routine after widespread antibiotic use in the 1940s-1960s.
- Pharmaceutical antibiotic development slowed by the late twentieth century due to unfavorable economics and complex regulation.
- A UK study found three days of amoxicillin produced the same recovery for pneumonia as seven days, suggesting longer courses can be unnecessary.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138448Wed, 05 Aug 2026 23:00:02 +0000Creator at ObomediaTen Million Dead by 2050: How Antibiotics Are Losing Control Antibiotics once turned routine infections into minor setbacks; today researchers project ten million deaths per year from drug-resistant infections by 2050. Ordinary acts-a prescription,...
Antibiotics once turned routine infections into minor setbacks; today researchers project ten million deaths per year from drug-resistant infections by 2050. Ordinary acts-a prescription, a farmer adding powder to a trough, a patient stopping pills early-have multiplied into a global selection engine for resistant bacteria; can the erosion of modern medicine be stopped in time?

In this episode, we lay out how the discovery of penicillin in 1928 and its rapid development in the 1940s rewired medicine, why the antibiotic pipeline slowed while resistance accelerated, and where resistant organisms are already spreading through hospitals, farms, water and food-what will it take to slow or reverse that trend?

Person: Alexander Fleming
Date: 1928
Event: Discovery of Penicillium notatum antibacterial effect
Period: 1940s-1960s antibiotic expansion
Projection: Ten million annual deaths by 2050

- Fleming observed a mold killing bacteria on a petri dish in 1928.
- Penicillin was developed into a usable medicine by a team at Oxford during the Second World War.
- Life expectancy rose and surgeries became routine after widespread antibiotic use in the 1940s-1960s.
- Pharmaceutical antibiotic development slowed by the late twentieth century due to unfavorable economics and complex regulation.
- A UK study found three days of amoxicillin produced the same recovery for pneumonia as seven days, suggesting longer courses can be unnecessary.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1465falsefullhttps://www.spreaker.com/episode/the-forged-cremation-note-that-sent-a-nurse-to-the-gallows--73138447
Fear that a single forged paper can erase a life - and a family - drives this episode: a cremation request dated 12 September 1935 that falsely declared Ada Baguley had no living relatives and asked for immediate cremation. Who forged the note, who benefited, and how did one person end up hanged while the forger walked free?

In this episode, we tell how a municipal cremation office, a doubtful note, and a vigilant Medical Officer for Health pulled two deaths back from erasure and revealed an unlicensed nursing home running at 32 Devon Drive. What did Cyril Banks uncover that exposed fraud, forged wills, and a deadly breach of trust?

Person: Ada Baguley
Date: 12 September 1935
Location: 32 Devon Drive, Nottingham
Person: Dorothea Nancy Waddingham (aka Nurse Waddingham)
Person: Ronald Joseph Sullivan

- The cremation note arrived at the Nottingham municipal cremation office on 12 September 1935 requesting immediate cremation and stating Ada Baguley had no living relatives.
- Ada Baguley’s original will was destroyed in May 1935 and replaced by a new will leaving everything to Dorothea Waddingham and Ronald Sullivan.
- Dorothea Waddingham was born Dorothy Nancie Merelina Allan Chandler on 21 June 1899 and had no nursing qualification or state registration.
- Ronald Joseph Sullivan, a World War One veteran who had earned a Military Medal, wrote the cremation note in his own handwriting and telephoned Dr. H. H. Mansfield on 10 September 1935 reporting Ada in a coma.
- Within forty-eight hours of the note’s arrival, Cyril Banks read it, contacted authorities, and over the following weeks exposed the fraudulent nursing home and events that led to one person being sent to the gallows.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138447Tue, 04 Aug 2026 23:00:02 +0000Creator at ObomediaThe Forged Cremation Note That Sent a Nurse to the Gallows Fear that a single forged paper can erase a life - and a family - drives this episode: a cremation request dated 12 September 1935 that falsely declared Ada Baguley had no living relatives...
Fear that a single forged paper can erase a life - and a family - drives this episode: a cremation request dated 12 September 1935 that falsely declared Ada Baguley had no living relatives and asked for immediate cremation. Who forged the note, who benefited, and how did one person end up hanged while the forger walked free?

In this episode, we tell how a municipal cremation office, a doubtful note, and a vigilant Medical Officer for Health pulled two deaths back from erasure and revealed an unlicensed nursing home running at 32 Devon Drive. What did Cyril Banks uncover that exposed fraud, forged wills, and a deadly breach of trust?

Person: Ada Baguley
Date: 12 September 1935
Location: 32 Devon Drive, Nottingham
Person: Dorothea Nancy Waddingham (aka Nurse Waddingham)
Person: Ronald Joseph Sullivan

- The cremation note arrived at the Nottingham municipal cremation office on 12 September 1935 requesting immediate cremation and stating Ada Baguley had no living relatives.
- Ada Baguley’s original will was destroyed in May 1935 and replaced by a new will leaving everything to Dorothea Waddingham and Ronald Sullivan.
- Dorothea Waddingham was born Dorothy Nancie Merelina Allan Chandler on 21 June 1899 and had no nursing qualification or state registration.
- Ronald Joseph Sullivan, a World War One veteran who had earned a Military Medal, wrote the cremation note in his own handwriting and telephoned Dr. H. H. Mansfield on 10 September 1935 reporting Ada in a coma.
- Within forty-eight hours of the note’s arrival, Cyril Banks read it, contacted authorities, and over the following weeks exposed the fraudulent nursing home and events that led to one person being sent to the gallows.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1339falsefullhttps://www.spreaker.com/episode/when-trust-killed-canada-s-blood-scandal-and-the-8-000-dead--73138443
Trust turned deadly: Justice Horace Horace recorded 8,000 Canadians dead or expected to die after infected transfusions, and a test that could have prevented thousands sat unused for years-so why did institutions choose cost and caution over safety?

In this episode, we tell how decisions about testing, procurement, and recalls by the Red Cross, suppliers, and government committees shaped Canada’s national blood system and led to mass infections-could a different choice at critical moments have stopped the toll?

Person: Justice Horace Horace
Date: November 1997
Event: Final report placing 8,000 dead or expected to die
Organization: Canadian Red Cross
Product: Concentrated Factor VIII by Armour Pharmaceutical

- 8,000 people were recorded by Horace as dead or expected to die from infected blood.
- Approximately 133 Canadians contracted HIV from blood products between March and November 1985.
- Connaught Laboratories shifted from nonprofit to private ownership by the 1980s.
- Seven children were infected after a failed heat treatment of concentrated Factor VIII in 1986-1987.
- More than 30,000 Canadians contracted hepatitis C from blood products received between 1980 and 1990.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138443Mon, 03 Aug 2026 23:00:02 +0000Creator at ObomediaWhen Trust Killed: Canada's Blood Scandal and the 8,000 Dead Trust turned deadly: Justice Horace Horace recorded 8,000 Canadians dead or expected to die after infected transfusions, and a test that could have prevented thousands sat unused for...
Trust turned deadly: Justice Horace Horace recorded 8,000 Canadians dead or expected to die after infected transfusions, and a test that could have prevented thousands sat unused for years-so why did institutions choose cost and caution over safety?

In this episode, we tell how decisions about testing, procurement, and recalls by the Red Cross, suppliers, and government committees shaped Canada’s national blood system and led to mass infections-could a different choice at critical moments have stopped the toll?

Person: Justice Horace Horace
Date: November 1997
Event: Final report placing 8,000 dead or expected to die
Organization: Canadian Red Cross
Product: Concentrated Factor VIII by Armour Pharmaceutical

- 8,000 people were recorded by Horace as dead or expected to die from infected blood.
- Approximately 133 Canadians contracted HIV from blood products between March and November 1985.
- Connaught Laboratories shifted from nonprofit to private ownership by the 1980s.
- Seven children were infected after a failed heat treatment of concentrated Factor VIII in 1986-1987.
- More than 30,000 Canadians contracted hepatitis C from blood products received between 1980 and 1990.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1324falsefullhttps://www.spreaker.com/episode/bloody-thursday-how-doctors-tried-to-save-pearl-roundabout-s-dead--73138441
Fear of sudden violence and the concrete cost of state force: over 1,000 police moved in at 3:00 AM on 17 February 2011 and by dawn four protesters lay dead - how did a field clinic and a volunteer surgeon confront a crackdown with no warning? What exactly happened in the tear-gassed tents that night?

In this episode, we present what unfolded at Pearl Roundabout and the people present, the decisions that preceded the raid, and the immediate medical aftermath as recorded by official inquiries and eyewitnesses. Who were the four men who died, and how were medics like Dr. Sadiq Alekry involved as events turned deadly?

Date: 17 February 2011
Location: Pearl Roundabout, Bahrain
Person: Dr. Sadiq Alekry
Case: Bloody Thursday raid
Event: Nighttime police operation without warning

- Approximately 1,000 police officers moved toward the sleeping camp at roughly 3:00 AM on 17 February 2011.
- Between 1,500 and 3,000 people were sleeping in tents at Pearl Roundabout when the raid began.
- Police arrived in more than 100 civilian cars carrying plainclothes officers and cut open tents with knives.
- Ali Mansour Ahmed Khudair was shot in the chest and autopsy found 91 pellets inside his body.
- Mahmoud Makki Abutaki was shot in the back and medical staff removed about 200 pellets of birdshot from his chest and arms.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138441Sun, 02 Aug 2026 23:00:02 +0000Creator at ObomediaBloody Thursday: How Doctors Tried to Save Pearl Roundabout's Dead Fear of sudden violence and the concrete cost of state force: over 1,000 police moved in at 3:00 AM on 17 February 2011 and by dawn four protesters lay dead - how did a field clinic...
Fear of sudden violence and the concrete cost of state force: over 1,000 police moved in at 3:00 AM on 17 February 2011 and by dawn four protesters lay dead - how did a field clinic and a volunteer surgeon confront a crackdown with no warning? What exactly happened in the tear-gassed tents that night?

In this episode, we present what unfolded at Pearl Roundabout and the people present, the decisions that preceded the raid, and the immediate medical aftermath as recorded by official inquiries and eyewitnesses. Who were the four men who died, and how were medics like Dr. Sadiq Alekry involved as events turned deadly?

Date: 17 February 2011
Location: Pearl Roundabout, Bahrain
Person: Dr. Sadiq Alekry
Case: Bloody Thursday raid
Event: Nighttime police operation without warning

- Approximately 1,000 police officers moved toward the sleeping camp at roughly 3:00 AM on 17 February 2011.
- Between 1,500 and 3,000 people were sleeping in tents at Pearl Roundabout when the raid began.
- Police arrived in more than 100 civilian cars carrying plainclothes officers and cut open tents with knives.
- Ali Mansour Ahmed Khudair was shot in the chest and autopsy found 91 pellets inside his body.
- Mahmoud Makki Abutaki was shot in the back and medical staff removed about 200 pellets of birdshot from his chest and arms.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1245falsefullhttps://www.spreaker.com/episode/cinco-dias-de-fiebre-declarada-normal-planta-quien-lo-dijo-y-por-que--73138434
A revered Korean rocker was kept burning with fever for five days inside a private hospital while doctors repeatedly told him it was "normal"-a lie that preceded unauthorized surgery and a perforated pericardium. How did a gastrointestinal admission turn into a secret stomach reduction, two punctured organs, and a cremation order signed before the truth came out?

In this episode, we tell the events surrounding Shin Hae-chul’s stay at Sky Hospital in October 2014, tracing his career as a musician and the medical decisions that followed his admission; what happened in the operating room and why the fever was never properly investigated are the central questions.

Person: Shin Hae-chul
Date: October 17, 2014
Location: Sky Hospital, Seoul
Physician: Dr. Kang Se-hoon
Event: Unauthorized stomach reduction surgery with subsequent perforations

- Shin Hae-chul was 46 years old when he was admitted on October 17, 2014 for a gastrointestinal procedure.
- Dr. Kang Se-hoon performed a stomach reduction during that surgery, which Shin had not consented to.
- Two structures were perforated during the procedure: the upper small intestine and the pericardium.
- Shin ran a fever for five days while hospital staff repeatedly described it as "normal" post-operative inflammation.
- A cremation order was signed before the wider public understood the full sequence of events, and friends made a last-minute call that delayed cremation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138434Sat, 01 Aug 2026 23:00:02 +0000Creator at Obomediacinco días de fiebre declarada normal. Planta: ¿quién lo dijo y por qué? A revered Korean rocker was kept burning with fever for five days inside a private hospital while doctors repeatedly told him it was "normal"-a lie that preceded unauthorized...
A revered Korean rocker was kept burning with fever for five days inside a private hospital while doctors repeatedly told him it was "normal"-a lie that preceded unauthorized surgery and a perforated pericardium. How did a gastrointestinal admission turn into a secret stomach reduction, two punctured organs, and a cremation order signed before the truth came out?

In this episode, we tell the events surrounding Shin Hae-chul’s stay at Sky Hospital in October 2014, tracing his career as a musician and the medical decisions that followed his admission; what happened in the operating room and why the fever was never properly investigated are the central questions.

Person: Shin Hae-chul
Date: October 17, 2014
Location: Sky Hospital, Seoul
Physician: Dr. Kang Se-hoon
Event: Unauthorized stomach reduction surgery with subsequent perforations

- Shin Hae-chul was 46 years old when he was admitted on October 17, 2014 for a gastrointestinal procedure.
- Dr. Kang Se-hoon performed a stomach reduction during that surgery, which Shin had not consented to.
- Two structures were perforated during the procedure: the upper small intestine and the pericardium.
- Shin ran a fever for five days while hospital staff repeatedly described it as "normal" post-operative inflammation.
- A cremation order was signed before the wider public understood the full sequence of events, and friends made a last-minute call that delayed cremation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1091falsefullhttps://www.spreaker.com/episode/the-doctors-who-drugged-prisoners-inside-lexington-s-lsd-experiments--73138430
Six hundred micrograms of LSD was given after seventy-seven consecutive days of daily dosing - quadruple the amount that could dissolve a man's sense of reality - and the men sat quietly, reading and watching television. How did federal custody, medical research, and intelligence agency requests combine inside a single institution to produce results the World Health Organization relied on, and what price did the subjects pay?

In this episode, we walk through the history and practices of the Addiction Research Center in Lexington, Kentucky, describing its dual role as hospital, prison, and laboratory and the experiments that followed the arrival of LSD in 1956. What exactly was being asked of the men who were patients, prisoners, and research subjects all at once?

Person: Harris Isbell
Location: Lexington, Kentucky
Institution: Public Health Service Hospital / Addiction Research Center
Date: 1956 (LSD arrival); 1945 (Isbell became Director of Research)
Published papers: more than 125 over eighteen years

- Subjects received 600 micrograms of LSD after seventy-seven consecutive days of daily dosing.
- Barbiturate study in 1950 kept five male subjects on escalating doses for seventy-three days or more, producing convulsions, delirium, and hallucinations on abrupt cessation.
- Alcohol study in 1955 maintained six subjects in constant moderate intoxication for 48 to 87 days at about one quart of 80-proof alcohol per day, with withdrawal causing tremors, convulsions in two, and delirium with hallucinations in four.
- Compensation for participation consisted of drugs (usually opiates) and private living quarters rather than money.
- Harris Isbell received the U.S. Public Health Service Meritorious Service Meritorious in 1962 and was publicly praised by Attorney General Robert F. Kennedy that same year.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138430Fri, 31 Jul 2026 23:00:02 +0000Creator at ObomediaThe Doctors Who Drugged Prisoners: Inside Lexington's LSD Experiments Six hundred micrograms of LSD was given after seventy-seven consecutive days of daily dosing - quadruple the amount that could dissolve a man's sense of reality - and the men sat...
Six hundred micrograms of LSD was given after seventy-seven consecutive days of daily dosing - quadruple the amount that could dissolve a man's sense of reality - and the men sat quietly, reading and watching television. How did federal custody, medical research, and intelligence agency requests combine inside a single institution to produce results the World Health Organization relied on, and what price did the subjects pay?

In this episode, we walk through the history and practices of the Addiction Research Center in Lexington, Kentucky, describing its dual role as hospital, prison, and laboratory and the experiments that followed the arrival of LSD in 1956. What exactly was being asked of the men who were patients, prisoners, and research subjects all at once?

Person: Harris Isbell
Location: Lexington, Kentucky
Institution: Public Health Service Hospital / Addiction Research Center
Date: 1956 (LSD arrival); 1945 (Isbell became Director of Research)
Published papers: more than 125 over eighteen years

- Subjects received 600 micrograms of LSD after seventy-seven consecutive days of daily dosing.
- Barbiturate study in 1950 kept five male subjects on escalating doses for seventy-three days or more, producing convulsions, delirium, and hallucinations on abrupt cessation.
- Alcohol study in 1955 maintained six subjects in constant moderate intoxication for 48 to 87 days at about one quart of 80-proof alcohol per day, with withdrawal causing tremors, convulsions in two, and delirium with hallucinations in four.
- Compensation for participation consisted of drugs (usually opiates) and private living quarters rather than money.
- Harris Isbell received the U.S. Public Health Service Meritorious Service Meritorious in 1962 and was publicly praised by Attorney General Robert F. Kennedy that same year.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1346falsefullhttps://www.spreaker.com/episode/when-a-cure-breaks-bones-the-case-that-shielded-doctors--73138428
A landmark 1957 case turned a man’s fractured hips into a legal refuge for medical practice: both acetabula broke during ECT at Friern Hospital after no muscle relaxant or restraints were used, and the jury found no negligence. How did expert testimony about accepted 1950s medical risks and practices convince a court that the treatment, though it shattered bones, was not legally blameworthy?

In this episode, we recount the facts of the trial and the clinical context that shaped the verdict: what happened at Friern Hospital, why muscle relaxants and restraints were controversial, and how the court weighed medical consensus against a patient’s harm. What does Bolam’s loss reveal about who decides acceptable medical risk?

Person: Bolam
Date: 1957
Location: Friern Hospital, London
Event: Electro-convulsive therapy (ECT) resulting in bilateral acetabular fractures
Status: Jury found no negligence

- Both acetabula (pelvic sockets) were fractured when Bolam convulsed during ECT.
- No muscle relaxant was administered before the electrical current was applied.
- No attendants physically restrained Bolam during the induced seizure.
- Expert testimony showed a significant body of medical opinion in 1957 opposed using muscle relaxants for ECT due to respiratory and cardiovascular risks.
- Experts testified that physical restraints could increase fracture risk by applying opposing external force during violent convulsions.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138428Thu, 30 Jul 2026 23:00:02 +0000Creator at ObomediaWhen a Cure Breaks Bones: The Case That Shielded Doctors A landmark 1957 case turned a man’s fractured hips into a legal refuge for medical practice: both acetabula broke during ECT at Friern Hospital after no muscle relaxant or restraints were...
A landmark 1957 case turned a man’s fractured hips into a legal refuge for medical practice: both acetabula broke during ECT at Friern Hospital after no muscle relaxant or restraints were used, and the jury found no negligence. How did expert testimony about accepted 1950s medical risks and practices convince a court that the treatment, though it shattered bones, was not legally blameworthy?

In this episode, we recount the facts of the trial and the clinical context that shaped the verdict: what happened at Friern Hospital, why muscle relaxants and restraints were controversial, and how the court weighed medical consensus against a patient’s harm. What does Bolam’s loss reveal about who decides acceptable medical risk?

Person: Bolam
Date: 1957
Location: Friern Hospital, London
Event: Electro-convulsive therapy (ECT) resulting in bilateral acetabular fractures
Status: Jury found no negligence

- Both acetabula (pelvic sockets) were fractured when Bolam convulsed during ECT.
- No muscle relaxant was administered before the electrical current was applied.
- No attendants physically restrained Bolam during the induced seizure.
- Expert testimony showed a significant body of medical opinion in 1957 opposed using muscle relaxants for ECT due to respiratory and cardiovascular risks.
- Experts testified that physical restraints could increase fracture risk by applying opposing external force during violent convulsions.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1342falsefullhttps://www.spreaker.com/episode/how-a-1-50-subsidy-turned-orphans-into-psychiatric-patients--73138423
One dollar and fifty cents a day reshaped thousands of lives in Quebec when orphanages were renamed psychiatric hospitals to collect higher federal subsidies. The switch affected some 22,000 people classified as mentally ill and turned children with no legal advocates into institutional patients - but who authorized the reclassifications and why were no officials ever charged?

In this episode, we tell the documented story of how funding formulas and a 1940s provincial decision transformed orphan care into psychiatric confinement, tracing the roles of government orders, church-run institutions, and the law that allowed vague commitments. How did a published subsidy gap lead to mass reclassification and lifelong consequences for children who could not refuse?

Person: Maurice Duplessis
Period: 1930s-1950s
Law: Loi sur les Asiles d'aliénés (1909)
Estimated subsidy gain: C$70,000,000 (religious communities, 1999 values)
Reclassified population: about 22,000 people labeled mentally ill

- The federal subsidy was $2.75 per day for psychiatric patients versus $1.25 per day for orphans, a $1.50 difference.
- A government commission found one-third of roughly 22,000 people classified as mentally ill had been reclassified for financial reasons.
- Researchers Léo-Paul Lauzon and Martin Poirier estimated religious communities received approximately C$70,000,000 from the reclassification (1999 values).
- The provincial government reportedly saved C$37,000,000 by redesignating a single orphanage (1999 values).
- The Loi sur les Asiles d'aliénés (1909) allowed commitment without a specific diagnosis if a person threatened "social order."

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138423Wed, 29 Jul 2026 23:00:02 +0000Creator at ObomediaHow a $1.50 Subsidy Turned Orphans into Psychiatric Patients One dollar and fifty cents a day reshaped thousands of lives in Quebec when orphanages were renamed psychiatric hospitals to collect higher federal subsidies. The switch affected some...
One dollar and fifty cents a day reshaped thousands of lives in Quebec when orphanages were renamed psychiatric hospitals to collect higher federal subsidies. The switch affected some 22,000 people classified as mentally ill and turned children with no legal advocates into institutional patients - but who authorized the reclassifications and why were no officials ever charged?

In this episode, we tell the documented story of how funding formulas and a 1940s provincial decision transformed orphan care into psychiatric confinement, tracing the roles of government orders, church-run institutions, and the law that allowed vague commitments. How did a published subsidy gap lead to mass reclassification and lifelong consequences for children who could not refuse?

Person: Maurice Duplessis
Period: 1930s-1950s
Law: Loi sur les Asiles d'aliénés (1909)
Estimated subsidy gain: C$70,000,000 (religious communities, 1999 values)
Reclassified population: about 22,000 people labeled mentally ill

- The federal subsidy was $2.75 per day for psychiatric patients versus $1.25 per day for orphans, a $1.50 difference.
- A government commission found one-third of roughly 22,000 people classified as mentally ill had been reclassified for financial reasons.
- Researchers Léo-Paul Lauzon and Martin Poirier estimated religious communities received approximately C$70,000,000 from the reclassification (1999 values).
- The provincial government reportedly saved C$37,000,000 by redesignating a single orphanage (1999 values).
- The Loi sur les Asiles d'aliénés (1909) allowed commitment without a specific diagnosis if a person threatened "social order."

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1157falsefullhttps://www.spreaker.com/episode/000-dead-why-hospitals-kill-far-more-than-courts-admit--73138420
The scale is staggering: peer‑reviewed research estimates 400,000 Americans die each year from preventable hospital errors - more than the entire U.S. World War II death toll - yet only about 17,000 malpractice cases reach courts annually. How does a healthcare system that records 1.14 million patient safety incidents across 37 million Medicare hospitalizations let so many deaths disappear from legal accountability?

In this episode, we lay out the documented record of where those numbers come from, how studies and federal data compiled them, and the practical barriers families face when seeking accountability. What happens between an adverse event in a hospital chart and the courtroom that leaves nineteen of twenty families without legal recourse?

Person: John T. James
Date: 1984 study (landmark estimate)
Date: 2002 CDC hospital-acquired infection accounting
Data: 37 million Medicare hospitalizations reviewed (2000-2002)
Statistic: 1.14 million patient safety incidents identified

- 1984 study estimated 44,000-98,000 annual deaths from preventable hospital errors.
- 2002 CDC reported 75,000 annual deaths from hospital-acquired infections.
- Medicare review (2000-2002) of 37 million hospitalizations found 1.14 million patient safety incidents.
- October 2008 produced $324 million in excess Medicare charges attributed to medical errors in one month.
- Peer‑reviewed analysis by John T. James placed annual deaths from preventable hospital errors at 400,000.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138420Tue, 28 Jul 2026 23:00:02 +0000Creator at Obomedia,000 Dead: Why Hospitals Kill Far More Than Courts Admit The scale is staggering: peer‑reviewed research estimates 400,000 Americans die each year from preventable hospital errors - more than the entire U.S. World War II death toll - yet only about...
The scale is staggering: peer‑reviewed research estimates 400,000 Americans die each year from preventable hospital errors - more than the entire U.S. World War II death toll - yet only about 17,000 malpractice cases reach courts annually. How does a healthcare system that records 1.14 million patient safety incidents across 37 million Medicare hospitalizations let so many deaths disappear from legal accountability?

In this episode, we lay out the documented record of where those numbers come from, how studies and federal data compiled them, and the practical barriers families face when seeking accountability. What happens between an adverse event in a hospital chart and the courtroom that leaves nineteen of twenty families without legal recourse?

Person: John T. James
Date: 1984 study (landmark estimate)
Date: 2002 CDC hospital-acquired infection accounting
Data: 37 million Medicare hospitalizations reviewed (2000-2002)
Statistic: 1.14 million patient safety incidents identified

- 1984 study estimated 44,000-98,000 annual deaths from preventable hospital errors.
- 2002 CDC reported 75,000 annual deaths from hospital-acquired infections.
- Medicare review (2000-2002) of 37 million hospitalizations found 1.14 million patient safety incidents.
- October 2008 produced $324 million in excess Medicare charges attributed to medical errors in one month.
- Peer‑reviewed analysis by John T. James placed annual deaths from preventable hospital errors at 400,000.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1293falsefullhttps://www.spreaker.com/episode/the-western-blot-that-promised-hope-then-vanished--73138418
Hope curdled into uncertainty: a postcard-sized western blot, dark bands on pale film, helped launch simufilam into human trials that eventually enrolled nearly seventeen hundred Alzheimer’s patients - then the drug failed completely in Phase III. How did a single image become the hinge between federal indictments, four investigations, and the disappearance of original data, and what still keeps this case unresolved?

In this episode, we follow the timeline from the mid-2000s papers through NIH funding and human trials to the drug’s discontinuation on November 25, 2024, laying out the scientific claims, institutional decisions, and missing evidence that leave the central question unanswered: was the foundational science ever real?

Person: Lindsay Burns
Person: Hoau-Yan Wang
Event: Simufilam discontinued on November 25, 2024
Case: Federal indictment with charges later dropped with prejudice
Patients: nearly 1,700 enrolled in clinical trials

- The western blot in question was described as a strip of film no larger than a postcard with dark bands on a pale background.
- Simufilam (originally PTI-125) targeted filamin A, a cytoskeletal protein roughly 300 kilodaltons in molecular weight.
- NIH funding supported early clinical work beginning in March 2020, following papers published through 2012 and later.
- Cassava Sciences discontinued simufilam after Phase III trials produced zero measurable benefit.
- A scientist was indicted by a federal grand jury and had every charge dropped the night before trial, with prejudice.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138418Mon, 27 Jul 2026 23:00:02 +0000Creator at ObomediaThe Western Blot That Promised Hope - Then Vanished Hope curdled into uncertainty: a postcard-sized western blot, dark bands on pale film, helped launch simufilam into human trials that eventually enrolled nearly seventeen hundred Alzheimer’s...
Hope curdled into uncertainty: a postcard-sized western blot, dark bands on pale film, helped launch simufilam into human trials that eventually enrolled nearly seventeen hundred Alzheimer’s patients - then the drug failed completely in Phase III. How did a single image become the hinge between federal indictments, four investigations, and the disappearance of original data, and what still keeps this case unresolved?

In this episode, we follow the timeline from the mid-2000s papers through NIH funding and human trials to the drug’s discontinuation on November 25, 2024, laying out the scientific claims, institutional decisions, and missing evidence that leave the central question unanswered: was the foundational science ever real?

Person: Lindsay Burns
Person: Hoau-Yan Wang
Event: Simufilam discontinued on November 25, 2024
Case: Federal indictment with charges later dropped with prejudice
Patients: nearly 1,700 enrolled in clinical trials

- The western blot in question was described as a strip of film no larger than a postcard with dark bands on a pale background.
- Simufilam (originally PTI-125) targeted filamin A, a cytoskeletal protein roughly 300 kilodaltons in molecular weight.
- NIH funding supported early clinical work beginning in March 2020, following papers published through 2012 and later.
- Cassava Sciences discontinued simufilam after Phase III trials produced zero measurable benefit.
- A scientist was indicted by a federal grand jury and had every charge dropped the night before trial, with prejudice.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1403falsefullhttps://www.spreaker.com/episode/the-night-before-trial-when-alzheimer-s-hope-vanished-without-evidence--73138415
Hope turned to doubt when a "two-thousand-twenty press release" claimed an outside laboratory rescued failed biomarker results - but that lab was the same scientist's group behind the original experiments. Hundreds of patients enrolled in trials built on that single-lab science, federal prosecutors later alleged sixteen million dollars in fraudulent grant applications, and then every charge disappeared the night before the trial; what happened to the data that could have settled it all?

In this episode, we lay out the sequence of events that took simufilam from a theory about the scaffolding protein filamin A to a publicly traded company's flagship drug candidate, following trials, funding, and public statements - and we ask why the crucial evidence proving or disproving the work never surfaced.

Person: Hoau-Yan Wang
Person: Lindsay Burns
Event: May 2020 Phase IIb biomarker analysis failed to meet targets
Date: September 2020 Cassava announced "outside laboratory" analysis reversed results
Allegation: Federal grand jury alleged sixteen million dollars in fraudulent grant applications

- The foundational mechanism-of-action evidence for simufilam originated entirely from Wang's laboratory at CUNY.
- Cassava Sciences published a press release in 2020 stating an "outside laboratory" confirmed biomarker improvements four months after a failed Phase IIb result.
- The "outside laboratory" that reportedly reanalyzed the data was Wang's own lab, the same group responsible for the original experiments.
- Hundreds of Alzheimer's patients enrolled in clinical trials based on the science produced by Wang's laboratory and co-authored papers with Lindsay Burns.
- Three leading neuroscientists publicly described the research as implausible, and a federal grand jury later brought allegations tied to sixteen million dollars in grant applications.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138415Sun, 26 Jul 2026 23:00:02 +0000Creator at ObomediaThe Night Before Trial: When Alzheimer's Hope Vanished Without Evidence Hope turned to doubt when a "two-thousand-twenty press release" claimed an outside laboratory rescued failed biomarker results - but that lab was the same scientist's group...
Hope turned to doubt when a "two-thousand-twenty press release" claimed an outside laboratory rescued failed biomarker results - but that lab was the same scientist's group behind the original experiments. Hundreds of patients enrolled in trials built on that single-lab science, federal prosecutors later alleged sixteen million dollars in fraudulent grant applications, and then every charge disappeared the night before the trial; what happened to the data that could have settled it all?

In this episode, we lay out the sequence of events that took simufilam from a theory about the scaffolding protein filamin A to a publicly traded company's flagship drug candidate, following trials, funding, and public statements - and we ask why the crucial evidence proving or disproving the work never surfaced.

Person: Hoau-Yan Wang
Person: Lindsay Burns
Event: May 2020 Phase IIb biomarker analysis failed to meet targets
Date: September 2020 Cassava announced "outside laboratory" analysis reversed results
Allegation: Federal grand jury alleged sixteen million dollars in fraudulent grant applications

- The foundational mechanism-of-action evidence for simufilam originated entirely from Wang's laboratory at CUNY.
- Cassava Sciences published a press release in 2020 stating an "outside laboratory" confirmed biomarker improvements four months after a failed Phase IIb result.
- The "outside laboratory" that reportedly reanalyzed the data was Wang's own lab, the same group responsible for the original experiments.
- Hundreds of Alzheimer's patients enrolled in clinical trials based on the science produced by Wang's laboratory and co-authored papers with Lindsay Burns.
- Three leading neuroscientists publicly described the research as implausible, and a federal grand jury later brought allegations tied to sixteen million dollars in grant applications.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1481falsefullhttps://www.spreaker.com/episode/midnight-charges-retracted-papers-and-the-drug-that-never-worked--73138407
Curiosity that flirts with dread: sixteen million dollars in public funding, a single protein called filamin A, and a drug hailed as a cure before Phase 3 trials quietly folded on November 25, 2024 - so what went wrong, and was the science ever solid? Searchers for medical history and scandal will find retractions, expressions of concern, a grand jury, and a midnight withdrawal of charges that deepen the mystery: was it bad science or something worse?

In this episode, we follow the chronology and documents behind simufilam and the labs that produced its evidence, tracing work from opioid receptor studies to Alzheimer's trials and the unresolved questions that linger about the underlying data. What led regulators, journals, and a university to raise alarms even as patients were recruited into trials?

Person: Lindsay Burns
Person: Hoau-Yan Wang
Protein: filamin A (FLNA)
Drug: simufilam (PTI-125)
Date: November 25, 2024

- $16,000,000 in public money was associated with the development of simufilam.
- Simufilam clinical trials were discontinued quietly on November 25, 2024, during Phase 3 with no demonstrated benefit.
- Two papers in PLOS One (2008 and 2009) co-authored by Burns and Wang were retracted in 2022 for pixel-level similarities in figures.
- The Journal of Neuroscience paper from 2012 received an expression of concern in 2022 but was not retracted.
- An open-label study of simufilam began enrolling patients in March 2020.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138407Sat, 25 Jul 2026 23:00:03 +0000Creator at ObomediaMidnight Charges, Retracted Papers, and the Drug That Never Worked Curiosity that flirts with dread: sixteen million dollars in public funding, a single protein called filamin A, and a drug hailed as a cure before Phase 3 trials quietly folded on...
Curiosity that flirts with dread: sixteen million dollars in public funding, a single protein called filamin A, and a drug hailed as a cure before Phase 3 trials quietly folded on November 25, 2024 - so what went wrong, and was the science ever solid? Searchers for medical history and scandal will find retractions, expressions of concern, a grand jury, and a midnight withdrawal of charges that deepen the mystery: was it bad science or something worse?

In this episode, we follow the chronology and documents behind simufilam and the labs that produced its evidence, tracing work from opioid receptor studies to Alzheimer's trials and the unresolved questions that linger about the underlying data. What led regulators, journals, and a university to raise alarms even as patients were recruited into trials?

Person: Lindsay Burns
Person: Hoau-Yan Wang
Protein: filamin A (FLNA)
Drug: simufilam (PTI-125)
Date: November 25, 2024

- $16,000,000 in public money was associated with the development of simufilam.
- Simufilam clinical trials were discontinued quietly on November 25, 2024, during Phase 3 with no demonstrated benefit.
- Two papers in PLOS One (2008 and 2009) co-authored by Burns and Wang were retracted in 2022 for pixel-level similarities in figures.
- The Journal of Neuroscience paper from 2012 received an expression of concern in 2022 but was not retracted.
- An open-label study of simufilam began enrolling patients in March 2020.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1307falsefullhttps://www.spreaker.com/episode/midnight-drop-how-a-16m-alzheimer-s-miracle-vanished--73138404
Hope turned to doubt overnight: a $16 million NIH grant, hundreds of patients in trials, and a drug called simufilam that rested on a disputed protein called filamin A - then every criminal charge was dropped at midnight. What happened to the biomarker data, the images that triggered retractions, and the independent verification that never arrived?

In this episode, we lay out the timeline from the 2012 Journal of Neuroscience paper that introduced PTI-125 to the 2025 courtroom where charges were dismissed, tracing the grant, the clinical trials, the failed and later conflicting biomarker results, and the unresolved scientific record. How did foundational research, public funding, and patient trials converge - and vanish - without a clear resolution?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Event: Retraction of foundational opioid-related FLNA papers in 2022
Date: Phase IIb failed biomarker analysis in May 2020
Amount: $16,000,000 federal grant from NIH

- 2012: PTI-125 (later renamed simufilam) first described in the Journal of Neuroscience.
- 2017: Mouse data supporting the mechanism published in Neurobiology of Aging.
- 2018: National Institutes of Health awarded Cassava Sciences $16,000,000 to support early clinical trials.
- May 2020: Cassava's Phase IIb cerebrospinal fluid biomarker analysis initially failed to show the expected biological signal.
- 2022: Foundational FLNA opioid-related papers by Wang and Maya Frankfurt were retracted due to similarities in background pixels in western blot images.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138404Fri, 24 Jul 2026 23:00:02 +0000Creator at ObomediaMidnight Drop: How a $16M Alzheimer's Miracle Vanished Hope turned to doubt overnight: a $16 million NIH grant, hundreds of patients in trials, and a drug called simufilam that rested on a disputed protein called filamin A - then every criminal...
Hope turned to doubt overnight: a $16 million NIH grant, hundreds of patients in trials, and a drug called simufilam that rested on a disputed protein called filamin A - then every criminal charge was dropped at midnight. What happened to the biomarker data, the images that triggered retractions, and the independent verification that never arrived?

In this episode, we lay out the timeline from the 2012 Journal of Neuroscience paper that introduced PTI-125 to the 2025 courtroom where charges were dismissed, tracing the grant, the clinical trials, the failed and later conflicting biomarker results, and the unresolved scientific record. How did foundational research, public funding, and patient trials converge - and vanish - without a clear resolution?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Event: Retraction of foundational opioid-related FLNA papers in 2022
Date: Phase IIb failed biomarker analysis in May 2020
Amount: $16,000,000 federal grant from NIH

- 2012: PTI-125 (later renamed simufilam) first described in the Journal of Neuroscience.
- 2017: Mouse data supporting the mechanism published in Neurobiology of Aging.
- 2018: National Institutes of Health awarded Cassava Sciences $16,000,000 to support early clinical trials.
- May 2020: Cassava's Phase IIb cerebrospinal fluid biomarker analysis initially failed to show the expected biological signal.
- 2022: Foundational FLNA opioid-related papers by Wang and Maya Frankfurt were retracted due to similarities in background pixels in western blot images.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1298falsefullhttps://www.spreaker.com/episode/the-protein-that-promised-a-cure-and-vanished-from-the-data--73138402
Hope turned to doubt when pixel-for-pixel repeats in lab images and a single lab's dominance over the evidence underpinned a drug that enrolled over 400 people with Alzheimer's - so what happened to the missing verification that should have stopped human trials? Who knew about the data shifts, and why did a failed biomarker readout get reversed months later?

In this episode, we follow the path from a scaffolding protein called filamin A to a compound taken into human trials, tracing publications, funding, and the contested biomarker results to ask whether the scientific basis for simufilam was ever independently confirmed.

Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Cassava Sciences (formerly Pain Therapeutics)
Drug: simufilam (PTI-125)
Enrollment: more than 400 people by August 2022

- In 2012 Wang and Burns published a key paper linking filamin A to Alzheimer's in the Journal of Neuroscience.
- In 2017 a follow-up study in Neurobiology of Aging reported that PTI-125 improved pathology in transgenic Alzheimer's-model mice.
- In 2018 the NIH awarded funding to Cassava Sciences for early human trials of simufilam.
- By March 2020 open-label human studies had begun with blood biomarker measurements taken from enrolled patients.
- In May 2020 a Phase IIb biomarker analysis failed to support the hypothesized effects, but in September 2020 Cassava announced that an outside lab had produced improved biomarker results.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138402Fri, 24 Jul 2026 04:37:36 +0000Creator at ObomediaThe Protein That Promised a Cure - and Vanished from the Data Hope turned to doubt when pixel-for-pixel repeats in lab images and a single lab's dominance over the evidence underpinned a drug that enrolled over 400 people with Alzheimer's - so what...
Hope turned to doubt when pixel-for-pixel repeats in lab images and a single lab's dominance over the evidence underpinned a drug that enrolled over 400 people with Alzheimer's - so what happened to the missing verification that should have stopped human trials? Who knew about the data shifts, and why did a failed biomarker readout get reversed months later?

In this episode, we follow the path from a scaffolding protein called filamin A to a compound taken into human trials, tracing publications, funding, and the contested biomarker results to ask whether the scientific basis for simufilam was ever independently confirmed.

Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Cassava Sciences (formerly Pain Therapeutics)
Drug: simufilam (PTI-125)
Enrollment: more than 400 people by August 2022

- In 2012 Wang and Burns published a key paper linking filamin A to Alzheimer's in the Journal of Neuroscience.
- In 2017 a follow-up study in Neurobiology of Aging reported that PTI-125 improved pathology in transgenic Alzheimer's-model mice.
- In 2018 the NIH awarded funding to Cassava Sciences for early human trials of simufilam.
- By March 2020 open-label human studies had begun with blood biomarker measurements taken from enrolled patients.
- In May 2020 a Phase IIb biomarker analysis failed to support the hypothesized effects, but in September 2020 Cassava announced that an outside lab had produced improved biomarker results.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1401falsefullhttps://www.spreaker.com/episode/the-case-of-the-vanishing-blots-how-simufilam-s-evidence-disappeared--73138397
A single set of laboratory photographs - western blots - became the fulcrum of a dispute that touched federal grand juries, NIH funding, and hundreds of Alzheimer’s patients. Pixels matching across images from supposedly separate experiments, an outside lab that turned out to be the same academic group behind the drug, and a night-before-trial DOJ decision leave one central question: how did the visual evidence underpinning simufilam vanish into ambiguity?

In this episode, we trace the chronology of simufilam’s rise and the contested data that sustained it, laying out the key players, the published papers, and the discovery that blurred the line between independent confirmation and internal reanalysis. What does the record show about the provenance of the western blots, and why did four federal investigations still not resolve that question?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Person: Thomas Südhof
Date: September 2020
Event: Re-analysis of biomarker data presented as from an outside laboratory

- Cassava Sciences announced an outside laboratory confirmed simufilam’s biomarker improvements in September 2020.
- The “outside laboratory” that re-analyzed the failed May 2020 cerebrospinal fluid biomarkers was Wang’s CUNY lab.
- Simufilam (PTI-125) was built on findings about filamin A (FLNA) reported in PLOS One papers co-authored by Wang, Burns, and Maya Frankfurt.
- NIH funding was awarded in 2018 and open-label studies began in March 2020 for simufilam.
- Four simultaneous federal investigations occurred and the original laboratory data was never produced, leaving no court-established guilt or institutional proof of misconduct.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138397Fri, 24 Jul 2026 04:37:32 +0000Creator at ObomediaThe Case of the Vanishing Blots: How Simufilam's Evidence Disappeared A single set of laboratory photographs - western blots - became the fulcrum of a dispute that touched federal grand juries, NIH funding, and hundreds of Alzheimer’s patients....
A single set of laboratory photographs - western blots - became the fulcrum of a dispute that touched federal grand juries, NIH funding, and hundreds of Alzheimer’s patients. Pixels matching across images from supposedly separate experiments, an outside lab that turned out to be the same academic group behind the drug, and a night-before-trial DOJ decision leave one central question: how did the visual evidence underpinning simufilam vanish into ambiguity?

In this episode, we trace the chronology of simufilam’s rise and the contested data that sustained it, laying out the key players, the published papers, and the discovery that blurred the line between independent confirmation and internal reanalysis. What does the record show about the provenance of the western blots, and why did four federal investigations still not resolve that question?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Person: Thomas Südhof
Date: September 2020
Event: Re-analysis of biomarker data presented as from an outside laboratory

- Cassava Sciences announced an outside laboratory confirmed simufilam’s biomarker improvements in September 2020.
- The “outside laboratory” that re-analyzed the failed May 2020 cerebrospinal fluid biomarkers was Wang’s CUNY lab.
- Simufilam (PTI-125) was built on findings about filamin A (FLNA) reported in PLOS One papers co-authored by Wang, Burns, and Maya Frankfurt.
- NIH funding was awarded in 2018 and open-label studies began in March 2020 for simufilam.
- Four simultaneous federal investigations occurred and the original laboratory data was never produced, leaving no court-established guilt or institutional proof of misconduct.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1387falsefullhttps://www.spreaker.com/episode/the-drug-that-nausea-kept-from-becoming-a-psychedelic-mystery--73138390
Nausea ended nearly every human trial before quipazine could show whether it was psychedelic - at 25 mg oral doses subjects had severe gastrointestinal distress, while rodents and monkeys showed clear LSD-like effects. How did a compound that substituted fully for LSD in animals fail so completely in people?

In this episode, we trace quipazine’s discovery in 1966, its pharmacological profile across serotonin receptors, and the contrasting human and animal data that left researchers baffled. Can the same molecule trigger vomiting and mimic psychedelics at once, and what does that tell us about translating animal models to human consciousness?

Person: quipazine
Date: 1966 (first appearance in literature)
Dose (human): 25 mg oral produced nausea and gastrointestinal distress
Receptor affinity: strongest for 5-HT3; also binds 5-HT2A, 5-HT2B, 5-HT2C, 5-HT1B, 5-HT1A
Animal finding: substituted fully for LSD in rodents and monkeys; produced head-twitch response in rodents

- The literature records a single footnoted human report listing a 0.5 mg dose with an effect noted (printed with "sic").
- At 25 mg oral in human subjects quipazine caused nausea, flatulence, cramps, and diarrhea with no LSD-like effects observed.
- Quipazine’s strongest receptor affinity is for 5-HT3, a receptor whose activation provokes nausea and vomiting in humans.
- In 1977 rodents given quipazine showed the head-twitch response, blocked by the 5-HT2A antagonist ketanserin.
- Drug discrimination studies found quipazine substituted fully for LSD, DOM, and in reverse tests LSD, mescaline, and psilocybin substituted fully for quipazine in animals.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138390Fri, 24 Jul 2026 04:37:27 +0000Creator at ObomediaThe Drug That Nausea Kept From Becoming a Psychedelic Mystery Nausea ended nearly every human trial before quipazine could show whether it was psychedelic - at 25 mg oral doses subjects had severe gastrointestinal distress, while rodents and...
Nausea ended nearly every human trial before quipazine could show whether it was psychedelic - at 25 mg oral doses subjects had severe gastrointestinal distress, while rodents and monkeys showed clear LSD-like effects. How did a compound that substituted fully for LSD in animals fail so completely in people?

In this episode, we trace quipazine’s discovery in 1966, its pharmacological profile across serotonin receptors, and the contrasting human and animal data that left researchers baffled. Can the same molecule trigger vomiting and mimic psychedelics at once, and what does that tell us about translating animal models to human consciousness?

Person: quipazine
Date: 1966 (first appearance in literature)
Dose (human): 25 mg oral produced nausea and gastrointestinal distress
Receptor affinity: strongest for 5-HT3; also binds 5-HT2A, 5-HT2B, 5-HT2C, 5-HT1B, 5-HT1A
Animal finding: substituted fully for LSD in rodents and monkeys; produced head-twitch response in rodents

- The literature records a single footnoted human report listing a 0.5 mg dose with an effect noted (printed with "sic").
- At 25 mg oral in human subjects quipazine caused nausea, flatulence, cramps, and diarrhea with no LSD-like effects observed.
- Quipazine’s strongest receptor affinity is for 5-HT3, a receptor whose activation provokes nausea and vomiting in humans.
- In 1977 rodents given quipazine showed the head-twitch response, blocked by the 5-HT2A antagonist ketanserin.
- Drug discrimination studies found quipazine substituted fully for LSD, DOM, and in reverse tests LSD, mescaline, and psilocybin substituted fully for quipazine in animals.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>879falsefullhttps://www.spreaker.com/episode/the-sic-that-screamed-half-a-milligram-full-psychedelic-mystery--73138385
Half a milligram of quipazine is printed in the scientific record with a sic-an editor’s signal that the number looks wrong but was left as written-and that same tiny dose is reported to have produced a full psychedelic response. How could a compound that caused reliable nausea and blocked human testing also show unmistakable psychedelic markers in animals at doses supposedly far below prior thresholds?

In this episode, we trace the paper trail from a 1966 research optimism to animal head-twitch responses in 1977, primate vomiting reports, and stalled human trials halted by dose-limiting nausea, and we ask whether the anomalous half-milligram report is a clerical fluke, a hint of hidden pharmacology, or evidence that quipazine’s effects were never fully testable.

Person: James Winter
Date: 1966
Date: 1977
Compound: quipazine
Drug class: serotonin agonist

- The published report records a dose of 0.5 milligram with the editorial insertion "sic".
- In 1977, rodents exposed to quipazine produced the head-twitch response associated with psychedelics.
- Monkeys given quipazine showed agitation, disrupted motor patterns, altered social interaction, and projectile vomiting.
- Early human trials were limited by nausea, with a maximum tolerated dose recorded at 25 milligrams and no confirmed LSD-like effects below that ceiling.
- James Winter proposed in 1994 using ondansetron to block nausea and reveal quipazine’s potential psychoactive effects.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138385Fri, 24 Jul 2026 04:37:24 +0000Creator at ObomediaThe Sic That Screamed: Half a Milligram, Full Psychedelic Mystery Half a milligram of quipazine is printed in the scientific record with a sic-an editor’s signal that the number looks wrong but was left as written-and that same tiny dose is...
Half a milligram of quipazine is printed in the scientific record with a sic-an editor’s signal that the number looks wrong but was left as written-and that same tiny dose is reported to have produced a full psychedelic response. How could a compound that caused reliable nausea and blocked human testing also show unmistakable psychedelic markers in animals at doses supposedly far below prior thresholds?

In this episode, we trace the paper trail from a 1966 research optimism to animal head-twitch responses in 1977, primate vomiting reports, and stalled human trials halted by dose-limiting nausea, and we ask whether the anomalous half-milligram report is a clerical fluke, a hint of hidden pharmacology, or evidence that quipazine’s effects were never fully testable.

Person: James Winter
Date: 1966
Date: 1977
Compound: quipazine
Drug class: serotonin agonist

- The published report records a dose of 0.5 milligram with the editorial insertion "sic".
- In 1977, rodents exposed to quipazine produced the head-twitch response associated with psychedelics.
- Monkeys given quipazine showed agitation, disrupted motor patterns, altered social interaction, and projectile vomiting.
- Early human trials were limited by nausea, with a maximum tolerated dose recorded at 25 milligrams and no confirmed LSD-like effects below that ceiling.
- James Winter proposed in 1994 using ondansetron to block nausea and reveal quipazine’s potential psychoactive effects.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1303falsefullhttps://www.spreaker.com/episode/a-molecule-proving-psychedelic-in-animals-for-decades-blocked-entirely-by-nausea--73138381
A single compound produced the classic head‑twitch and substituted for LSD across decades of rodent studies, yet it never advanced in humans - because the same molecule caused projectile vomiting in primates that rodents cannot report. How did a reproducible psychedelic signal in animals get concealed by a basic anatomical difference, and what does that mean for interpreting decades of serotonin research?

In this episode, we lay out the experimental trail from the compound’s 1966 synthesis through repeated rodent assays and primate trials, and follow how an ordinary physiological effect altered the course of scientific and clinical judgment. What happens when a reliable animal marker misses the one symptom that would make all the difference?

Person: quipazine (one-(2-quinolinyl)piperazine)
Date: 1966 (synthesis), 2007 (recording mentioned)
Topic: serotonergic psychedelic activity and head-twitch response
Event: projectile vomiting observed in primate trials
Period: 1960s-2000s (decades of animal studies)

- The compound quipazine was synthesized in 1966 and later used as a serotonin receptor probe.
- In the 1970s, quipazine reliably produced the mouse head-twitch response, a standard marker of psychedelic-like serotonergic activity.
- Drug-discrimination studies showed animals trained on LSD pressed the same lever when given quipazine, indicating subjective equivalence in nonverbal assays.
- Rodents cannot vomit anatomically, so rodent studies could not reveal nausea or emesis caused by quipazine.
- Primate trials showed LSD-like behaviors accompanied by projectile vomiting, halting further meaningful human trials.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138381Fri, 24 Jul 2026 04:37:20 +0000Creator at ObomediaA molecule proving psychedelic in animals for decades - blocked entirely by nausea A single compound produced the classic head‑twitch and substituted for LSD across decades of rodent studies, yet it never advanced in humans - because the same...
A single compound produced the classic head‑twitch and substituted for LSD across decades of rodent studies, yet it never advanced in humans - because the same molecule caused projectile vomiting in primates that rodents cannot report. How did a reproducible psychedelic signal in animals get concealed by a basic anatomical difference, and what does that mean for interpreting decades of serotonin research?

In this episode, we lay out the experimental trail from the compound’s 1966 synthesis through repeated rodent assays and primate trials, and follow how an ordinary physiological effect altered the course of scientific and clinical judgment. What happens when a reliable animal marker misses the one symptom that would make all the difference?

Person: quipazine (one-(2-quinolinyl)piperazine)
Date: 1966 (synthesis), 2007 (recording mentioned)
Topic: serotonergic psychedelic activity and head-twitch response
Event: projectile vomiting observed in primate trials
Period: 1960s-2000s (decades of animal studies)

- The compound quipazine was synthesized in 1966 and later used as a serotonin receptor probe.
- In the 1970s, quipazine reliably produced the mouse head-twitch response, a standard marker of psychedelic-like serotonergic activity.
- Drug-discrimination studies showed animals trained on LSD pressed the same lever when given quipazine, indicating subjective equivalence in nonverbal assays.
- Rodents cannot vomit anatomically, so rodent studies could not reveal nausea or emesis caused by quipazine.
- Primate trials showed LSD-like behaviors accompanied by projectile vomiting, halting further meaningful human trials.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1353falsefullhttps://www.spreaker.com/episode/the-molecule-that-mimicked-lsd-but-made-humans-vomit-first--73138378
A molecule that behaved like LSD in every animal test still failed humans because the body rejected it first: quipazine produced full animal substitution and head-twitch responses, yet in primates and humans it provoked pronounced, persistent vomiting that made psychedelic effects irrelevant. How did a compound pass rigorous behavioral signatures for half a century and still never arrive in human consciousness?

In this episode, we trace quipazine’s unusual history through animal discrimination studies, primate trials, and the lone human reports, and ask whether the architectural clash between receptors explains the long puzzle. Could blocking one receptor have revealed the psychedelic effects that animals repeatedly signaled?

Person: James Winter
Date: 2007 (anonymous human report recorded; published 2011)
Date: 1994 (Winter’s proposal)
Topic: quipazine pharmacology
Event: doctoral thesis at Columbia University sealed until 2030

- Quipazine produced full substitution in drug discrimination studies trained on LSD, not partial or approximate.
- Quipazine reliably evoked the head-twitch response in mice, a key 5-HT2A activation marker.
- In primates, quipazine caused pronounced, persistent projectile vomiting linked to 5-HT3 activation.
- A human trial at 25 mg produced no LSD-like subjective effects and intolerable gastrointestinal side effects.
- A published document lists a 0.5 mg dose flagged with "sic," unexplained and anomalously low.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138378Fri, 24 Jul 2026 04:37:16 +0000Creator at ObomediaThe Molecule That Mimicked LSD - But Made Humans Vomit First A molecule that behaved like LSD in every animal test still failed humans because the body rejected it first: quipazine produced full animal substitution and head-twitch responses, yet in...
A molecule that behaved like LSD in every animal test still failed humans because the body rejected it first: quipazine produced full animal substitution and head-twitch responses, yet in primates and humans it provoked pronounced, persistent vomiting that made psychedelic effects irrelevant. How did a compound pass rigorous behavioral signatures for half a century and still never arrive in human consciousness?

In this episode, we trace quipazine’s unusual history through animal discrimination studies, primate trials, and the lone human reports, and ask whether the architectural clash between receptors explains the long puzzle. Could blocking one receptor have revealed the psychedelic effects that animals repeatedly signaled?

Person: James Winter
Date: 2007 (anonymous human report recorded; published 2011)
Date: 1994 (Winter’s proposal)
Topic: quipazine pharmacology
Event: doctoral thesis at Columbia University sealed until 2030

- Quipazine produced full substitution in drug discrimination studies trained on LSD, not partial or approximate.
- Quipazine reliably evoked the head-twitch response in mice, a key 5-HT2A activation marker.
- In primates, quipazine caused pronounced, persistent projectile vomiting linked to 5-HT3 activation.
- A human trial at 25 mg produced no LSD-like subjective effects and intolerable gastrointestinal side effects.
- A published document lists a 0.5 mg dose flagged with "sic," unexplained and anomalously low.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1268falsefullhttps://www.spreaker.com/episode/the-antidepressant-that-vomited-its-way-toward-being-a-psychedelic--73138375
A forgotten drug from 1966 behaved like a true psychedelic in animals yet produced projectile vomiting in monkeys and severe gastrointestinal distress in humans at 25 mg - so how could the same molecule show LSD-like head-twitches and still fail to produce visions in people? What if a single receptor blockade could have unlocked its psychedelic effects?

In this episode, we trace the published record from the first syntheses through animal conditioning studies, receptor pharmacology, and halted human exposure to ask whether quipazine’s paradox could ever have been resolved and what remained unpublished in later work.

Person: Jerrold C. Winter
Date: 1966
Compound: quipazine (one-(two-quinolinyl)piperazine; 2-QP)
Dose reported in humans: 25 mg
Behavioral marker: head-twitch response in rodents and monkeys

- Quipazine was first described in the scientific literature in 1966.
- By 1971 researchers characterized quipazine as antidepressant-like in laboratory animals.
- In 1977 animal studies documented quipazine produced a head-twitch response similar to LSD, psilocybin, and mescaline.
- Human subjects given 25 mg reported nausea, flatulence, and severe gastrointestinal distress with no visions.
- Quipazine is a potent agonist at 5-HT3 (causing vomiting) but its psychedelic-like animal effects were mediated through 5-HT2A, blocked by ketanserin.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138375Fri, 24 Jul 2026 04:37:12 +0000Creator at ObomediaThe Antidepressant That Vomited Its Way Toward Being a Psychedelic A forgotten drug from 1966 behaved like a true psychedelic in animals yet produced projectile vomiting in monkeys and severe gastrointestinal distress in humans at 25 mg - so how...
A forgotten drug from 1966 behaved like a true psychedelic in animals yet produced projectile vomiting in monkeys and severe gastrointestinal distress in humans at 25 mg - so how could the same molecule show LSD-like head-twitches and still fail to produce visions in people? What if a single receptor blockade could have unlocked its psychedelic effects?

In this episode, we trace the published record from the first syntheses through animal conditioning studies, receptor pharmacology, and halted human exposure to ask whether quipazine’s paradox could ever have been resolved and what remained unpublished in later work.

Person: Jerrold C. Winter
Date: 1966
Compound: quipazine (one-(two-quinolinyl)piperazine; 2-QP)
Dose reported in humans: 25 mg
Behavioral marker: head-twitch response in rodents and monkeys

- Quipazine was first described in the scientific literature in 1966.
- By 1971 researchers characterized quipazine as antidepressant-like in laboratory animals.
- In 1977 animal studies documented quipazine produced a head-twitch response similar to LSD, psilocybin, and mescaline.
- Human subjects given 25 mg reported nausea, flatulence, and severe gastrointestinal distress with no visions.
- Quipazine is a potent agonist at 5-HT3 (causing vomiting) but its psychedelic-like animal effects were mediated through 5-HT2A, blocked by ketanserin.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1469falsefullhttps://www.spreaker.com/episode/the-molecule-that-wanted-to-trip-but-made-you-vomit--73138371
Amazingly, a compound first reported in 1966 triggered every animal marker of a classical psychedelic but produced no full psychedelic reports in humans for forty-one years because it reliably caused nausea and vomiting. How did a molecule that fully substituted for LSD in drug-discrimination tests stall for decades at the threshold of human validation?

In this episode, we trace quipazine’s path from a 1966 arylpiperazine antidepressant candidate to a drug that produced reproducible head-twitch responses in mice, rats, and monkeys yet induced dose-limiting gastrointestinal distress in humans - and consider the implications of recent academic work and a single 2007 anecdote that may change the story.

Person: Alexander Shulgin
Date: 1966 first literature appearance
Topic: quipazine pharmacology and behavioral effects
Event: 2007 anonymous report of a full psychedelic response
Institution: Columbia University embargoed thesis (2025, sealed until 2030)

- Quipazine produced head-twitch responses in mice, rats, and monkeys linked to 5-HT2A activation.
- In drug-discrimination studies quipazine fully substituted for LSD and DOM, and partially for mescaline.
- Oral 25 mg in humans caused nausea, flatulence, gastrointestinal discomfort, and diarrhea without LSD-like subjective effects.
- Quipazine activates 5-HT3 receptors producing reliable nausea and projectile vomiting in nonhuman primates.
- A 2007 anonymous individual combined quipazine with a presumed ondansetron and reported a full psychedelic response; the account was published by Shulgin in 2011.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138371Fri, 24 Jul 2026 04:37:08 +0000Creator at ObomediaThe Molecule That Wanted to Trip - But Made You Vomit Amazingly, a compound first reported in 1966 triggered every animal marker of a classical psychedelic but produced no full psychedelic reports in humans for forty-one years because it reliably...
Amazingly, a compound first reported in 1966 triggered every animal marker of a classical psychedelic but produced no full psychedelic reports in humans for forty-one years because it reliably caused nausea and vomiting. How did a molecule that fully substituted for LSD in drug-discrimination tests stall for decades at the threshold of human validation?

In this episode, we trace quipazine’s path from a 1966 arylpiperazine antidepressant candidate to a drug that produced reproducible head-twitch responses in mice, rats, and monkeys yet induced dose-limiting gastrointestinal distress in humans - and consider the implications of recent academic work and a single 2007 anecdote that may change the story.

Person: Alexander Shulgin
Date: 1966 first literature appearance
Topic: quipazine pharmacology and behavioral effects
Event: 2007 anonymous report of a full psychedelic response
Institution: Columbia University embargoed thesis (2025, sealed until 2030)

- Quipazine produced head-twitch responses in mice, rats, and monkeys linked to 5-HT2A activation.
- In drug-discrimination studies quipazine fully substituted for LSD and DOM, and partially for mescaline.
- Oral 25 mg in humans caused nausea, flatulence, gastrointestinal discomfort, and diarrhea without LSD-like subjective effects.
- Quipazine activates 5-HT3 receptors producing reliable nausea and projectile vomiting in nonhuman primates.
- A 2007 anonymous individual combined quipazine with a presumed ondansetron and reported a full psychedelic response; the account was published by Shulgin in 2011.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1463falsefullhttps://www.spreaker.com/episode/when-the-miracle-metabolism-drug-became-a-hidden-cancer-weapon--73138369
A drug designed to burn fat and boost endurance was shelved after causing rapid, multi-organ cancers in mice, then resurfaced as a $1,000-per-10g performance enhancer sold openly online - so how did a compound abandoned by GlaxoSmithKline end up in elite athletes' bodies? What happened between Phase II trials and the underground market that let a cancer-linked drug become a sports hazard?

In this episode, we trace the drug's path from formal pharmaceutical collaboration and clinical trials to high-profile publications and the black market, and we ask how the same PPARδ activation that delivered metabolic benefits also drove tumor growth.

Person: Ronald M. Evans
Company: GlaxoSmithKline
Partner: Ligand Pharmaceuticals
Compound: GW501516 (Cardarine)
Year of abandonment: 2007

- GW501516 produced rapid multi-organ cancers in mice and rats at 3 mg/kg/day in preclinical studies.
- Phase I and Phase II clinical trials for GW501516 ran through 2002-2007 before the program was stopped.
- A Cell paper in 2007 reported dramatically increased physical endurance in mice given GW501516 at higher doses.
- After the 2007 publication, GW501516 was sold online as "Cardarine" for roughly $1,000 for 10 grams with no prescription.
- In 2009, the World Anti-Doping Agency added GW501516 and related PPARδ modulators to the prohibited list.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138369Fri, 24 Jul 2026 04:37:04 +0000Creator at ObomediaWhen the Miracle Metabolism Drug Became a Hidden Cancer Weapon A drug designed to burn fat and boost endurance was shelved after causing rapid, multi-organ cancers in mice, then resurfaced as a $1,000-per-10g performance enhancer sold openly online...
A drug designed to burn fat and boost endurance was shelved after causing rapid, multi-organ cancers in mice, then resurfaced as a $1,000-per-10g performance enhancer sold openly online - so how did a compound abandoned by GlaxoSmithKline end up in elite athletes' bodies? What happened between Phase II trials and the underground market that let a cancer-linked drug become a sports hazard?

In this episode, we trace the drug's path from formal pharmaceutical collaboration and clinical trials to high-profile publications and the black market, and we ask how the same PPARδ activation that delivered metabolic benefits also drove tumor growth.

Person: Ronald M. Evans
Company: GlaxoSmithKline
Partner: Ligand Pharmaceuticals
Compound: GW501516 (Cardarine)
Year of abandonment: 2007

- GW501516 produced rapid multi-organ cancers in mice and rats at 3 mg/kg/day in preclinical studies.
- Phase I and Phase II clinical trials for GW501516 ran through 2002-2007 before the program was stopped.
- A Cell paper in 2007 reported dramatically increased physical endurance in mice given GW501516 at higher doses.
- After the 2007 publication, GW501516 was sold online as "Cardarine" for roughly $1,000 for 10 grams with no prescription.
- In 2009, the World Anti-Doping Agency added GW501516 and related PPARδ modulators to the prohibited list.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1516falsefullhttps://www.spreaker.com/episode/abandoned-by-gsk-stolen-by-sport-the-deadly-rise-of-cardarine--73138368
A single lab result erased a sold-out Madison Square Garden fight when a compound never approved for humans turned up in Jarrell Miller’s system - and that compound had caused rapid cancers in multiple organs in rats and mice at 3 mg/kg/day. How did a drug developed by GlaxoSmithKline, quietly abandoned after those animal findings, become a black-market performance enhancer celebrated in top journals and newspapers?

In this episode, we lay out the documented chain of events from pharmaceutical research to public celebration and illicit use, tracing the paperwork, publications, and public coverage that let the positive story outpace the cancer data. What allowed the record of rapid tumors to be buried while the image of miraculous endurance spread?

Person: Jarrell Miller
Event: Madison Square Garden fight cancellation, April 2019
Compound: GW501516 (Cardarine)
Dose in animal studies: 3 mg/kg/day
Publication: Cell paper reporting dramatic endurance effects in mice

- The Madison Square Garden fight between Jarrell Miller and Anthony Joshua was canceled three weeks before the bout due to a positive test.
- GlaxoSmithKline and Ligand Pharmaceuticals began developing GW501516 in 1992 and published a formal paper in 2001.
- Phase one trials began in 2000 and phase one and two trials ran in 2002, with Ligand receiving a $1,000,000 milestone payment from GSK in 2003.
- Animal studies at 3 mg/kg/day in rats and mice produced rapid cancers in multiple organs, prompting GSK to shut down the program by 2007 without public explanation.
- In 2007, a separate lab published a Cell paper showing mice given GW501516 at higher doses exhibited dramatic increases in physical performance, prompting mainstream media coverage.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138368Fri, 24 Jul 2026 04:37:00 +0000Creator at ObomediaAbandoned by GSK, Stolen by Sport: The Deadly Rise of Cardarine A single lab result erased a sold-out Madison Square Garden fight when a compound never approved for humans turned up in Jarrell Miller’s system - and that compound had caused rapid...
A single lab result erased a sold-out Madison Square Garden fight when a compound never approved for humans turned up in Jarrell Miller’s system - and that compound had caused rapid cancers in multiple organs in rats and mice at 3 mg/kg/day. How did a drug developed by GlaxoSmithKline, quietly abandoned after those animal findings, become a black-market performance enhancer celebrated in top journals and newspapers?

In this episode, we lay out the documented chain of events from pharmaceutical research to public celebration and illicit use, tracing the paperwork, publications, and public coverage that let the positive story outpace the cancer data. What allowed the record of rapid tumors to be buried while the image of miraculous endurance spread?

Person: Jarrell Miller
Event: Madison Square Garden fight cancellation, April 2019
Compound: GW501516 (Cardarine)
Dose in animal studies: 3 mg/kg/day
Publication: Cell paper reporting dramatic endurance effects in mice

- The Madison Square Garden fight between Jarrell Miller and Anthony Joshua was canceled three weeks before the bout due to a positive test.
- GlaxoSmithKline and Ligand Pharmaceuticals began developing GW501516 in 1992 and published a formal paper in 2001.
- Phase one trials began in 2000 and phase one and two trials ran in 2002, with Ligand receiving a $1,000,000 milestone payment from GSK in 2003.
- Animal studies at 3 mg/kg/day in rats and mice produced rapid cancers in multiple organs, prompting GSK to shut down the program by 2007 without public explanation.
- In 2007, a separate lab published a Cell paper showing mice given GW501516 at higher doses exhibited dramatic increases in physical performance, prompting mainstream media coverage.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1458falsefullhttps://www.spreaker.com/episode/a-mushroom-derived-sleep-drug-halted-at-phase-3-because-it-looked-like-lsd--73138367
Sleep medicine’s promise and peril converge in one sentence: "Looks like LSD to me." Gaboxadol, a mushroom‑derived compound that increased slow‑wave sleep and raised the lethal-dose margin more than fourteenfold compared with muscimol, passed Phase 2 with clear clinical benefit - yet it was stopped before it reached patients. How did a drug that restored deep, restorative sleep vanish because it “looked” like something else?

In this episode, we tell the story of gaboxadol from lab bench to corporate decision, covering its origin from muscimol in Amanita muscaria, the key trial results that showed increased slow‑wave sleep and noise‑resistant sleep maintenance, and the boardroom moment that ended the program. What exactly in the data and the decision-making sealed its fate?

Person: Robert Morris
Topic: gaboxadol (mushroom‑derived sleep drug)
Author: Lancel (published relevant 1996 findings)
Period: late 1990s
Event: Phase 2 trials showing increased slow‑wave sleep

- The lethal dose of muscimol in animal models was 22 mg/kg.
- Gaboxadol’s equivalent lethal figure exceeded 320 mg/kg (over 14× higher).
- One researcher self‑administered 10 mg and reported effects “like having drunk two or three beers” with no visual disturbance.
- At doses ≤15 mg, psychiatric side effect rates were statistically indistinguishable from placebo.
- A Merck executive’s four‑word remark - "Looks like LSD to me." - preceded the program’s termination.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138367Fri, 24 Jul 2026 04:36:56 +0000Creator at ObomediaA mushroom-derived sleep drug halted at Phase 3 - because it looked like LSD Sleep medicine’s promise and peril converge in one sentence: "Looks like LSD to me." Gaboxadol, a mushroom‑derived compound that increased slow‑wave sleep and raised the...
Sleep medicine’s promise and peril converge in one sentence: "Looks like LSD to me." Gaboxadol, a mushroom‑derived compound that increased slow‑wave sleep and raised the lethal-dose margin more than fourteenfold compared with muscimol, passed Phase 2 with clear clinical benefit - yet it was stopped before it reached patients. How did a drug that restored deep, restorative sleep vanish because it “looked” like something else?

In this episode, we tell the story of gaboxadol from lab bench to corporate decision, covering its origin from muscimol in Amanita muscaria, the key trial results that showed increased slow‑wave sleep and noise‑resistant sleep maintenance, and the boardroom moment that ended the program. What exactly in the data and the decision-making sealed its fate?

Person: Robert Morris
Topic: gaboxadol (mushroom‑derived sleep drug)
Author: Lancel (published relevant 1996 findings)
Period: late 1990s
Event: Phase 2 trials showing increased slow‑wave sleep

- The lethal dose of muscimol in animal models was 22 mg/kg.
- Gaboxadol’s equivalent lethal figure exceeded 320 mg/kg (over 14× higher).
- One researcher self‑administered 10 mg and reported effects “like having drunk two or three beers” with no visual disturbance.
- At doses ≤15 mg, psychiatric side effect rates were statistically indistinguishable from placebo.
- A Merck executive’s four‑word remark - "Looks like LSD to me." - preceded the program’s termination.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1297falsefullhttps://www.spreaker.com/episode/the-urine-revolution-how-a-pregnancy-hormone-remade-medicine--73138366
Pregnant urine yielded a crystalline estrogen in 1929 that was being injected into women within months - and that molecule, estrone, became one of the most prescribed hormones of the twentieth century. How did estrone go from urine to worldwide pharmaceutical industry before anyone fully understood its biology?

In this episode, we tell the story of how estrone moved from laboratory isolation to rapid commercial use across multiple companies and formulations, and why clinicians began using it for menopausal symptoms, hypogonadism, and certain cancers. What tensions arose when clinical adoption raced ahead of mechanistic understanding?

Person: Bernhard Zondek and Selmar Aschheim
Date: 1929
Location: Europe and North America
Period: 1920s-1940s
Topic: Estrone isolation and clinical use

- 1927: Zondek and Aschheim demonstrated that pregnant women’s urine contained large amounts of estrogenic compounds.
- 1929: Multiple teams isolated a crystalline estrogenic compound identified as estrone in the same year.
- 1929: Squibb, Schering, and Parke-Davis released Amniotin, Progynon, and Theelin within the same calendar year estrone was crystallized.
- Dosing for menopausal symptoms typically ranged from 0.1 to 2 milligrams per week by intramuscular injection, or 0.1 to 0.5 mg two to three times weekly.
- 1944: Parke-Davis introduced Theelin Aqueous Suspension using microcrystalline particles to create a slow-release depot after intramuscular injection.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138366Fri, 24 Jul 2026 04:36:52 +0000Creator at ObomediaThe Urine Revolution: How a Pregnancy Hormone Remade Medicine Pregnant urine yielded a crystalline estrogen in 1929 that was being injected into women within months - and that molecule, estrone, became one of the most prescribed hormones of the...
Pregnant urine yielded a crystalline estrogen in 1929 that was being injected into women within months - and that molecule, estrone, became one of the most prescribed hormones of the twentieth century. How did estrone go from urine to worldwide pharmaceutical industry before anyone fully understood its biology?

In this episode, we tell the story of how estrone moved from laboratory isolation to rapid commercial use across multiple companies and formulations, and why clinicians began using it for menopausal symptoms, hypogonadism, and certain cancers. What tensions arose when clinical adoption raced ahead of mechanistic understanding?

Person: Bernhard Zondek and Selmar Aschheim
Date: 1929
Location: Europe and North America
Period: 1920s-1940s
Topic: Estrone isolation and clinical use

- 1927: Zondek and Aschheim demonstrated that pregnant women’s urine contained large amounts of estrogenic compounds.
- 1929: Multiple teams isolated a crystalline estrogenic compound identified as estrone in the same year.
- 1929: Squibb, Schering, and Parke-Davis released Amniotin, Progynon, and Theelin within the same calendar year estrone was crystallized.
- Dosing for menopausal symptoms typically ranged from 0.1 to 2 milligrams per week by intramuscular injection, or 0.1 to 0.5 mg two to three times weekly.
- 1944: Parke-Davis introduced Theelin Aqueous Suspension using microcrystalline particles to create a slow-release depot after intramuscular injection.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1441falsefullhttps://www.spreaker.com/episode/when-a-single-injection-killed-the-estradiol-undecylate-mystery--73138364
Forty to sixty days of hormone control from a single shot-and in one trial sixteen of twenty-one men developed cardiovascular complications and two died. How could an estrogen used across Europe and Japan for decades, with doses of 10-50 mg designed to last months, produce such dramatic harm in a subgroup of patients?

In this episode, we lay out the clinical trial evidence, pharmacology, and published research that followed estradiol undecylate from its 1953 description to its late‑20th century decline, asking how depot chemistry, patient variability, and trial design combined to create a medical puzzle: was the drug’s promise outweighed by unpredictable risk?

Person: Karl Junkmann
Date: 1953 (first description)
Drug: Estradiol undecylate
Dose range: 10-50 mg (therapeutic), 100 mg (reported pharmacokinetics)
Trial: Jacobi Phase 3, 1978, 191 men across 12 German centers

- The molecule had an 11‑carbon ester chain, making it highly lipophilic and slow‑releasing.
- A single 10-12.5 mg injection could sustain therapeutic levels for 40-60 days; 25-50 mg for 2-4 months.
- After a 100 mg injection, mean peak blood concentration was ~500 pg/mL on day 1 and ~340 pg/mL by day 14.
- Blood levels varied up to tenfold between patients given the same dose and injection technique.
- In a cited subgroup, 21 men entered a trial with no heart disease history; 16 developed cardiovascular complications and 2 died.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138364Fri, 24 Jul 2026 04:36:48 +0000Creator at ObomediaWhen a Single Injection Killed: The Estradiol Undecylate Mystery Forty to sixty days of hormone control from a single shot-and in one trial sixteen of twenty-one men developed cardiovascular complications and two died. How could an estrogen used...
Forty to sixty days of hormone control from a single shot-and in one trial sixteen of twenty-one men developed cardiovascular complications and two died. How could an estrogen used across Europe and Japan for decades, with doses of 10-50 mg designed to last months, produce such dramatic harm in a subgroup of patients?

In this episode, we lay out the clinical trial evidence, pharmacology, and published research that followed estradiol undecylate from its 1953 description to its late‑20th century decline, asking how depot chemistry, patient variability, and trial design combined to create a medical puzzle: was the drug’s promise outweighed by unpredictable risk?

Person: Karl Junkmann
Date: 1953 (first description)
Drug: Estradiol undecylate
Dose range: 10-50 mg (therapeutic), 100 mg (reported pharmacokinetics)
Trial: Jacobi Phase 3, 1978, 191 men across 12 German centers

- The molecule had an 11‑carbon ester chain, making it highly lipophilic and slow‑releasing.
- A single 10-12.5 mg injection could sustain therapeutic levels for 40-60 days; 25-50 mg for 2-4 months.
- After a 100 mg injection, mean peak blood concentration was ~500 pg/mL on day 1 and ~340 pg/mL by day 14.
- Blood levels varied up to tenfold between patients given the same dose and injection technique.
- In a cited subgroup, 21 men entered a trial with no heart disease history; 16 developed cardiovascular complications and 2 died.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1446falsefullhttps://www.spreaker.com/episode/when-a-monthly-estrogen-shot-raised-men-s-levels-17-fold--73138363
A routine monthly injection sent one man’s estradiol to seventeen times his baseline within six months, while the men receiving it had been screened to have healthy hearts - a detail that should stop you cold. What was estradiol undecylate, how did a 100 mg oil ampoule produce sustained estradiol levels of nearly 600 pg/mL, and what unanswered risks lingered when the drug was retired?

In this episode, we tell the documented history of estradiol undecylate from its 1953 West German origins to multicenter trials in the 1980s, outlining how a slow‑release ester transformed male hormone profiles and matched antiandrogens in tumor response - but raised hard questions about safety and long‑term outcomes.

Person: Karl Junkmann
Date: 1953 (compound described)
Location: West Germany
Topic: Estradiol undecylate clinical use
Period: 1950s-1980s

- Typical baseline male estradiol before treatment: 36 pg/mL.
- Estradiol trough after three monthly injections: 486 pg/mL.
- Estradiol trough after six monthly injections: 598 pg/mL (≈17× baseline).
- Typical testosterone before treatment: 416 ng/dL; after three months: 38 ng/dL (91% reduction); after six months: 29.6 ng/dL.
- Mainz trial enrollment: 191 men across 12 centers; 96 received estradiol undecylate, 95 received cyproterone acetate (300 mg/week).

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138363Fri, 24 Jul 2026 04:36:44 +0000Creator at ObomediaWhen a Monthly Estrogen Shot Raised Men's Levels 17-Fold A routine monthly injection sent one man’s estradiol to seventeen times his baseline within six months, while the men receiving it had been screened to have healthy hearts - a detail that...
A routine monthly injection sent one man’s estradiol to seventeen times his baseline within six months, while the men receiving it had been screened to have healthy hearts - a detail that should stop you cold. What was estradiol undecylate, how did a 100 mg oil ampoule produce sustained estradiol levels of nearly 600 pg/mL, and what unanswered risks lingered when the drug was retired?

In this episode, we tell the documented history of estradiol undecylate from its 1953 West German origins to multicenter trials in the 1980s, outlining how a slow‑release ester transformed male hormone profiles and matched antiandrogens in tumor response - but raised hard questions about safety and long‑term outcomes.

Person: Karl Junkmann
Date: 1953 (compound described)
Location: West Germany
Topic: Estradiol undecylate clinical use
Period: 1950s-1980s

- Typical baseline male estradiol before treatment: 36 pg/mL.
- Estradiol trough after three monthly injections: 486 pg/mL.
- Estradiol trough after six monthly injections: 598 pg/mL (≈17× baseline).
- Typical testosterone before treatment: 416 ng/dL; after three months: 38 ng/dL (91% reduction); after six months: 29.6 ng/dL.
- Mainz trial enrollment: 191 men across 12 centers; 96 received estradiol undecylate, 95 received cyproterone acetate (300 mg/week).

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1380falsefullhttps://www.spreaker.com/episode/the-frog-that-almost-cured-pain-the-vanishing-milligram-mystery--73138362
Less than one milligram of dried extract - smaller than a grain of salt - was the last physical trace of nearly two decades of fieldwork across Ecuador and the only sample that could reveal a compound two hundred times more potent than morphine. How did a tiny colorful frog that locals never used end up harboring a molecule that promised to end chronic pain, and could that molecule still be read after seventeen years in a vial?

In this episode, we follow the timeline of field collections, legal protection, and laboratory technology that intersected around a single fading sample. From Daly and Myers' 1974-1979 collections to the 1991 mass spectrometer analysis and the 1992 structural confirmation, what remained to be answered about origin and authenticity?

Person: John W. Daly
Person: Charles Myers
Period: 1974-1979 (field collections)
Date: 1991 (mass spectrometer analysis)
Event: 1992 confirmation of epibatidine structure

- Daly and Myers collected skins from roughly 3,000 frogs across multiple locations in Ecuador between 1974 and 1979.
- The analgesic compound demonstrated a dose-dependent, reproducible effect in mice first documented in 1974.
- In 1976, frogs at one Ecuadorian site produced no detectable compound despite being the same species at similar elevation.
- The International Union for Conservation of Nature listed Epipedobates anthonyi as protected in 1984, restricting legal collection.
- By 1991, less than one milligram of the dried biological extract remained to be analyzed by a high-resolution mass spectrometer.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138362Fri, 24 Jul 2026 04:36:40 +0000Creator at ObomediaThe Frog That Almost Cured Pain - The Vanishing Milligram Mystery Less than one milligram of dried extract - smaller than a grain of salt - was the last physical trace of nearly two decades of fieldwork across Ecuador and the only sample that could...
Less than one milligram of dried extract - smaller than a grain of salt - was the last physical trace of nearly two decades of fieldwork across Ecuador and the only sample that could reveal a compound two hundred times more potent than morphine. How did a tiny colorful frog that locals never used end up harboring a molecule that promised to end chronic pain, and could that molecule still be read after seventeen years in a vial?

In this episode, we follow the timeline of field collections, legal protection, and laboratory technology that intersected around a single fading sample. From Daly and Myers' 1974-1979 collections to the 1991 mass spectrometer analysis and the 1992 structural confirmation, what remained to be answered about origin and authenticity?

Person: John W. Daly
Person: Charles Myers
Period: 1974-1979 (field collections)
Date: 1991 (mass spectrometer analysis)
Event: 1992 confirmation of epibatidine structure

- Daly and Myers collected skins from roughly 3,000 frogs across multiple locations in Ecuador between 1974 and 1979.
- The analgesic compound demonstrated a dose-dependent, reproducible effect in mice first documented in 1974.
- In 1976, frogs at one Ecuadorian site produced no detectable compound despite being the same species at similar elevation.
- The International Union for Conservation of Nature listed Epipedobates anthonyi as protected in 1984, restricting legal collection.
- By 1991, less than one milligram of the dried biological extract remained to be analyzed by a high-resolution mass spectrometer.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1315falsefullhttps://www.spreaker.com/episode/the-mole-that-healed-then-vanished-doet-s-lost-miracle-drug--73138361
A buried 1960s compound produced euphoria, talkativeness, and a day-long energizing clarity in volunteers at doses smaller than a single grain of table salt - and not one person hallucinated. How did a molecule with a clean clinical profile, a corporate patent, and Johns Hopkins trials end up illegal alongside heroin, and what did that decision mean for medicine?

In this episode, we tell the story of DOET from its synthesis at Dow Chemical to human trials at Johns Hopkins, tracing Alexander Shulgin’s chemical tweak, the published patent, and Solomon Snyder’s clinical results that showed safety and functional enhancement - so why did the law close the door after the trials?

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1967 (compound received by Snyder), 1968 (first trial), 1971 (dose-ranging trial), February 1973 (made illegal), 1974 (safety study published)
Location: Dow Chemical, Johns Hopkins University
Topic: DOET (four-ethyl-2,5-dimethoxyamphetamine)
Status: Patent filed 1966, patent published 1970, classified illegal in 1973

- Volunteers were given 1.5 mg of DOET hydrochloride in the first trial, an amount smaller than a single grain of table salt.
- Subjective effects peaked between three and four hours and resolved by the fifth or sixth hour in the 1968 trial.
- Trials reported euphoria, heightened talkativeness, increased self-awareness, dilated pupils, and no hallucinations or cognitive impairment at tested doses.
- Shulgin’s chemical change from DOM to DOET replaced a methyl group with an ethyl group at the four-position, producing a different experiential profile.
- DOET was made illegal in the United States in February 1973, before a safety study was published in 1974.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138361Fri, 24 Jul 2026 04:36:36 +0000Creator at ObomediaThe Mole That Healed Then Vanished: DOET's Lost Miracle Drug A buried 1960s compound produced euphoria, talkativeness, and a day-long energizing clarity in volunteers at doses smaller than a single grain of table salt - and not one person...
A buried 1960s compound produced euphoria, talkativeness, and a day-long energizing clarity in volunteers at doses smaller than a single grain of table salt - and not one person hallucinated. How did a molecule with a clean clinical profile, a corporate patent, and Johns Hopkins trials end up illegal alongside heroin, and what did that decision mean for medicine?

In this episode, we tell the story of DOET from its synthesis at Dow Chemical to human trials at Johns Hopkins, tracing Alexander Shulgin’s chemical tweak, the published patent, and Solomon Snyder’s clinical results that showed safety and functional enhancement - so why did the law close the door after the trials?

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1967 (compound received by Snyder), 1968 (first trial), 1971 (dose-ranging trial), February 1973 (made illegal), 1974 (safety study published)
Location: Dow Chemical, Johns Hopkins University
Topic: DOET (four-ethyl-2,5-dimethoxyamphetamine)
Status: Patent filed 1966, patent published 1970, classified illegal in 1973

- Volunteers were given 1.5 mg of DOET hydrochloride in the first trial, an amount smaller than a single grain of table salt.
- Subjective effects peaked between three and four hours and resolved by the fifth or sixth hour in the 1968 trial.
- Trials reported euphoria, heightened talkativeness, increased self-awareness, dilated pupils, and no hallucinations or cognitive impairment at tested doses.
- Shulgin’s chemical change from DOM to DOET replaced a methyl group with an ethyl group at the four-position, producing a different experiential profile.
- DOET was made illegal in the United States in February 1973, before a safety study was published in 1974.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1346falsefullhttps://www.spreaker.com/episode/the-molecule-buried-by-panic-doet-s-promising-trials-and-banishment--73138359
A molecule with a fivefold safety margin and three consistent clinical trials vanished not because it failed science but because a street crisis thousands of miles away made the association fatal. DOET (Hecate) promised mood lifting without “tipping the mind into chaos,” yet a summer in San Francisco turned public panic into professional exile - what exactly was lost when DOET was buried?

In this episode, we trace the path from laboratory to banishment: a chemist at Dow who tested compounds on himself, the structural change from DOM to DOET that altered effects, and the social and legal upheaval that closed the window for development. How did an unrelated street distribution of a different compound doom a promising drug candidate?

Person: Alexander Shulgin
Company: Dow Chemical
Compound: DOET (Hecate)
Earlier compound: DOM (2,5-dimethoxy-4-methylamphetamine)
Event: Summer 1967 street distribution of DOM (STP) in Haight-Ashbury

- Shulgin synthesized DOM in 1963 and confirmed its psychedelic properties in 1964 through self-assessment.
- DOET differs from DOM by one structural change: a methyl group replaced by an ethyl group at the four-position.
- In 1966 Shulgin and Dow filed a patent on DOET while LSD became illegal in California the same year.
- Early tests showed DOET produced heightened awareness without DOM’s visual turbulence, but a colleague reported lethargy and profound depression one month after Shulgin’s positive self-report.
- The crisis that ended DOET’s prospects began in summer 1967 when Owsley Stanley distributed high-dose DOM labeled STP in San Francisco, causing multi-day effects and emergency room cases.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138359Fri, 24 Jul 2026 04:36:32 +0000Creator at ObomediaThe Molecule Buried by Panic: DOET's Promising Trials and Banishment A molecule with a fivefold safety margin and three consistent clinical trials vanished not because it failed science but because a street crisis thousands of miles away made the...
A molecule with a fivefold safety margin and three consistent clinical trials vanished not because it failed science but because a street crisis thousands of miles away made the association fatal. DOET (Hecate) promised mood lifting without “tipping the mind into chaos,” yet a summer in San Francisco turned public panic into professional exile - what exactly was lost when DOET was buried?

In this episode, we trace the path from laboratory to banishment: a chemist at Dow who tested compounds on himself, the structural change from DOM to DOET that altered effects, and the social and legal upheaval that closed the window for development. How did an unrelated street distribution of a different compound doom a promising drug candidate?

Person: Alexander Shulgin
Company: Dow Chemical
Compound: DOET (Hecate)
Earlier compound: DOM (2,5-dimethoxy-4-methylamphetamine)
Event: Summer 1967 street distribution of DOM (STP) in Haight-Ashbury

- Shulgin synthesized DOM in 1963 and confirmed its psychedelic properties in 1964 through self-assessment.
- DOET differs from DOM by one structural change: a methyl group replaced by an ethyl group at the four-position.
- In 1966 Shulgin and Dow filed a patent on DOET while LSD became illegal in California the same year.
- Early tests showed DOET produced heightened awareness without DOM’s visual turbulence, but a colleague reported lethargy and profound depression one month after Shulgin’s positive self-report.
- The crisis that ended DOET’s prospects began in summer 1967 when Owsley Stanley distributed high-dose DOM labeled STP in San Francisco, causing multi-day effects and emergency room cases.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1348falsefullhttps://www.spreaker.com/episode/the-molecule-that-should-have-been-medicine-how-doet-died--73138357
Five times the safety margin between a therapeutic dose and a hallucinogenic one made DOET anomalous among mid-century psychedelics, yet that five-fold gap did not save it from being classified Schedule I. How did a patented molecule with documented human trials and a clear therapeutic window die because of a handful of street-distributed pills in San Francisco?

In this episode, we trace the chain of events from Alexander Shulgin’s lab work at Dow Chemical to formal human trials at Johns Hopkins, and the summer of 1967 in Haight-Ashbury that changed everything. What happened on that street corner that overrode clinical data and halted a pharmaceutical program?

Person: Alexander Shulgin
Company: Dow Chemical
Researcher: Solomon H. Snyder
First published trial: 1968
Trial dose range: 0.75-4 mg (second trial)

- Shulgin synthesized DOM at Dow and then created DOET by replacing the 4-methyl group with an ethyl group.
- DOET was patented in 1966 with Shulgin and Dow named as assignees.
- First human trial (1968) used 1.5 mg oral DOET hydrochloride with onset at 1-1.5 hours and peak at 3-4 hours lasting 5-6 hours.
- The second trial (1971) reported a five-fold separation between therapeutic threshold and hallucinogenic dose, unlike LSD, DOM, and mescaline which showed 2-3 fold margins.
- In summer 1967 Owsley Stanley manufactured and freely distributed high-dose DOM tablets in Haight-Ashbury after LSD was made illegal in California.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138357Fri, 24 Jul 2026 04:36:28 +0000Creator at ObomediaThe Molecule That Should Have Been Medicine: How DOET Died Five times the safety margin between a therapeutic dose and a hallucinogenic one made DOET anomalous among mid-century psychedelics, yet that five-fold gap did not save it from being...
Five times the safety margin between a therapeutic dose and a hallucinogenic one made DOET anomalous among mid-century psychedelics, yet that five-fold gap did not save it from being classified Schedule I. How did a patented molecule with documented human trials and a clear therapeutic window die because of a handful of street-distributed pills in San Francisco?

In this episode, we trace the chain of events from Alexander Shulgin’s lab work at Dow Chemical to formal human trials at Johns Hopkins, and the summer of 1967 in Haight-Ashbury that changed everything. What happened on that street corner that overrode clinical data and halted a pharmaceutical program?

Person: Alexander Shulgin
Company: Dow Chemical
Researcher: Solomon H. Snyder
First published trial: 1968
Trial dose range: 0.75-4 mg (second trial)

- Shulgin synthesized DOM at Dow and then created DOET by replacing the 4-methyl group with an ethyl group.
- DOET was patented in 1966 with Shulgin and Dow named as assignees.
- First human trial (1968) used 1.5 mg oral DOET hydrochloride with onset at 1-1.5 hours and peak at 3-4 hours lasting 5-6 hours.
- The second trial (1971) reported a five-fold separation between therapeutic threshold and hallucinogenic dose, unlike LSD, DOM, and mescaline which showed 2-3 fold margins.
- In summer 1967 Owsley Stanley manufactured and freely distributed high-dose DOM tablets in Haight-Ashbury after LSD was made illegal in California.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1304falsefullhttps://www.spreaker.com/episode/the-medicine-that-never-crossed-the-threshold-doet-s-lost-promise--73138356
Calm euphoria at one milligram, no hallucinations, no cardiovascular effects - a drug that behaved like medicine but was buried because its cousin became a scandal. How did a compound that passed three clinical trials and earned a place among a chemist’s “ten classics” vanish from medicine?

In this episode, we tell the story of DOET’s discovery, its clinical results, and the events that stopped its development - and ask how a safe, nonhallucinogenic compound ended up abandoned after a chemical relative sparked a public health crisis.

Person: Alexander Shulgin
Compound: DOET
Clinical trials: 3
Patent filed: 1966
Program terminated: 1968

- DOET produced calm euphoria at doses as small as one milligram in clinical testing.
- DOET never caused hallucinations and left cardiovascular measures unchanged across trials.
- Alexander Shulgin and Dow Chemical co-filed the DOET patent in 1966.
- DOM, a chemical cousin synthesized by Shulgin in 1963, was distributed as STP in 1967 and caused multi-day toxic reactions at excessive doses.
- DOET clinical trials published by Solomon Snyder occurred in 1968, 1971, and 1974, all confirming safety and lack of hallucinations.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138356Fri, 24 Jul 2026 04:36:24 +0000Creator at ObomediaThe Medicine That Never Crossed the Threshold: DOET's Lost Promise Calm euphoria at one milligram, no hallucinations, no cardiovascular effects - a drug that behaved like medicine but was buried because its cousin became a scandal. How did a...
Calm euphoria at one milligram, no hallucinations, no cardiovascular effects - a drug that behaved like medicine but was buried because its cousin became a scandal. How did a compound that passed three clinical trials and earned a place among a chemist’s “ten classics” vanish from medicine?

In this episode, we tell the story of DOET’s discovery, its clinical results, and the events that stopped its development - and ask how a safe, nonhallucinogenic compound ended up abandoned after a chemical relative sparked a public health crisis.

Person: Alexander Shulgin
Compound: DOET
Clinical trials: 3
Patent filed: 1966
Program terminated: 1968

- DOET produced calm euphoria at doses as small as one milligram in clinical testing.
- DOET never caused hallucinations and left cardiovascular measures unchanged across trials.
- Alexander Shulgin and Dow Chemical co-filed the DOET patent in 1966.
- DOM, a chemical cousin synthesized by Shulgin in 1963, was distributed as STP in 1967 and caused multi-day toxic reactions at excessive doses.
- DOET clinical trials published by Solomon Snyder occurred in 1968, 1971, and 1974, all confirming safety and lack of hallucinations.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1147falsefullhttps://www.spreaker.com/episode/the-drug-that-healed-minds-then-vanished-after-san-francisco--73138355
A single lab notebook entry from 1966 describes a compound with a therapeutic window at least five times wider than LSD and clinical trials that produced euphoria, clarity, and social openness - then the whole program stopped after events in San Francisco. What happened to a drug that seemed safer and more controllable than other psychedelics, and why did it disappear despite no clinical failures?

In this episode, we follow the timeline of discovery, self-experimentation, and controlled trials that tested DOET (Hecate) from its synthesis in 1963 through Johns Hopkins studies in 1968-1971, and we ask whether the answers to its disappearance lie in science or in events outside the lab.

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1963-1971
Compound: DOET (four-ethyl-2,5-dimethoxyamphetamine)
Therapeutic window: at least five times wider than LSD

- DOET was first synthesized by Alexander Shulgin in 1963.
- Shulgin reported a 5-6 hour gentle, non-hallucinatory effect after self-administration.
- A Johns Hopkins trial in 1968 used a 1.5 mg oral hydrochloride dose with effects peaking at 3-4 hours.
- Solomon Snyder ran a second trial in 1971 with dose range 0.75 mg to 4 mg and consistent subject reports.
- The patent for DOET was filed by Dow Chemical in 1966 and published in 1970.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138355Fri, 24 Jul 2026 04:36:20 +0000Creator at ObomediaThe Drug That Healed Minds - Then Vanished After San Francisco A single lab notebook entry from 1966 describes a compound with a therapeutic window at least five times wider than LSD and clinical trials that produced euphoria, clarity, and social...
A single lab notebook entry from 1966 describes a compound with a therapeutic window at least five times wider than LSD and clinical trials that produced euphoria, clarity, and social openness - then the whole program stopped after events in San Francisco. What happened to a drug that seemed safer and more controllable than other psychedelics, and why did it disappear despite no clinical failures?

In this episode, we follow the timeline of discovery, self-experimentation, and controlled trials that tested DOET (Hecate) from its synthesis in 1963 through Johns Hopkins studies in 1968-1971, and we ask whether the answers to its disappearance lie in science or in events outside the lab.

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1963-1971
Compound: DOET (four-ethyl-2,5-dimethoxyamphetamine)
Therapeutic window: at least five times wider than LSD

- DOET was first synthesized by Alexander Shulgin in 1963.
- Shulgin reported a 5-6 hour gentle, non-hallucinatory effect after self-administration.
- A Johns Hopkins trial in 1968 used a 1.5 mg oral hydrochloride dose with effects peaking at 3-4 hours.
- Solomon Snyder ran a second trial in 1971 with dose range 0.75 mg to 4 mg and consistent subject reports.
- The patent for DOET was filed by Dow Chemical in 1966 and published in 1970.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1496falsefullhttps://www.spreaker.com/episode/the-drug-that-should-have-been-a-revolution-then-vanished-without-data--73138354
A single extra carbon turned a potent psychedelic scaffold into a drug that produced clarity, calm, and wakefulness at a 300 mg dose that should have hallucinated-but produced nothing perceptual. Why did a compound that reached human trials, reversed Parkinsonian symptoms in animals, and activated 5-HT2A without hallucinations end up erased from the public record?

In this episode, we trace the molecule from Alexander Shulgin’s Lafayette bench in 1968 through clinical testing at Bristol Laboratories in 1974, following the chemistry, reported human effects, and the missing clinical data that left key questions unanswered. What happened between Shulgin’s notebooks and the sealed files?

Person: Alexander Shulgin
Date: 1968 (synthesis) and 1974 (clinical trial)
Chemical name: four-methyl-2,5-dimethoxy-alpha-ethylphenethylamine
Company: Bristol Laboratories (code BL-3912A, proposed name Dimoxamine)
Receptor activity: potent, selective partial agonist at 5-HT2A and triggers dopamine release in nucleus accumbens

- Shulgin synthesized Ariadne in 1968 and self-administered it in 1969, reporting wakefulness and mental clarity without hallucinations.
- The human dosing described includes a 300 mg administration that produced no hallucinations despite being over ten times a minimum active amount.
- Ariadne differs from DOM by an ethyl group at the alpha position versus DOM’s methyl, a single-carbon change.
- Bristol Laboratories began multi-clinic clinical trials around 1974 under code BL-3912A targeting five conditions: depression, geriatric alertness, manic depression, Parkinson’s disease, and psychosis.
- Animal studies reportedly showed reversal of Parkinsonian symptoms comparable to the best drugs available at the time.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138354Fri, 24 Jul 2026 04:36:16 +0000Creator at ObomediaThe Drug That Should Have Been a Revolution-Then Vanished Without Data A single extra carbon turned a potent psychedelic scaffold into a drug that produced clarity, calm, and wakefulness at a 300 mg dose that should have hallucinated-but produced...
A single extra carbon turned a potent psychedelic scaffold into a drug that produced clarity, calm, and wakefulness at a 300 mg dose that should have hallucinated-but produced nothing perceptual. Why did a compound that reached human trials, reversed Parkinsonian symptoms in animals, and activated 5-HT2A without hallucinations end up erased from the public record?

In this episode, we trace the molecule from Alexander Shulgin’s Lafayette bench in 1968 through clinical testing at Bristol Laboratories in 1974, following the chemistry, reported human effects, and the missing clinical data that left key questions unanswered. What happened between Shulgin’s notebooks and the sealed files?

Person: Alexander Shulgin
Date: 1968 (synthesis) and 1974 (clinical trial)
Chemical name: four-methyl-2,5-dimethoxy-alpha-ethylphenethylamine
Company: Bristol Laboratories (code BL-3912A, proposed name Dimoxamine)
Receptor activity: potent, selective partial agonist at 5-HT2A and triggers dopamine release in nucleus accumbens

- Shulgin synthesized Ariadne in 1968 and self-administered it in 1969, reporting wakefulness and mental clarity without hallucinations.
- The human dosing described includes a 300 mg administration that produced no hallucinations despite being over ten times a minimum active amount.
- Ariadne differs from DOM by an ethyl group at the alpha position versus DOM’s methyl, a single-carbon change.
- Bristol Laboratories began multi-clinic clinical trials around 1974 under code BL-3912A targeting five conditions: depression, geriatric alertness, manic depression, Parkinson’s disease, and psychosis.
- Animal studies reportedly showed reversal of Parkinsonian symptoms comparable to the best drugs available at the time.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1491falsefullhttps://www.spreaker.com/episode/the-girl-whose-seizure-pill-silenced-her-adrenals-and-cancer-s-future--73138353
A single pediatric case in 1963 revealed that a seizure drug didn’t just stop petit mal attacks - it shut down adrenal hormone production, causing fatigue, low blood pressure, and electrolyte imbalance. How did an anticonvulsant sold in 24 countries become a reversible medical adrenalectomy, and what did that accidental effect mean for cancer treatment?

In this episode, we trace the clinical report of an unnamed young girl, the pharmacology of aminoglutethimide, and the chain of research that linked a seizure medication to profound endocrine suppression. How that discovery shifted thinking about hormone-sensitive cancers is the central question we follow.

Drug: aminoglutethimide
First reported case: 1963
Markets: 24 countries
Common brand names: Elipten, Orimeten, Cytadren
Mechanism: inhibition of CYP11A1, 21-hydroxylase, 11β-hydroxylase, and aldosterone synthase

- The girl developed clinical signs of adrenal insufficiency (fatigue, low blood pressure, disrupted sodium and potassium balance) while taking aminoglutethimide.
- Aminoglutethimide was a nonsteroidal glutarimide given as 250 mg oral tablets for petit mal epilepsy.
- By 1963 the compound had regulatory clearance in the United States, Canada, the United States, Australia, New Zealand, South Africa, and much of Europe.
- The drug was prescribed under multiple names (Elipten, Orimeten, Rodazol, Mamomit, Aminoblastin, Cytadren) though the compound was identical across markets.
- Researchers later mapped the drug’s action to inhibition of the cholesterol-to-pregnenolone step (CYP11A1) and three downstream steroidogenic enzymes, causing reversible suppression of cortisol, aldosterone, and sex hormone synthesis.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138353Fri, 24 Jul 2026 04:36:12 +0000Creator at ObomediaThe Girl Whose Seizure Pill Silenced Her Adrenals-and Cancer's Future A single pediatric case in 1963 revealed that a seizure drug didn’t just stop petit mal attacks - it shut down adrenal hormone production, causing fatigue, low blood pressure,...
A single pediatric case in 1963 revealed that a seizure drug didn’t just stop petit mal attacks - it shut down adrenal hormone production, causing fatigue, low blood pressure, and electrolyte imbalance. How did an anticonvulsant sold in 24 countries become a reversible medical adrenalectomy, and what did that accidental effect mean for cancer treatment?

In this episode, we trace the clinical report of an unnamed young girl, the pharmacology of aminoglutethimide, and the chain of research that linked a seizure medication to profound endocrine suppression. How that discovery shifted thinking about hormone-sensitive cancers is the central question we follow.

Drug: aminoglutethimide
First reported case: 1963
Markets: 24 countries
Common brand names: Elipten, Orimeten, Cytadren
Mechanism: inhibition of CYP11A1, 21-hydroxylase, 11β-hydroxylase, and aldosterone synthase

- The girl developed clinical signs of adrenal insufficiency (fatigue, low blood pressure, disrupted sodium and potassium balance) while taking aminoglutethimide.
- Aminoglutethimide was a nonsteroidal glutarimide given as 250 mg oral tablets for petit mal epilepsy.
- By 1963 the compound had regulatory clearance in the United States, Canada, the United States, Australia, New Zealand, South Africa, and much of Europe.
- The drug was prescribed under multiple names (Elipten, Orimeten, Rodazol, Mamomit, Aminoblastin, Cytadren) though the compound was identical across markets.
- Researchers later mapped the drug’s action to inhibition of the cholesterol-to-pregnenolone step (CYP11A1) and three downstream steroidogenic enzymes, causing reversible suppression of cortisol, aldosterone, and sex hormone synthesis.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1428falsefullhttps://www.spreaker.com/episode/when-the-medicine-cabinet-lies-the-15-year-drug-secret-revealed--73138351
Nearly 90% of over 100 drugs tested by the U.S. Army in the mid-1980s remained safe and effective, in some cases up to 15 years past their printed expiration dates - so why do bottles still tell us otherwise? What did the Shelf Life Extension Program actually prove about expiration dates, and who decided to keep those findings out of public view?

In this episode, we lay out the documented history of the Shelf Life Extension Program, the Department of Defense’s commissioning of the FDA, and the institutional findings that followed. We trace how manufacturer testing windows, storage conditions, and regulatory incentives shaped the dates on medicine labels - and ask what that means the next time you stand at your bathroom cabinet.

Person: Joel Davis
Program: Shelf Life Extension Program
Institution: United States Department of Defense
Finding: ~90% of 100+ medications tested were safe and effective beyond labeled expiration
Example: Ciprofloxacin effective 9 years past labeled expiration

- The testing took place in the mid-1980s when the U.S. Army opened its stockpiles.
- More than 100 medications were tested and about 90% were found safe and fully effective.
- Ciprofloxacin was found effective nine years after its official expiration date.
- Manufacturers typically test stability for two to three years, setting expiration dates based on that window.
- The program’s documented agreement limited public awareness of the findings.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138351Fri, 24 Jul 2026 04:36:08 +0000Creator at ObomediaWhen the Medicine Cabinet Lies: The 15-Year Drug Secret Revealed Nearly 90% of over 100 drugs tested by the U.S. Army in the mid-1980s remained safe and effective, in some cases up to 15 years past their printed expiration dates - so why do bottles...
Nearly 90% of over 100 drugs tested by the U.S. Army in the mid-1980s remained safe and effective, in some cases up to 15 years past their printed expiration dates - so why do bottles still tell us otherwise? What did the Shelf Life Extension Program actually prove about expiration dates, and who decided to keep those findings out of public view?

In this episode, we lay out the documented history of the Shelf Life Extension Program, the Department of Defense’s commissioning of the FDA, and the institutional findings that followed. We trace how manufacturer testing windows, storage conditions, and regulatory incentives shaped the dates on medicine labels - and ask what that means the next time you stand at your bathroom cabinet.

Person: Joel Davis
Program: Shelf Life Extension Program
Institution: United States Department of Defense
Finding: ~90% of 100+ medications tested were safe and effective beyond labeled expiration
Example: Ciprofloxacin effective 9 years past labeled expiration

- The testing took place in the mid-1980s when the U.S. Army opened its stockpiles.
- More than 100 medications were tested and about 90% were found safe and fully effective.
- Ciprofloxacin was found effective nine years after its official expiration date.
- Manufacturers typically test stability for two to three years, setting expiration dates based on that window.
- The program’s documented agreement limited public awareness of the findings.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1349falsefullhttps://www.spreaker.com/episode/the-yellow-slip-that-saved-lives-and-hid-a-dark-secret--73138350
Danger and salvation lived on a single yellow slip of paper that turned suspicion into a global safety system after thalidomide left thousands of children with malformed limbs. How did one form, designed by a polio survivor who delivered fifty babies from a wheelchair, become the foundation of modern drug surveillance - and then be tied to an allegation that he destroyed crucial evidence?

In this episode, we tell the life and work of William Howard Wallace Inman, from his childhood in Banstead and polio that put him in an iron lung, to designing the yellow card system after the thalidomide disaster, and the later claim in a government report that he may have removed evidence. What did the yellow card capture, and what could it never show?

Person: William Howard Wallace Inman
Date of birth: 1 August 1929
Location: Banstead, Surrey
Event: Creation of the yellow card adverse drug reaction reporting system
Institution: Addenbrooke's Hospital (first year of practice in 1956)

- Inman spent roughly two years living largely inside an iron lung during his bout with polio.
- He qualified in 1956 as Cambridge University's first clinical medical graduate via the university's own clinical pathway.
- Inman delivered fifty babies in his first year of practice at Addenbrooke's Hospital from a wheelchair.
- He worked as a medical adviser for ICI's pharmaceutical division from 1959 until 1964.
- Fifteen years after his death a government report surfaced alleging he may have destroyed material related to his work.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138350Fri, 24 Jul 2026 04:36:04 +0000Creator at ObomediaThe Yellow Slip That Saved Lives - and Hid a Dark Secret Danger and salvation lived on a single yellow slip of paper that turned suspicion into a global safety system after thalidomide left thousands of children with malformed limbs. How did one...
Danger and salvation lived on a single yellow slip of paper that turned suspicion into a global safety system after thalidomide left thousands of children with malformed limbs. How did one form, designed by a polio survivor who delivered fifty babies from a wheelchair, become the foundation of modern drug surveillance - and then be tied to an allegation that he destroyed crucial evidence?

In this episode, we tell the life and work of William Howard Wallace Inman, from his childhood in Banstead and polio that put him in an iron lung, to designing the yellow card system after the thalidomide disaster, and the later claim in a government report that he may have removed evidence. What did the yellow card capture, and what could it never show?

Person: William Howard Wallace Inman
Date of birth: 1 August 1929
Location: Banstead, Surrey
Event: Creation of the yellow card adverse drug reaction reporting system
Institution: Addenbrooke's Hospital (first year of practice in 1956)

- Inman spent roughly two years living largely inside an iron lung during his bout with polio.
- He qualified in 1956 as Cambridge University's first clinical medical graduate via the university's own clinical pathway.
- Inman delivered fifty babies in his first year of practice at Addenbrooke's Hospital from a wheelchair.
- He worked as a medical adviser for ICI's pharmaceutical division from 1959 until 1964.
- Fifteen years after his death a government report surfaced alleging he may have destroyed material related to his work.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1456falsefullhttps://www.spreaker.com/episode/the-ama-called-it-baby-killers-in-1911-the-syrup-sold-for-nineteen-more-years--73138349
Mothers trusted a small glass bottle whose tender label promised relief for teething infants, and the American Medical Association later printed a headline calling the product "Baby Killers" - yet the syrup continued to sell for nineteen more years. How did condemnation fail to produce removal, and what does that gap reveal about the limits of medical regulation?

In this episode, we trace the story of Mrs. Winslow's Soothing Syrup and the regulatory architecture that could not force its recall, then follow the throughline to diethylstilbestrol (DES) and the multi-generational harms that unfolded; how did institutions' knowledge diverge from their power to act?

Person: Mrs. Winslow's Soothing Syrup
Date: 1911
Event: American Medical Association article titled "Baby Killers"
Duration of continued sale after AMA article: 19 years (available in the United Kingdom until 1930)
Estimate of people exposed to DES before its recall: 5 to 10 million

- The AMA published a formal condemnation titled "Baby Killers" in 1911.
- Mrs. Winslow's Soothing Syrup remained available in the United Kingdom until 1930, nineteen years after the AMA article.
- No criminal charges or documented forced recall followed the AMA's 1911 condemnation.
- The United Kingdom' regulatory architecture to compel product removal developed slowly over the twentieth century.
- An estimated 5 to 10 million people were exposed to diethylstilbestrol (DES) before its recall.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138349Fri, 24 Jul 2026 04:36:00 +0000Creator at ObomediaThe AMA called it "Baby Killers" in 1911. The syrup sold for nineteen more years Mothers trusted a small glass bottle whose tender label promised relief for teething infants, and the American Medical Association later printed a headline calling the...
Mothers trusted a small glass bottle whose tender label promised relief for teething infants, and the American Medical Association later printed a headline calling the product "Baby Killers" - yet the syrup continued to sell for nineteen more years. How did condemnation fail to produce removal, and what does that gap reveal about the limits of medical regulation?

In this episode, we trace the story of Mrs. Winslow's Soothing Syrup and the regulatory architecture that could not force its recall, then follow the throughline to diethylstilbestrol (DES) and the multi-generational harms that unfolded; how did institutions' knowledge diverge from their power to act?

Person: Mrs. Winslow's Soothing Syrup
Date: 1911
Event: American Medical Association article titled "Baby Killers"
Duration of continued sale after AMA article: 19 years (available in the United Kingdom until 1930)
Estimate of people exposed to DES before its recall: 5 to 10 million

- The AMA published a formal condemnation titled "Baby Killers" in 1911.
- Mrs. Winslow's Soothing Syrup remained available in the United Kingdom until 1930, nineteen years after the AMA article.
- No criminal charges or documented forced recall followed the AMA's 1911 condemnation.
- The United Kingdom' regulatory architecture to compel product removal developed slowly over the twentieth century.
- An estimated 5 to 10 million people were exposed to diethylstilbestrol (DES) before its recall.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1372falsefullhttps://www.spreaker.com/episode/how-a-paralyzed-iowa-kid-built-a-3b-debt-empire-and-survived-trial--73138348
He rose from a stairwell paralysis doctors called permanent to build a three-billion-dollar debt company by treating people everyone else had written off - yet his prosecution collapsed and he was acquitted of every charge. How did a man who rebuilt his body and career refuse to run and instead let the evidence in a federal courtroom speak for him?

In this episode, we tell the life story and legal saga of William Bartmann, from Dubuque in 1948 through the founding and rise of Commercial Financial Services and the federal trial that followed, asking how his methods and the collapse of his company led to nearly 3,900 lost jobs.

Person: William Bartmann
Date (birth year): 1948
Location (origin): Dubuque, Iowa
Company: Commercial Financial Services
Outcome: Acquitted of every charge

- At age 17 Bartmann fell down a flight of stairs, was told his paralysis was permanent, and later regained the ability to walk through an undocumented physical regimen.
- Bartmann left school at 14, later earned a GED, a bachelor's degree from Loras College, and a law degree from Drake University.
- After rebuilding an oil equipment company he controlled, the business failed in 1985 and he incurred approximately $1,000,000 in personal debt from signed guarantees.
- By 1986 Bartmann had paid off his debts and founded Commercial Financial Services, which grew into a company valued at three billion dollars.
- More than 3,900 people lost their jobs when his company collapsed, and a bankruptcy trustee later stated that no fraud had been committed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138348Fri, 24 Jul 2026 04:35:56 +0000Creator at ObomediaHow a Paralyzed Iowa Kid Built a $3B Debt Empire-and Survived Trial He rose from a stairwell paralysis doctors called permanent to build a three-billion-dollar debt company by treating people everyone else had written off - yet his prosecution...
He rose from a stairwell paralysis doctors called permanent to build a three-billion-dollar debt company by treating people everyone else had written off - yet his prosecution collapsed and he was acquitted of every charge. How did a man who rebuilt his body and career refuse to run and instead let the evidence in a federal courtroom speak for him?

In this episode, we tell the life story and legal saga of William Bartmann, from Dubuque in 1948 through the founding and rise of Commercial Financial Services and the federal trial that followed, asking how his methods and the collapse of his company led to nearly 3,900 lost jobs.

Person: William Bartmann
Date (birth year): 1948
Location (origin): Dubuque, Iowa
Company: Commercial Financial Services
Outcome: Acquitted of every charge

- At age 17 Bartmann fell down a flight of stairs, was told his paralysis was permanent, and later regained the ability to walk through an undocumented physical regimen.
- Bartmann left school at 14, later earned a GED, a bachelor's degree from Loras College, and a law degree from Drake University.
- After rebuilding an oil equipment company he controlled, the business failed in 1985 and he incurred approximately $1,000,000 in personal debt from signed guarantees.
- By 1986 Bartmann had paid off his debts and founded Commercial Financial Services, which grew into a company valued at three billion dollars.
- More than 3,900 people lost their jobs when his company collapsed, and a bankruptcy trustee later stated that no fraud had been committed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1408falsefullhttps://www.spreaker.com/episode/when-floodwaters-rose-four-million-vanished-liechtenstein-s-quiet-scandal--73138347
A tiny Alpine state lost four million Swiss francs while its rivers were flooding three villages and two people died - and the man at the helm of government did not know. How did loyalty-based appointments turn a national bank into a hole that swallowed fortunes, relief efforts, and political accountability?

In this episode, we trace the life and career of Gustav Schädler from Triesenberg schoolteacher to prime minister, the political context of Liechtenstein in the 1920s, and the parallel collapse unfolding inside the National Bank that his party had staffed. Can a government built by insiders reckon with a financial betrayal that rose while floodwaters rose?

Person: Gustav Schädler
Date: 25 September 1927
Location: Triesenberg and Vaduz, Liechtenstein
Event: Alpine Rhine flood and concurrent embezzlement at the National Bank of Liechtenstein
Amount: approximately 4,000,000 Swiss francs

- Schädler was born on 18 November 1883 in Triesenberg and was one of five children.
- He studied at the University of Zurich from 1906 for six years and returned to teach in Vaduz in 1914.
- Prince Johann II appointed Schädler to the Landtag in 1919; he became prime minister on 6 June 1922 at age 38.
- In 1922 the Patriotic Union reorganized the National Bank's leadership, filling boards with party allies.
- Between 1926 and 1927 four men connected to the Patriotic Union moved approximately four million Swiss francs through speculative transactions at the bank.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138347Fri, 24 Jul 2026 04:35:52 +0000Creator at ObomediaWhen Floodwaters Rose, Four Million Vanished: Liechtenstein's Quiet Scandal A tiny Alpine state lost four million Swiss francs while its rivers were flooding three villages and two people died - and the man at the helm of government did not know....
A tiny Alpine state lost four million Swiss francs while its rivers were flooding three villages and two people died - and the man at the helm of government did not know. How did loyalty-based appointments turn a national bank into a hole that swallowed fortunes, relief efforts, and political accountability?

In this episode, we trace the life and career of Gustav Schädler from Triesenberg schoolteacher to prime minister, the political context of Liechtenstein in the 1920s, and the parallel collapse unfolding inside the National Bank that his party had staffed. Can a government built by insiders reckon with a financial betrayal that rose while floodwaters rose?

Person: Gustav Schädler
Date: 25 September 1927
Location: Triesenberg and Vaduz, Liechtenstein
Event: Alpine Rhine flood and concurrent embezzlement at the National Bank of Liechtenstein
Amount: approximately 4,000,000 Swiss francs

- Schädler was born on 18 November 1883 in Triesenberg and was one of five children.
- He studied at the University of Zurich from 1906 for six years and returned to teach in Vaduz in 1914.
- Prince Johann II appointed Schädler to the Landtag in 1919; he became prime minister on 6 June 1922 at age 38.
- In 1922 the Patriotic Union reorganized the National Bank's leadership, filling boards with party allies.
- Between 1926 and 1927 four men connected to the Patriotic Union moved approximately four million Swiss francs through speculative transactions at the bank.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1405falsefullhttps://www.spreaker.com/episode/the-president-who-died-abroad-zambia-s-battle-over-a-body--73138345
A former president died on an operating table in Pretoria and his remains remain overseas while two governments and two court systems fight over them - a dispute rooted in a presidency won by exactly 27,757 votes. How did a man who once finished seventh with 2.43% of the vote and lost his law licence become Zambia’s sixth president, and why is his body still in South Africa?

In this episode, we tell the life and political trajectory of Edgar Chagwa Lungu, from his birth in 1956 and law degree to the narrow victory that made him president and the cross-border legal battle over his remains. What does the contest over his body reveal about power, legitimacy, and the state he once led?

Person: Edgar Chagwa Lungu
Date of death: 5 June 2025
Age: 68
Margin of victory: 27,757 votes
Early vote share (2001): 2.43%

- Lungu was born on 11 November 1956 at Ndola Central Hospital in Northern Rhodesia.
- He earned a law degree from the University of Zambia in 1981 and married Esther in 1986; they had six children.
- In 2001 he finished seventh of eleven candidates with 2.43% of the vote in the Chawama contest.
- The Law Association of Zambia suspended his law licence in 2010 for professional misconduct.
- He was sworn in as Zambia’s sixth president on 26 January 2015 after winning a by-election by 27,757 votes.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138345Fri, 24 Jul 2026 04:35:48 +0000Creator at ObomediaThe President Who Died Abroad: Zambia's Battle Over a Body A former president died on an operating table in Pretoria and his remains remain overseas while two governments and two court systems fight over them - a dispute rooted in a presidency won...
A former president died on an operating table in Pretoria and his remains remain overseas while two governments and two court systems fight over them - a dispute rooted in a presidency won by exactly 27,757 votes. How did a man who once finished seventh with 2.43% of the vote and lost his law licence become Zambia’s sixth president, and why is his body still in South Africa?

In this episode, we tell the life and political trajectory of Edgar Chagwa Lungu, from his birth in 1956 and law degree to the narrow victory that made him president and the cross-border legal battle over his remains. What does the contest over his body reveal about power, legitimacy, and the state he once led?

Person: Edgar Chagwa Lungu
Date of death: 5 June 2025
Age: 68
Margin of victory: 27,757 votes
Early vote share (2001): 2.43%

- Lungu was born on 11 November 1956 at Ndola Central Hospital in Northern Rhodesia.
- He earned a law degree from the University of Zambia in 1981 and married Esther in 1986; they had six children.
- In 2001 he finished seventh of eleven candidates with 2.43% of the vote in the Chawama contest.
- The Law Association of Zambia suspended his law licence in 2010 for professional misconduct.
- He was sworn in as Zambia’s sixth president on 26 January 2015 after winning a by-election by 27,757 votes.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1292falsefullhttps://www.spreaker.com/episode/a-pregnant-woman-dies-at-30-km-h-the-airbag-killed-her-not-the-crash--73138342
Humid air, a cheap propellant and a sealed safety device turned a minor 30 km/h crash in Malaysia into a fatal event: a metal fragment from the inflator sliced a 42-year-old pregnant woman’s neck and she died at the scene - her daughter born afterward survived only three days. How did ammonium nitrate, a moisture-sensitive propellant, end up inside inflators meant to save lives, and why were so many inflators still unrepaired as of September 2024?

In this episode, we trace the history of the company that began with parachute lifelines in 1933 and grew into a global airbag supplier, follow the technical choice to use ammonium nitrate instead of tetrazole-based compounds, and outline the recalls, lawsuits, and repair-rate failures that allowed the problem to persist. What decisions and systemic failures let a safety device become one of the deadliest product failures in automotive history?

Person: Takezo Takada
Date: July 2014
Location: Malaysia
Event: Inflator rupture causing fatal neck injury
Period: 1933-2014 (company history to the inflator deployment)

- The crash speed was roughly 30 kilometers per hour when the airbag inflator ruptured.
- The driver was a 42-year-old pregnant woman who died at the scene; her daughter was delivered and died three days later.
- Takata began airbag production in 1988 and held roughly 20% of the global airbag market by 2014.
- Takata acquired Petri AG in 2000 and renamed it Takata AG while expanding production across four continents.
- As of September 2024, thirty-five deaths globally were counted in connection with the inflator defects, with vehicles still unrepaired.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138342Fri, 24 Jul 2026 04:35:44 +0000Creator at ObomediaA pregnant woman dies at 30 km/h - the airbag killed her, not the crash Humid air, a cheap propellant and a sealed safety device turned a minor 30 km/h crash in Malaysia into a fatal event: a metal fragment from the inflator sliced a 42-year-old...
Humid air, a cheap propellant and a sealed safety device turned a minor 30 km/h crash in Malaysia into a fatal event: a metal fragment from the inflator sliced a 42-year-old pregnant woman’s neck and she died at the scene - her daughter born afterward survived only three days. How did ammonium nitrate, a moisture-sensitive propellant, end up inside inflators meant to save lives, and why were so many inflators still unrepaired as of September 2024?

In this episode, we trace the history of the company that began with parachute lifelines in 1933 and grew into a global airbag supplier, follow the technical choice to use ammonium nitrate instead of tetrazole-based compounds, and outline the recalls, lawsuits, and repair-rate failures that allowed the problem to persist. What decisions and systemic failures let a safety device become one of the deadliest product failures in automotive history?

Person: Takezo Takada
Date: July 2014
Location: Malaysia
Event: Inflator rupture causing fatal neck injury
Period: 1933-2014 (company history to the inflator deployment)

- The crash speed was roughly 30 kilometers per hour when the airbag inflator ruptured.
- The driver was a 42-year-old pregnant woman who died at the scene; her daughter was delivered and died three days later.
- Takata began airbag production in 1988 and held roughly 20% of the global airbag market by 2014.
- Takata acquired Petri AG in 2000 and renamed it Takata AG while expanding production across four continents.
- As of September 2024, thirty-five deaths globally were counted in connection with the inflator defects, with vehicles still unrepaired.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1401falsefullhttps://www.spreaker.com/episode/the-company-that-dosed-a-town-inside-minamata-s-silent-massacre--73138341
A company hospital admitted a five-year-old who could not walk, speak, or stop convulsing - while the firm that ran that hospital had been dumping methylmercury into the bay for years. Fish-becoming-poison, cats “dancing,” and two kilograms of mercury per ton of sediment paint a town poisoned from its food chain; how did this last for decades without being stopped?

In this episode, we tell the chronological record of what happened in Minamata, who was involved, and how the science, corporate decisions, and suppression unfolded - ending with the question of why accountability took so long.

Person: Hajime Hosokawa
Date: May 1, 1956
Location: Minamata Bay, Kyushu, Japan
Event: Identification of epidemic of unknown central nervous system disease
Status: Forty patients identified by October 1956; fourteen deaths (35% mortality)

- Chisso Corporation operated a chemical factory in Minamata since 1908 and ran the town’s hospital.
- In August 1951 the factory switched catalysts and began producing methylmercury as roughly 5% of its liquid effluent.
- By October 1956 forty patients had been identified and fourteen had died (35% mortality).
- Sediment at the bottom of Hyakken Harbour contained two kilograms of mercury per ton of mud, confirmed in February 1959.
- Chisso had signed compensation agreements with local fishing cooperatives in 1926 and 1943 and later created a subsidiary to extract and sell mercury from contaminated sediment.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138341Fri, 24 Jul 2026 04:35:40 +0000Creator at ObomediaThe Company That Dosed a Town: Inside Minamata's Silent Massacre A company hospital admitted a five-year-old who could not walk, speak, or stop convulsing - while the firm that ran that hospital had been dumping methylmercury into the bay for...
A company hospital admitted a five-year-old who could not walk, speak, or stop convulsing - while the firm that ran that hospital had been dumping methylmercury into the bay for years. Fish-becoming-poison, cats “dancing,” and two kilograms of mercury per ton of sediment paint a town poisoned from its food chain; how did this last for decades without being stopped?

In this episode, we tell the chronological record of what happened in Minamata, who was involved, and how the science, corporate decisions, and suppression unfolded - ending with the question of why accountability took so long.

Person: Hajime Hosokawa
Date: May 1, 1956
Location: Minamata Bay, Kyushu, Japan
Event: Identification of epidemic of unknown central nervous system disease
Status: Forty patients identified by October 1956; fourteen deaths (35% mortality)

- Chisso Corporation operated a chemical factory in Minamata since 1908 and ran the town’s hospital.
- In August 1951 the factory switched catalysts and began producing methylmercury as roughly 5% of its liquid effluent.
- By October 1956 forty patients had been identified and fourteen had died (35% mortality).
- Sediment at the bottom of Hyakken Harbour contained two kilograms of mercury per ton of mud, confirmed in February 1959.
- Chisso had signed compensation agreements with local fishing cooperatives in 1926 and 1943 and later created a subsidiary to extract and sell mercury from contaminated sediment.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1407falsefullhttps://www.spreaker.com/episode/the-tiny-crater-the-uncounted-dead-inside-al-ahli-mystery--73138340
A single whoosh and a crater less than one meter long left a courtyard burning and somewhere between 100 and 471 people dead - yet no independent investigation has ever confirmed what caused it. How could such a tiny impact coincide with one of the deadliest single events in Gaza during October 2023?

In this episode, we lay out the timeline, the physical details, and the competing conclusions that followed the strike at al-Ahli Mystery Hospital, and we ask what the evidence itself can tell us about who was there, what they faced, and why the outcome remains unresolved.

Person: Anglican Archbishop Justin Welby
Date: October 17, 2023
Location: al-Ahli Mystery Hospital, Gaza City
Event: Fireball in hospital courtyard after a whoosh and bright flash
Period: October 2023

- A crater at the courtyard site measured less than 1 meter long and about 30 centimeters deep.
- Casualty estimates from different sources range from 100 to 471 people killed.
- About 1,000 displaced Palestinians were sheltering in the hospital courtyard that evening.
- Approximately 600 patients and staff remained inside the hospital at the time of the strike.
- Four explosions occurred in the five minutes before the final whoosh and flash at 18:59:55 local time.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138340Fri, 24 Jul 2026 04:35:36 +0000Creator at ObomediaThe Tiny Crater, The Uncounted Dead: Inside Al-Ahli Mystery A single whoosh and a crater less than one meter long left a courtyard burning and somewhere between 100 and 471 people dead - yet no independent investigation has ever confirmed what...
A single whoosh and a crater less than one meter long left a courtyard burning and somewhere between 100 and 471 people dead - yet no independent investigation has ever confirmed what caused it. How could such a tiny impact coincide with one of the deadliest single events in Gaza during October 2023?

In this episode, we lay out the timeline, the physical details, and the competing conclusions that followed the strike at al-Ahli Mystery Hospital, and we ask what the evidence itself can tell us about who was there, what they faced, and why the outcome remains unresolved.

Person: Anglican Archbishop Justin Welby
Date: October 17, 2023
Location: al-Ahli Mystery Hospital, Gaza City
Event: Fireball in hospital courtyard after a whoosh and bright flash
Period: October 2023

- A crater at the courtyard site measured less than 1 meter long and about 30 centimeters deep.
- Casualty estimates from different sources range from 100 to 471 people killed.
- About 1,000 displaced Palestinians were sheltering in the hospital courtyard that evening.
- Approximately 600 patients and staff remained inside the hospital at the time of the strike.
- Four explosions occurred in the five minutes before the final whoosh and flash at 18:59:55 local time.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1394falsefullhttps://www.spreaker.com/episode/when-invisible-crystals-killed-thousands-of-pets-the-melamine-mystery--73138338
A quiet industrial ingredient hid tiny white crystals you could see with the naked eye, and by the time anyone connected the dots thousands of cats and dogs were dead; how did a chemical used in plastics end up in pet food sold under about one hundred trusted brand names? What were those spoke-like crystals, and why did two otherwise innocuous substances combine inside kidneys to kill with such efficiency?

In this episode, we tell the sequence of events from contaminated wheat gluten arriving from Xuzhou Anying Biologic Technology Development Company to the March 16, 2007 recall, charting the failures and missed signals that let contaminated cans reach millions of bowls. How did internal taste-test deaths and visible crystals finally force action, and why did routine checks fail to stop this?

Person: Dr. Stephen Sundlof
Date: March 16, 2007
Company: Menu Foods
Supplier: Xuzhou Anying Biologic Technology Development Company
Event: Recall of more than 5,300 products

- The first formal complaints reached Menu Foods on February 20, 2007.
- Menu Foods announced a recall on March 16, 2007, removing over 5,300 products.
- Cornell received the first contaminated batches between March 13 and March 15, 2007.
- The supplier of the wheat gluten was Xuzhou Anying Biologic Technology Development Company in China.
- Internal taste-test cats at Menu Foods began dying before the public recall.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138338Fri, 24 Jul 2026 04:35:32 +0000Creator at ObomediaWhen Invisible Crystals Killed Thousands of Pets: The Melamine Mystery A quiet industrial ingredient hid tiny white crystals you could see with the naked eye, and by the time anyone connected the dots thousands of cats and dogs were dead; how did a...
A quiet industrial ingredient hid tiny white crystals you could see with the naked eye, and by the time anyone connected the dots thousands of cats and dogs were dead; how did a chemical used in plastics end up in pet food sold under about one hundred trusted brand names? What were those spoke-like crystals, and why did two otherwise innocuous substances combine inside kidneys to kill with such efficiency?

In this episode, we tell the sequence of events from contaminated wheat gluten arriving from Xuzhou Anying Biologic Technology Development Company to the March 16, 2007 recall, charting the failures and missed signals that let contaminated cans reach millions of bowls. How did internal taste-test deaths and visible crystals finally force action, and why did routine checks fail to stop this?

Person: Dr. Stephen Sundlof
Date: March 16, 2007
Company: Menu Foods
Supplier: Xuzhou Anying Biologic Technology Development Company
Event: Recall of more than 5,300 products

- The first formal complaints reached Menu Foods on February 20, 2007.
- Menu Foods announced a recall on March 16, 2007, removing over 5,300 products.
- Cornell received the first contaminated batches between March 13 and March 15, 2007.
- The supplier of the wheat gluten was Xuzhou Anying Biologic Technology Development Company in China.
- Internal taste-test cats at Menu Foods began dying before the public recall.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1321falsefullhttps://www.spreaker.com/episode/children-playing-in-snow-how-a-town-was-slowly-poisoned--73138336
The discovery that children packed asbestos dust into snowball-like clumps and threw them at each other evokes a slow, intimate horror: half an inch of grey-white dust settling on every windowsill within an hour of factory startup. How could a company know about asbestos risks from 1933 onward and let a whole neighborhood breathe that dust for decades?

In this episode, you will hear detailed testimonies from Armley residents, the timeline of Midland Works’ production and the legal records that linked exposure to corporate knowledge, all leading to the question of why compensation arrived too late for many of the victims.

Person: Arthur Margereson
Person: June Hancock
Location: Armley, Leeds
Company: J. W. Roberts Ltd
Product: Limpet (raw asbestos mixed with water and cement)

- Factory produced asbestos insulation mattresses by 196 and Limpet by 1931.
- About 1,000 homes were within walking distance of Canal Road where Midland Works stood.
- At its peak Midland Works employed around 250 people.
- Sworn testimony described half an inch of asbestos dust settling on windowsills within one hour of factory startup.
- A court finding in 1933 established J. W. Roberts Ltd knew the risks posed by asbestos dust exposure.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138336Fri, 24 Jul 2026 04:35:28 +0000Creator at ObomediaChildren Playing in "Snow": How a Town Was Slowly Poisoned The discovery that children packed asbestos dust into snowball-like clumps and threw them at each other evokes a slow, intimate horror: half an inch of grey-white dust settling on every...
The discovery that children packed asbestos dust into snowball-like clumps and threw them at each other evokes a slow, intimate horror: half an inch of grey-white dust settling on every windowsill within an hour of factory startup. How could a company know about asbestos risks from 1933 onward and let a whole neighborhood breathe that dust for decades?

In this episode, you will hear detailed testimonies from Armley residents, the timeline of Midland Works’ production and the legal records that linked exposure to corporate knowledge, all leading to the question of why compensation arrived too late for many of the victims.

Person: Arthur Margereson
Person: June Hancock
Location: Armley, Leeds
Company: J. W. Roberts Ltd
Product: Limpet (raw asbestos mixed with water and cement)

- Factory produced asbestos insulation mattresses by 196 and Limpet by 1931.
- About 1,000 homes were within walking distance of Canal Road where Midland Works stood.
- At its peak Midland Works employed around 250 people.
- Sworn testimony described half an inch of asbestos dust settling on windowsills within one hour of factory startup.
- A court finding in 1933 established J. W. Roberts Ltd knew the risks posed by asbestos dust exposure.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1307falsefullhttps://www.spreaker.com/episode/when-the-healer-became-executioner-karl-brandt-and-medicine-s-reckoning--73138335
A physician who specialized in spinal injuries and once repaired the nervous system became the man who proposed carbon monoxide as a "humane" method of killing; how does clinical training become the architecture of state murder? This episode traces the path from medical apprenticeship to Aktion T4 and asks the central, unresolved question: where did authorization for industrialized killing begin and who made it medical?

In this episode, we lay out the life, influences, and choices that led Karl Brandt from a 1928 medical degree to a central role in Nazi killing bureaucracy, and we follow the paperwork, policies, and trial work that reframed medical ethics for the modern world - but how did theory turn into a system that processed seventy thousand lives?

Person: Karl Brandt
Date of birth: January 8, 1904
Event: Aktion T4 killings
First documented victim: Gerhard Kretschmar, July 25, 1939
Estimated deaths (1939-1941): 70,000

- Brandt earned his medical degree in 1928 and specialized in spinal injuries.
- He studied under Alfred Hoche, who promoted the concept of "ballast existences."
- Brandt joined the Nazi Party by January 1932 and the SA by 1933, and became Hitler's escort physician in summer 1934.
- On July 25, 1939, Brandt authorized the killing of five-month-old Gerhard Kretschmar, the first documented victim leading to Aktion T4.
- Between 1939 and 1941, Aktion T4 killed an estimated 70,000 people using methods Brandt helped recommend, including carbon monoxide.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138335Fri, 24 Jul 2026 04:35:24 +0000Creator at ObomediaWhen the Healer Became Executioner: Karl Brandt and Medicine's Reckoning A physician who specialized in spinal injuries and once repaired the nervous system became the man who proposed carbon monoxide as a "humane" method of killing; how does...
A physician who specialized in spinal injuries and once repaired the nervous system became the man who proposed carbon monoxide as a "humane" method of killing; how does clinical training become the architecture of state murder? This episode traces the path from medical apprenticeship to Aktion T4 and asks the central, unresolved question: where did authorization for industrialized killing begin and who made it medical?

In this episode, we lay out the life, influences, and choices that led Karl Brandt from a 1928 medical degree to a central role in Nazi killing bureaucracy, and we follow the paperwork, policies, and trial work that reframed medical ethics for the modern world - but how did theory turn into a system that processed seventy thousand lives?

Person: Karl Brandt
Date of birth: January 8, 1904
Event: Aktion T4 killings
First documented victim: Gerhard Kretschmar, July 25, 1939
Estimated deaths (1939-1941): 70,000

- Brandt earned his medical degree in 1928 and specialized in spinal injuries.
- He studied under Alfred Hoche, who promoted the concept of "ballast existences."
- Brandt joined the Nazi Party by January 1932 and the SA by 1933, and became Hitler's escort physician in summer 1934.
- On July 25, 1939, Brandt authorized the killing of five-month-old Gerhard Kretschmar, the first documented victim leading to Aktion T4.
- Between 1939 and 1941, Aktion T4 killed an estimated 70,000 people using methods Brandt helped recommend, including carbon monoxide.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1295falsefullhttps://www.spreaker.com/episode/signed-away-how-britain-s-blood-scandal-silenced-1-217-voices--73138334
Fear that the system meant to protect you instead betrayed you: 1,217 people sued the British government after contaminated factor concentrates infected them with HIV, and 130 died before the case ended - but a secret memo and a sealed settlement kept the full truth from courtrooms for decades. What was hidden in six hundred files and a 27-year-old memo that officials knew would have changed the trial?

In this episode, we trace the HIV Haemophilia Litigation from the arrival of factor concentrates and imported plasma to the courtroom where Public Interest Immunity blocked 600 Department of Health folders, and to the December 1990 settlement that contained a clause survivors later called a legal trap. How did decisions about imports, heat treatment, and secrecy shape the fate of haemophiliacs in Britain?

Person: 1,217 plaintiffs
Date: litigation began April 1989; settlement December 1990
Event: HIV Haemophilia Litigation
Country: United Kingdom
Document: memo hidden for 27 years

- 1,217 people brought a legal case against the British government.
- 130 plaintiffs died before the litigation ended.
- 600 Department of Health folders (covering 1972-1986) were withheld from the court under Public Interest Immunity.
- By November 1989, 163 plaintiffs had developed full AIDS and 107 had already died.
- A memo found in the National Archives stated officials believed the government would have lost if the case had gone to trial.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138334Fri, 24 Jul 2026 04:35:20 +0000Creator at ObomediaSigned Away: How Britain's Blood Scandal Silenced 1,217 Voices Fear that the system meant to protect you instead betrayed you: 1,217 people sued the British government after contaminated factor concentrates infected them with HIV, and 130 died...
Fear that the system meant to protect you instead betrayed you: 1,217 people sued the British government after contaminated factor concentrates infected them with HIV, and 130 died before the case ended - but a secret memo and a sealed settlement kept the full truth from courtrooms for decades. What was hidden in six hundred files and a 27-year-old memo that officials knew would have changed the trial?

In this episode, we trace the HIV Haemophilia Litigation from the arrival of factor concentrates and imported plasma to the courtroom where Public Interest Immunity blocked 600 Department of Health folders, and to the December 1990 settlement that contained a clause survivors later called a legal trap. How did decisions about imports, heat treatment, and secrecy shape the fate of haemophiliacs in Britain?

Person: 1,217 plaintiffs
Date: litigation began April 1989; settlement December 1990
Event: HIV Haemophilia Litigation
Country: United Kingdom
Document: memo hidden for 27 years

- 1,217 people brought a legal case against the British government.
- 130 plaintiffs died before the litigation ended.
- 600 Department of Health folders (covering 1972-1986) were withheld from the court under Public Interest Immunity.
- By November 1989, 163 plaintiffs had developed full AIDS and 107 had already died.
- A memo found in the National Archives stated officials believed the government would have lost if the case had gone to trial.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1362falsefullhttps://www.spreaker.com/episode/the-teaspoon-that-triggered-thirteen-tomahawks--73138331
A single teaspoon of soil collected near a pharmaceutical factory in Khartoum in December 1997 reportedly tested at 2.5 times the detectable threshold for EMPTA, a VX precursor - and within eight months thirteen Tomahawks missiles reduced that factory to rubble. How did one fourteen-month-old soil sample help justify a transcontinental military strike that destroyed Sudan’s main medicine supplier and cost hundreds their jobs?

In this episode, we trace what the available documents say about the intelligence, the decision timeline, and who pushed for action, focusing on what the soil sample actually showed and what it did not. What did policymakers believe, what was unknown to them, and what followed after the missiles hit?

Person: Salah Idris
Date: December 1997 (soil collected); August 20, 1998 (strike)
Location: al-Shifa Pharmaceutical Industries, Khartoum North
Event: Operation Infinite Reach - thirteen Tomahawks missiles on al-Shifa; 60-75 missiles on Khost camps
Status: Kroll report (Feb 1999) found no link between al-Shifa or Salah Idris and terrorist organizations

- The soil sample tested at 2.5 times the detectable threshold for EMPTA, a VX precursor.
- Al-Shifa employed roughly 300 workers and supplied more than 50% of Sudan’s domestic medicines.
- Al-Shifa held a UN contract worth approximately $199,000 to supply medicines under Oil-for-Food.
- Thirteen Tomahawks missiles struck al-Shifa on the night of August 20, 1998; 60-75 missiles struck camps in Khost.
- Salah Idris purchased the factory in March 1998 and later hired Kroll; their February 1999 report found no terrorist links.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138331Fri, 24 Jul 2026 04:35:16 +0000Creator at ObomediaThe Teaspoon That Triggered Thirteen Tomahawks A single teaspoon of soil collected near a pharmaceutical factory in Khartoum in December 1997 reportedly tested at 2.5 times the detectable threshold for EMPTA, a VX precursor - and within eight...
A single teaspoon of soil collected near a pharmaceutical factory in Khartoum in December 1997 reportedly tested at 2.5 times the detectable threshold for EMPTA, a VX precursor - and within eight months thirteen Tomahawks missiles reduced that factory to rubble. How did one fourteen-month-old soil sample help justify a transcontinental military strike that destroyed Sudan’s main medicine supplier and cost hundreds their jobs?

In this episode, we trace what the available documents say about the intelligence, the decision timeline, and who pushed for action, focusing on what the soil sample actually showed and what it did not. What did policymakers believe, what was unknown to them, and what followed after the missiles hit?

Person: Salah Idris
Date: December 1997 (soil collected); August 20, 1998 (strike)
Location: al-Shifa Pharmaceutical Industries, Khartoum North
Event: Operation Infinite Reach - thirteen Tomahawks missiles on al-Shifa; 60-75 missiles on Khost camps
Status: Kroll report (Feb 1999) found no link between al-Shifa or Salah Idris and terrorist organizations

- The soil sample tested at 2.5 times the detectable threshold for EMPTA, a VX precursor.
- Al-Shifa employed roughly 300 workers and supplied more than 50% of Sudan’s domestic medicines.
- Al-Shifa held a UN contract worth approximately $199,000 to supply medicines under Oil-for-Food.
- Thirteen Tomahawks missiles struck al-Shifa on the night of August 20, 1998; 60-75 missiles struck camps in Khost.
- Salah Idris purchased the factory in March 1998 and later hired Kroll; their February 1999 report found no terrorist links.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1335falsefullhttps://www.spreaker.com/episode/when-medicine-becomes-punishment-the-diagnostics-of-political-repression--73138328
Powerful institutions turned medical language into a method of removal: in 1989 American psychiatrists requested exams for 48 people labeled "schizophrenic" and were allowed to see only 27, after roughly half had been quietly released while their files still claimed illness - how did diagnosis become a tool for silencing dissent?

In this episode, we follow the cases and paperwork that link Soviet "sluggish schizophrenia" to earlier and later examples of medicalized repression, tracing what the American delegation found and what those findings imply about clinicians’ authority. What connects a 19th‑century American diagnosis, Soviet psychiatric doctrine, and modern political abuse of psychiatry?

Person: Vladimir Bukovsky
Date: Spring 1989
Location: Soviet Union
Topic: Sluggish schizophrenia and political abuse of psychiatry

- 48 names were requested for examination by the American psychiatric team in 1989.
- Soviet authorities permitted the American doctors to see 27 individuals.
- Roughly half of the hospitalized patients on the list had been quietly released in the two months between submission and the delegation’s arrival.
- The World Psychiatric Association formally condemned the Soviet Union for political abuse of psychiatry in 1977.
- Samuel A. Cartwright published the 1851 paper naming drapetomania and prescribing removal of both big toes as treatment.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138328Fri, 24 Jul 2026 04:35:12 +0000Creator at ObomediaWhen Medicine Becomes Punishment: The Diagnostics of Political Repression Powerful institutions turned medical language into a method of removal: in 1989 American psychiatrists requested exams for 48 people labeled "schizophrenic" and were allowed...
Powerful institutions turned medical language into a method of removal: in 1989 American psychiatrists requested exams for 48 people labeled "schizophrenic" and were allowed to see only 27, after roughly half had been quietly released while their files still claimed illness - how did diagnosis become a tool for silencing dissent?

In this episode, we follow the cases and paperwork that link Soviet "sluggish schizophrenia" to earlier and later examples of medicalized repression, tracing what the American delegation found and what those findings imply about clinicians’ authority. What connects a 19th‑century American diagnosis, Soviet psychiatric doctrine, and modern political abuse of psychiatry?

Person: Vladimir Bukovsky
Date: Spring 1989
Location: Soviet Union
Topic: Sluggish schizophrenia and political abuse of psychiatry

- 48 names were requested for examination by the American psychiatric team in 1989.
- Soviet authorities permitted the American doctors to see 27 individuals.
- Roughly half of the hospitalized patients on the list had been quietly released in the two months between submission and the delegation’s arrival.
- The World Psychiatric Association formally condemned the Soviet Union for political abuse of psychiatry in 1977.
- Samuel A. Cartwright published the 1851 paper naming drapetomania and prescribing removal of both big toes as treatment.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1338falsefullhttps://www.spreaker.com/episode/when-trust-kills-the-nanny-who-emptied-three-inhalers--73138325
Trust looks ordinary until it isn't: three inhalers emptied and a family remade by a cascade of losses that began with a doctor's appointment gone wrong. How did a few everyday objects and a woman calling herself Peyton Flanders dismantle an entire household from the inside?

In this episode, we narrate the plot and production details of the film that staged this betrayal, following the screenplay's two-year, thirty-draft gestation and the sequence of events that the story constructs - from an OB-GYN visit to a suicide, a frozen estate, and a nanny who systematically takes over a family. How did those scripted choices make the danger feel plausibly real?

Film: The Hand That Rocks the Cradle
Screenwriter: Amanda Silver
Director entry date: October 1990
Box office: $140,000,000 return on $11,900,000 budget
Release date: January 10, 1992

- Three inhalers were shown emptied and sitting on a bathroom shelf in the film's central image.
- Amanda Silver spent roughly two years and approximately thirty drafts on the screenplay.
- The film opened nationwide on January 10, 1992, and held the number-one box office spot for four consecutive weeks.
- The production documented the Bartel family home as 808 North Yakima Avenue in Tacoma and the Mott home as 2502 37th Avenue West in Seattle.
- Rebecca De Mornay was cast against type as Peyton Flanders after Curtis Hanson joined the project in October 1990.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138325Fri, 24 Jul 2026 04:35:08 +0000Creator at ObomediaWhen Trust Kills: The Nanny Who Emptied Three Inhalers Trust looks ordinary until it isn't: three inhalers emptied and a family remade by a cascade of losses that began with a doctor's appointment gone wrong. How did a few everyday objects and a...
Trust looks ordinary until it isn't: three inhalers emptied and a family remade by a cascade of losses that began with a doctor's appointment gone wrong. How did a few everyday objects and a woman calling herself Peyton Flanders dismantle an entire household from the inside?

In this episode, we narrate the plot and production details of the film that staged this betrayal, following the screenplay's two-year, thirty-draft gestation and the sequence of events that the story constructs - from an OB-GYN visit to a suicide, a frozen estate, and a nanny who systematically takes over a family. How did those scripted choices make the danger feel plausibly real?

Film: The Hand That Rocks the Cradle
Screenwriter: Amanda Silver
Director entry date: October 1990
Box office: $140,000,000 return on $11,900,000 budget
Release date: January 10, 1992

- Three inhalers were shown emptied and sitting on a bathroom shelf in the film's central image.
- Amanda Silver spent roughly two years and approximately thirty drafts on the screenplay.
- The film opened nationwide on January 10, 1992, and held the number-one box office spot for four consecutive weeks.
- The production documented the Bartel family home as 808 North Yakima Avenue in Tacoma and the Mott home as 2502 37th Avenue West in Seattle.
- Rebecca De Mornay was cast against type as Peyton Flanders after Curtis Hanson joined the project in October 1990.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1225falsefullhttps://www.spreaker.com/episode/five-straps-ten-days-how-restraint-killed-kelly-savage--73138324
A young man immobilized by five leather straps within hours of admission - two on the wrists, two on the ankles and one across the waist - and left bound for ten days during Japan’s Golden Week. How did restraint, applied to a patient whose intake notes said his symptoms were not severe, become the instrument that ended Kelly Savage’s life?

In this episode, we follow the timeline from Kelly Robert Savage’s background and recovery-focused studies to his involuntary admission to Yamato Hospital on April 30, 2017, and the puzzling, contradictory medical record that followed; can the available documents and a cautious cardiologist’s report explain what happened during those ten days?

Person: Kelly Robert Savage
Date of admission: April 30, 2017
Location: Yamato Hospital, Kanagawa Prefecture, Japan
Duration restrained: ten days
Birth date: December 27, 1989

- Kelly had five leather straps applied within hours of admission: two wrist straps, two ankle straps, and one waist strap.
- The hospital intake notes recorded that his symptoms were “not severe” at the time of admission.
- Kelly was restrained continuously from April 30 through at least May 9, encompassing Golden Week when the family was denied visitors May 3-7.
- Medical records obtained by the family contained directly contradictory entries, describing Kelly as both calm and in severe distress in overlapping notes.
- The only specialist report mentioned, a cardiologist’s report, did not reach a definitive verdict but offered a cautious clinical speculation about the cause of death.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138324Fri, 24 Jul 2026 04:35:04 +0000Creator at ObomediaFive Straps, Ten Days: How Restraint Killed Kelly Savage A young man immobilized by five leather straps within hours of admission - two on the wrists, two on the ankles and one across the waist - and left bound for ten days during Japan’s Golden...
A young man immobilized by five leather straps within hours of admission - two on the wrists, two on the ankles and one across the waist - and left bound for ten days during Japan’s Golden Week. How did restraint, applied to a patient whose intake notes said his symptoms were not severe, become the instrument that ended Kelly Savage’s life?

In this episode, we follow the timeline from Kelly Robert Savage’s background and recovery-focused studies to his involuntary admission to Yamato Hospital on April 30, 2017, and the puzzling, contradictory medical record that followed; can the available documents and a cautious cardiologist’s report explain what happened during those ten days?

Person: Kelly Robert Savage
Date of admission: April 30, 2017
Location: Yamato Hospital, Kanagawa Prefecture, Japan
Duration restrained: ten days
Birth date: December 27, 1989

- Kelly had five leather straps applied within hours of admission: two wrist straps, two ankle straps, and one waist strap.
- The hospital intake notes recorded that his symptoms were “not severe” at the time of admission.
- Kelly was restrained continuously from April 30 through at least May 9, encompassing Golden Week when the family was denied visitors May 3-7.
- Medical records obtained by the family contained directly contradictory entries, describing Kelly as both calm and in severe distress in overlapping notes.
- The only specialist report mentioned, a cardiologist’s report, did not reach a definitive verdict but offered a cautious clinical speculation about the cause of death.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1293falsefullhttps://www.spreaker.com/episode/how-henrietta-sarah-and-the-science-that-stole-their-bodies--73138323
The same scientific breakthroughs that cured polio and mapped genes were built on tissue taken without consent; a single cervical biopsy in 1951 produced cells that still replicate today - and this episode traces how that act fit into a two-century chain of practices that treated Black bodies as sources of material, not persons. How did exhibitions, dissections, and medical routines converge to make extraction seem like science rather than theft?

In this episode, we tell the story of two women and the institutional history that connected them, following Henrietta Lacks from a Baltimore hospital to a global cell line and Sarah Baartman from the South African frontier to European museums, asking how consent was bypassed and what legacy that created.

Person: Henrietta Lacks
Date: 1951
Event: Biopsy taken at Johns Hopkins Hospital without patient consent
Case: HeLa cell line named from first two letters of her name
Person: Sarah Baartman

- Henrietta Lacks was thirty when a biopsy was taken in January 1951 and she died in October 1951 at age thirty-one.
- The tumor excised was described as “the size of a nickel,” and a portion was sent to Dr. George Gey’s laboratory.
- HeLa cells replicated indefinitely and were shared worldwide within years, contributing to polio vaccine development and gene mapping.
- Henrietta’s children were aged between one and ten when she died and grew up largely in poverty without the benefits of the research her cells enabled.
- Sarah Baartman was exhibited in Europe for five years, died in 1815, and had her brain, genitalia, skeleton, and a full body cast preserved and displayed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73138323Fri, 24 Jul 2026 04:35:00 +0000Creator at ObomediaHow Henrietta, Sarah and the Science That Stole Their Bodies The same scientific breakthroughs that cured polio and mapped genes were built on tissue taken without consent; a single cervical biopsy in 1951 produced cells that still replicate today...
The same scientific breakthroughs that cured polio and mapped genes were built on tissue taken without consent; a single cervical biopsy in 1951 produced cells that still replicate today - and this episode traces how that act fit into a two-century chain of practices that treated Black bodies as sources of material, not persons. How did exhibitions, dissections, and medical routines converge to make extraction seem like science rather than theft?

In this episode, we tell the story of two women and the institutional history that connected them, following Henrietta Lacks from a Baltimore hospital to a global cell line and Sarah Baartman from the South African frontier to European museums, asking how consent was bypassed and what legacy that created.

Person: Henrietta Lacks
Date: 1951
Event: Biopsy taken at Johns Hopkins Hospital without patient consent
Case: HeLa cell line named from first two letters of her name
Person: Sarah Baartman

- Henrietta Lacks was thirty when a biopsy was taken in January 1951 and she died in October 1951 at age thirty-one.
- The tumor excised was described as “the size of a nickel,” and a portion was sent to Dr. George Gey’s laboratory.
- HeLa cells replicated indefinitely and were shared worldwide within years, contributing to polio vaccine development and gene mapping.
- Henrietta’s children were aged between one and ten when she died and grew up largely in poverty without the benefits of the research her cells enabled.
- Sarah Baartman was exhibited in Europe for five years, died in 1815, and had her brain, genitalia, skeleton, and a full body cast preserved and displayed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1251falsefull